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Abstract
The European Food Safety Authority has produced this Guidance on human and animal health aspects
(Part 1) of the risk assessment of nanoscience and nanotechnology applications in the food and feed
chain. It covers the application areas within EFSA’s remit, e.g. novel foods, food contact materials,
food/feed additives and pesticides. The Guidance takes account of the new developments that have
taken place since publication of the previous Guidance in 2011. Potential future developments are
suggested in the scientiﬁc literature for nanoencapsulated delivery systems and nanocomposites in
applications such as novel foods, food/feed additives, biocides, pesticides and food contact materials.
Therefore, the Guidance has taken account of relevant new scientiﬁc studies that provide more
insights to physicochemical properties, exposure assessment and hazard characterisation of
nanomaterials. It speciﬁcally elaborates on physicochemical characterisation of nanomaterials in terms
of how to establish whether a material is a nanomaterial, the key parameters that should be
measured, the methods and techniques that can be used for characterisation of nanomaterials and
their determination in complex matrices. It also details the aspects relating to exposure assessment
and hazard identiﬁcation and characterisation. In particular, nanospeciﬁc considerations relating to
in vivo/in vitro toxicological studies are discussed and a tiered framework for toxicological testing is
outlined. It describes in vitro degradation, toxicokinetics, genotoxicity as well as general issues relating
to testing of nanomaterials. Depending on the initial tier results, studies may be needed to investigate
reproductive and developmental toxicity, immunotoxicity, allergenicity, neurotoxicity, effects on gut
microbiome and endocrine activity. The possible use of read-across to ﬁll data gaps as well as the
potential use of integrated testing strategies and the knowledge of modes/mechanisms of action are
also discussed. The Guidance proposes approaches to risk characterisation and uncertainty analysis,
and provides recommendations for further research in this area.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
1) Upon request of the European Food Safety Authority (EFSA), the Scientiﬁc Committee has
undertaken a thorough revision of the previous Guidance on risk assessment of nanoscience
and nanotechnology applications in the food and feed chain published in 2011. This Part 1
of the updated Guidance relates to human and animal health aspects of nanomaterial
applications in the areas within EFSA’s remit. Part 2 of the Guidance will separately address
those aspects that relate to environmental risk assessment.
2) The requested revision should take into account the relevant applications areas including
novel foods, food contact materials (FCMs), food/feed additives and pesticides as well as
physicochemical characterisation and the other data needed for safety assessment of
nanomaterials in food/feed.
3) The present Guidance therefore provides an overview on information requirements and how
to perform risk assessment of nanomaterials in the food and feed area (e.g. novel food, FCMs,
food/feed additives and pesticides). For example, under the new EU Regulation on Novel Food
(EU) No. 2015/2283, a food consisting of engineered nanomaterials will be considered a
novel food and as such will require authorisation. The Regulation stipulates that risk
assessment of novel foods shall be carried out by EFSA, which shall also be responsible for
verifying that the most up-to-date test methods have been used to assess their safety.
4) The present Guidance is aimed at providing a structured pathway for carrying out safety
assessment of nanomaterials in the food and feed area. This Guidance is applicable to (see
Section 1.3):
a) a material that meets the criteria for an engineered nanomaterial (see Section 1.2.3) as
outlined in Novel Food Regulation (EU) No 2015/2283 and Regulation (EU) No 1169/2011
on the Provision of Food Information to Consumers, i.e. nanomaterials that, amongst other
criteria, have particle sizes in the deﬁned nanoscale (1–100 nm);
b) a material that contains particles having a size above 100 nm which could
retain properties that are characteristic of the nanoscale (see Section 3.1), for example
related to the large speciﬁc surface area of the materials or different toxicokinetic
behaviour (i.e. signiﬁcant changes in absorption, distribution and/or metabolism) as
compared with its non-nanomaterial (see Glossary). This may be the case for materials
resulting from production processes that are aimed at reducing the average diameter of
materials’ particles (e.g. micronisation).
c) a material that is not engineered as nanomaterial but contains a fraction of
particles, less than 50% in the number–size distribution (as per the
recommended European Commission deﬁnition), with one or more external
dimensions in the size range 1–100 nm. This is expected to be the case of
manufacturing processes for powdered or particulate food chemicals that typically result
in materials with a range of sizes (see Section 4.2.2);
d) a nanomaterial having the same elemental composition but that occurs in a
different morphological shapes, sizes, crystalline forms and/or surface
properties as, for example a consequence of different production processes.
e) a nanoscale entity made of natural materials that has been deliberately produced to
have nano-enabled properties, or has been modiﬁed for use in the development of other
nanoscale materials, e.g. for encapsulating (bioactive) compounds (see Appendix E.6).
f) Although the European Commission recommendation on a deﬁnition for nanomaterial is
currently under review, and has not yet been adopted under the relevant regulatory
frameworks, the Scientiﬁc Committee advises to take this and any future reviews into
consideration when assessing safety of materials consisting of particles (see
section 1.2.2).
5) A decision ﬂow scheme, developed by the NanoDeﬁne project, is presented in this Guidance
(see Section 4.1) to facilitate ascertaining whether or not a material is nanomaterial
according to the European Commission recommended deﬁnition (see Section 1.2.2), and to
identify relevant methods and tools for its characterisation. The European Commission has
recommended a threshold of 50% of the particles in the number-based minimal external size
distribution to be in the nanoscale (1–100 nm) for a material to be regarded as a
nanomaterial. Although this recommendation on a deﬁnition of nanomaterial is currently
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under review, and has not yet been adopted under the relevant regulatory (food)
frameworks, the Scientiﬁc Committee advises to take this into consideration when assessing
safety of materials containing particles.
6) Where a material has been identiﬁed as a nanomaterial, it will need to be assessed for
safety and to fulﬁl requirements of this Guidance. It is nevertheless also important to
highlight that, irrespective of the presence of a nanomaterial, the existing requirements for
safety assessment according to guidance for conventional non-nanomaterials under
relevant regulations must be followed.
7) In principle, the current risk assessment paradigm for chemicals, which is based on hazard
identiﬁcation/characterisation together with exposure assessment and risk characterisation,
is also applicable to nanomaterials. However, as highlighted in this Guidance, reducing the
size of particulate materials to the nanoscale can impart certain changes in properties and
biokinetics behaviour, which may also lead to altered toxicological effects compared with
corresponding non-nanomaterial. Therefore, the safety of a nanomaterial should not be
automatically assumed to be similar/comparable to its corresponding non-nanomaterial or
another nanomaterial. This also means that, for a speciﬁc nanomaterial, data and
information would need to be provided on certain nanospeciﬁc properties (see
Section 4, Table 1 + Appendix B Table B.1), in addition to the data and information
generally required according to the relevant conventional regulation. Some of the currently
available testing methods may also need adaptation to take account of the speciﬁc
properties of nanomaterials. Therefore, safety assessment of nanomaterials must be
carried out in accordance with the provisions of this Guidance.
8) As part of problem formulation, a prerequisite for risk assessment of nanomaterials is an
unambiguous identiﬁcation and detailed characterisation of the constituting components
and impurities of the pristine core nanomaterial, as well as any entities on the particle
surface (including coatings). Information on physicochemical parameters can also provide
important pointers for potential toxicity of a nanomaterial, and thus help in deciding an
appropriate testing strategy. This Guidance (see Section 4.2.1) lists the main
physicochemical parameters that are considered essential for characterisation of
nanomaterials, although not all are applicable to each material. It recommends that
characterisation of the nanomaterial is carried out at different stages, e.g. in its the pristine
state as tested and on the material as used in products and applications. The Guidance
also outlines the currently available methods and tools that can be used for measuring the
parameters, as well as quality control aspects that should be considered. It recommends
that particle size distribution should be determined by more than one independent
technique (one of which being electron microscopy).
9) It is also noteworthy that a high degradation rate, for example caused by dissolution, will
render a nanomaterial into its corresponding non-nanomaterial form. Therefore, the
nanospeciﬁc considerations described in this Guidance are applicable to those materials
that do not quickly degrade (see Section 6.2.1 and Appendix D) to ions or molecules
under the physiological conditions of the food production and processing processes, the
food matrix and of the gastrointestinal (GI) system, and therefore have a chance of
interacting with biological entities at the local or systemic levels. Practical description of
when a nanomaterial is considered to have a high degradation rate is provided
in Section 6.2.
10) Throughout various Sections, the Guidance also identiﬁes the circumstances under which
some requirements for data generated speciﬁcally on the nanomaterial could be
waived. For example, where it can be shown that the use of a nanomaterial does not lead
to local or systemic exposure (to the speciﬁc nanomaterial or degradation products in the
form of a nanomaterial), or where there is no migration or transfer of a nanomaterial from
a FCM into the food. Also, because a nanomaterial can be developed in several forms with
different sizes, crystalline forms, shapes, surface characteristics, etc., this Guidance
describes the current potential use of a grouping/read-across approach to avoid case-
by-case testing of all variants of a given nanomaterial (see Section 6.3). It notes that, in
principle, toxicological data from a nanomaterial may be used for safety assessment of
another variant of the same nanomaterial, if it can be shown that there are close
similarities in their physicochemical properties and toxicokinetic behaviour. Justiﬁcation that
a source (nano)material exhibits toxicokinetic behaviour and hazards that are more ‘worst
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case’ than the target nanomaterial would also be possible (see Section 6.3). An up-to-date
review of the published literature is also important to take account of the available
information that may help in avoiding unnecessary testing.
11) The principles for exposure assessment of nanomaterials via food/feed are essentially
the same as for non-nanomaterials and will require consideration of the likely exposure
scenarios, and estimation of exposure based on consumption data and anticipated average
and high intakes in various population groups (see Section 5). Probabilistic methods may
also be useful in terms of determining ranges of plausible values. Where direct exposure
(e.g. via novel food, ﬂavourings, food additives), or indirect exposure (e.g. migration or
transfer from FCM, carry-over from feed via animals to food or a pesticide to crop) is
possible, it should be determined whether the nanomaterial or its degradation product(s)
remain present as particles in the food/feed matrix to inform risk characterisation.
Characteristics that may indicate a loss of nanospeciﬁc properties and thus reduce the
chance of exposure to the nanomaterial include: high degradation rate in water, food/feed
matrix or GI ﬂuids; (bio)degradability to non-nanosized products; formation of larger
aggregates (> 100 nm); nanoparticles being ﬁxed or embedded in other matrices (e.g.
polymer composites used as FCMs), etc. In the absence of exposure data, or where it is
not possible to determine the properties and amounts of nanosized particles in complex
matrices, it should be assumed as a worst-case that all nanomaterial added to a food/feed
product, is present, ingested and absorbed as the nanomaterial.
12) In Chapter 6, the Guidance outlines a structured approach for testing of nanomaterials for
identiﬁcation and characterisation of toxicological hazards, and describes relevant
in vitro and in vivo tests that can be used. The proposed approach is based on testing
nanomaterials under 3 different steps that are preceded by an initial step (Step 0), at
which the rate of degradation of the nanomaterial, e.g. due to dissolution, under
conditions representative of the GI tract is investigated. If a nanomaterial or its
degradation products in the form of a nanomaterial can be present in food/feed or food
simulant, information on degradation rate under conditions relevant for the GI tract should
be provided. Information on the interpretation of the degradation rate is provided in
Section 6.2. Exposure to a nanomaterial can occur if the nanomaterial does not quickly
degrade. In this case, the nanomaterial should be quantiﬁed and characterised at least by
the number-based particle size distribution under digestive tract conditions and whether
the particles consist of primary particles only or may also comprise aggregates and
agglomerates. In cases where a high degradation rate can be demonstrated under the
conditions of the human GI tract (see Section 6.2 and Appendix D), no uptake of the
nanomaterial is expected, but the resulting non-nano degradation products should undergo
risk assessment according to relevant EFSA guidance on conventional non-nanomaterial.
However, in case of complete digestion in GI ﬂuids, local exposure (e.g. in the upper GI
tract) needs to be considered.
13) Only nanomaterials that do not quickly degrade, e.g. by dissolution, under digestive tract
conditions are considered for testing under Step 1, which involves gathering the available
information as well as data from a set of in vitro studies. In particular, information on
carcinogenic, mutagenic, reprotoxic (CMR) properties of the nanomaterial or its components
is considered at Step 1. A degradation test under simulated lysosomal conditions is also
carried out (see Section 6.2.2), along with a battery of relevant in vitro toxicity tests
including genotoxicity, in consideration of the speciﬁc properties of nanomaterials. In this
regard, the bacterial reverse mutation assay (Ames test) is not considered suitable for
nanomaterials owing to the inability of bacterial cells that internalise particles. The use of
mammalian cell models is considered more suitable, and a suitable battery of tests is
described in this Guidance (Section 6.4) to address the critical genotoxicity endpoints.
14) If the information from Step 1 indicates that the nanomaterial is non-persistent and not
(geno)toxic, an argument may be made to waive further nanospeciﬁc testing in Step 2,
although safety assessment for conventional (non-nano)materials will still be needed. Step 2
involves a modiﬁed 90-day oral toxicity test in rodents (OECD TG 408 (2017a) with extended
parameters from OECD TG 407 (2008)) with a satellite group for the assessment of oral
absorption and tissue distribution at different time points (see Section 6.7). This should also
allow for the identiﬁcation of nanomaterials with the potential to accumulate and/or cause
immunological, proliferative and neurotoxic effects, and effects on reproductive organs or
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endocrine-mediated effects. Positive results from these tests may warrant further in-depth
investigations in Step 3. Under Step 3, toxicokinetic studies can be designed to investigate
the extent of accumulation of the nanomaterial during long-term exposure and to determine
any species differences in toxicokinetic behaviour between the test animals and humans.
These studies permit reﬁnement of the risk assessment by decreasing the uncertainty. Step 3
may also include specialised and in-depth testing for neurotoxicity, immunotoxicity or
endocrine-mediated effects. In view of the potential long-term exposure from food, potential
effects of nanomaterials on the gut microbiome should also be considered especially where a
nanomaterial has antimicrobial effects.
15) Risk characterisation combines all the information from hazard identiﬁcation and hazard
characterisation with exposure assessment and any other relevant information, e.g. from
read-across. As in the risk assessment paradigm for other chemicals, a weight of evidence
approach (see Section 7) is used taking into account the available information that may
comprise different types of data from different sources. In general, risk characterisation of a
nanomaterial would consider the same elements as for conventional chemical substances –
i.e. data and information relating to physicochemical properties, exposure and toxicological
effects. Where the data have been derived from appropriately conducted studies using
validated methods and considering nanospeciﬁc issues where relevant, there may be no
reason to use uncertainty factors for a nanomaterial that are any higher than those used for
a conventional material. However, where data are either insufﬁcient or have been derived
from inadequate tests (see Sections 6.9 and 7) for nanomaterials, applying additional
uncertainty factors may be considered for safety assessment of a nanomaterial.
16) The Guidance describes how to carry out and present analysis of uncertainty (see
Section 8) relating to physicochemical characterisation, exposure assessment, and hazard
identiﬁcation and characterisation for nanomaterials. The Guidance discusses speciﬁc
aspects relating to nanomaterial applications for food/feed additives, pesticides, nano-
carriers, novel foods, contaminants and FCMs. The Guidance also notes ongoing
developments in areas relating to alternative testing approaches, mode of action and
adverse outcome pathway approaches.
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1. Introduction
This Guidance builds upon the opinion of the Scientiﬁc Committee of 2009 ‘The Potential Risks
Arising from Nanoscience and Nanotechnologies on Food and Feed Safety’ (EFSA Scientiﬁc Committee,
2009a) and more speciﬁcally Section 6 (page 34) with the title ‘Guidance for risk assessment (RA) of
nanomaterial in food and feed area’, as well as on the subsequent ‘Guidance on the risk assessment of
the application of nanoscience and nanotechnologies in the food and feed chain’ (EFSA Scientiﬁc
Committee, 2011a). The two above-mentioned documents provided an overview of how to perform a
risk assessment of nanomaterial in the food and feed area. The risk assessment paradigm is
appropriate for these applications, and consequently relevant data and information for the various
steps (see below) should be made available to the risk assessor to carry out a risk assessment.
There are already several EFSA guidance documents that include the concept of the ‘size’ of
substances, e.g. from the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP
Panel) (‘Guidance for the preparation of dossiers for sensory additives’, EFSA FEEDAP Panel, 2012a) and
from the Panel on Food Contact Materials (FCM), Enzymes, Flavourings and Processing aids (CEF Panel)
(EFSA CEF Panel, 2016a). For polymers used in FCM, for instance, the general rule is that smaller sized
additives migrate faster and at higher rates than those of larger sizes. This is also valid for nanoparticles
as migrants in polymer nano-composites according to recent publications (Simon et al., 2008; Franz and
Welle, 2017) on migration modelling of nanoparticles from food contact polymers.
As a general principle, the test requirements stipulated in current EFSA guidance documents for
conventional materials1 and EU legislation for various food and feed areas should be applied to a
nanomaterial according to its intended use and should be followed. However, the risk assessment of
nanomaterial, in terms of testing requirements and procedures, requires additional considerations that
are indicated in this Guidance. This Guidance also covers the additional information needed for
physicochemical characterisation owing to the speciﬁc characteristics and properties of nanomaterial.
The speciﬁc information related to the characteristics and properties of the nanomaterial, along with the
information stipulated in the relevant EFSA Guidance documents for the speciﬁc intended use of the
nanomaterial (e.g. novel foods, FCMs, food/feed additives and pesticides), is used for a case-by-case risk
assessment.
There are substantial ongoing developments in alternatives to in vivo testing approaches but
validated in vitro/in silico methods for speciﬁc endpoints are still limited which necessitates information
from in vivo testing be used for risk assessment purposes. The use of animals for risk assessment
should be considered thoroughly during the design of experimental studies and applicants are advised
to consult the Scientiﬁc Committee opinion in the document ‘Existing approaches incorporating
replacement, reduction and reﬁnement of animal testing: applicability in food and feed risk
assessment’ (EFSA Scientiﬁc Committee, 2009b). It is also recommended that use of any existing data
generated for other relevant regulations (e.g. REACH) should also be made to minimise/avoid animal
testing. This Guidance also identiﬁes circumstances under which some data requirements for the risk
assessment could be waived (e.g. when, before ingestion, a nanomaterial is degraded in the food/feed
matrix into an approved non-nanomaterial).
1.1. Background as provided by EFSA
In 2011 the Scientiﬁc Committee (SC) of EFSA published its ‘Guidance on the risk assessment of
the application of nanoscience and nanotechnologies in the food and feed chain’ (EFSA Scientiﬁc
Committee, 2011a). The approaches described therein concern mainly human exposure via the oral
route and are to be implemented by applicants and risk assessors. The EFSA Panels cover
nanomaterials in their assessments by cross-referring to the 2011 SC Guidance. Some food contact
materials (FCM) and food/feed additives that are currently under assessment by EFSA Panels include
nanomaterial, but data generated speciﬁcally on the nanomaterial. Nanomaterials may be present in
FCM or additives either because nanomaterials are intentionally used or because some of the material
contains nanomaterial resulting from the production processes. Both situations, however, require
consideration during risk assessment (of the material under evaluation).
In 2014, to prepare for future applications, EFSA procured an inventory of nanomaterials/applications
on the market or reasonably foreseen to be placed on the market (Peters et al., 2014a). In the report,
55 types of nanomaterials for agri/feed/food were identiﬁed. This literature search also resulted in the
1 Relevant regulatory framework, administrative and EFSA scientiﬁc guidance documents per regulated product area are listed in
http://www.efsa.europa.eu/sites/default/files/applications/apdeskhow.pdf
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highest number of records for nanoencapsulates, silver and titanium dioxide and showed that food
additives and FCM are the most frequently indicated applications. Future developments are expected in
the ﬁeld of nanoencapsulates and nano-composites in applications such as novel foods, food/feed
additives, biocides, FCM, and especially pesticides (Kah et al., 2013; Perlatti et al., 2013; Kah and
Hofmann, 2014; Kookana et al., 2014; Cano Robles and Mendoza Cantu, 2017; Chaudhry et al., 2017).
As mentioned in the conclusions of the 2011 SC Guidance, it will require updating to stay aligned
with innovations and fast developments in this area. This is in line with EFSA’s strategy of revision of
cross-cutting guidance documents (EFSA Scientiﬁc Committee, 2015), as well as with the scientiﬁc
motivation and criteria to consider in updating EFSA scientiﬁc assessments document (EFSA Scientiﬁc
Committee, 2017a).
There are also legal developments that warrant the updating of the 2011 SC Guidance. Novel Food
Regulation (EU) No 2015/2283,2 for example states that EFSA will have to verify that, where a novel
food consists of engineered nanomaterials, the most up-to-date analytical methods will be/are used to
assess their safety and that the scientiﬁc appropriateness of the methods used are substantiated by
the applicants. Art. 12 Regulation (EC) No 1333/2008 stipulated that ‘When a food additive is already
included in a Community list and there is a signiﬁcant change in its production methods or in the
starting materials used, or there is a change in particle size, for example through nanotechnology, the
food additive prepared by those new methods or materials shall be considered as a different additive
and a new entry in the Community lists or a change in the speciﬁcations shall be required before it can
be placed on the market’.
Scientiﬁc developments and experiences from EFSA activities in this ﬁeld that warrant the updating
of the 2011 SC Guidance, can be classiﬁed in four areas: (1) scope extension; (2) nanomaterial
characterisation needs; (3) needs for food/feed assessment; and (4) needs for environmental risk
assessment. All these considerations have to be taken on board when updating the existing 2011 SC
Guidance and when developing a new environmental risk assessment guidance document for
nanomaterials.
1.2. Terms of Reference as provided by EFSA
The EFSA SC is requested to update the previous guidance document on human and animal risk
assessment when nanoscience and nanotechnology are applied in the food and feed chain. The
present Guidance on nanomaterials deals with risk assessment for three main categories of products/
applications; (i) those that are intended for consumption by humans or animals (e.g. novel foods,
food/feed additives); (ii) plant protection products and (iii) nanomaterials that are incorporated into
products that come into contact with food (i.e. FCM and articles).
This update should also take into account the general extensions needed to cover novel foods, food
contact materials, food/feed additives and pesticides as well as an update of the physicochemical
measurements and the other data needed for food/feed assessment.
In support of this work,
• EFSA is asked to set up a Working Group (WG) covering the expertise needed for the concerned
EFSA Panels: PPR, NDA, ANS, CEF, FEEDAP and CONTAM, and relevant EFSA Units (in particular
the EFSA Pesticides Unit), complemented with external experts for speciﬁc aspects.
• It is also asked to host experts from relevant external institutions dealing with risk assessment
of nanomaterials – such as ECHA, EEA, EMA, US-FDA, US-EPA, WHO, European Commission’s
non-food Scientiﬁc Committees, including liaison with the Scientiﬁc Committee on Occupational
Exposure Limits (SCOEL) and DG ENV – or that develop standards in this area (such as JRC,
OECD Working Party on Manufactured Nanomaterials;3 EU FP7 research projects like
NanoGenotox, NANoREG and NanoDeﬁne; and institutes for metrology or standards
development like ISO/CEN, NMIs). These experts could be invited to the SC WG as observer
and this cooperation will enable the coherent linkage of all these institutions’ activities into this
mandate, therewith avoiding duplication of work and ensuring consistency of terminology and
methodologies.
2 Regulation (EU) No 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1–22. See
http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32015R2283&from=EN
3 OECD (Organization for economic cooperation and development), online. http://www.oecd.org/department/0,3355,en_2649_
37015404_1_1_1_1_1,00.html
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• EFSA is also requested to formalise the input and expertise from stakeholders through
consultations, e.g. with hearing experts, an EFSA discussion group or the public consultation.
1.2.1. Interpretation of the Terms of Reference
Dermal and inhalation exposure were added to cover the main routes of exposure to
nanopesticides and feed additives.
Environmental risk assessment will be addressed in a separate document (Part 2) as requested in
the Terms of Reference provided by EFSA.
1.2.2. Deﬁnition of nanomaterial
The International Organization for Standardization (ISO) has deﬁned nanomaterial as a material
with any external dimension on the nanoscale (‘nano-object’) or having an internal or surface structure
in the nanoscale (‘nanostructured material’) (ISO, 2015). In particular, a nano-object is deﬁned as a
discrete piece of material with one, two or three external dimensions on the nanoscale. ‘Nanoparticles’
are nano-objects with all external dimensions on the nanoscale, where the lengths of the longest and
shortest axes do not differ signiﬁcantly. If the dimensions differ signiﬁcantly, typically by more than a
factor of three, other terms, such as ‘nanoﬁbre’ (two external dimensions in the nanoscale) or
‘nanoplate’ (one external dimension on the nanoscale) may be preferred to the term nanoparticle. In
turn, a ‘nanostructured material’ is deﬁned as a material having internal or surface nanostructure, i.e.
a composition of interrelated constituent parts in which one or more of those parts is a nanoscale
region. ‘Nanoscale’ is deﬁned as ranging from approximately 1 to 100 nm (ISO, 2015).
According to the ISO nanotechnologies vocabulary, which can be freely consulted on www.iso.org/
obp, ‘engineered nano-object’ is deﬁned as a nano-object designed for a speciﬁc purpose or function,
‘manufactured nano-object’ as a nano-object intentionally produced to have selected properties or
composition and ‘incidental nano-object’ as a nano-object generated as an unintentional by-product of
a process (ISO, 2015).
Size is the key parameter for the identiﬁcation of a nanomaterial. All nanomaterials occur with a
size distribution, i.e. the constituting entities do not all have the same size. Often particulate materials
comprise particles with lengths both below and above 100 nm. Owing to the reactivity of
nanoparticles, mainly related to their high surface free energy, larger clusters (‘secondary particles’)
often result from agglomeration and/or aggregation of constituting primary particles. In some cases,
the size distribution of manufactured nanomaterials covers a rather wide length range.
The European Commission issued a Recommendation for a deﬁnition of a nanomaterial in 2011 to
provide a common basis for regulatory purposes across most areas of EU policy (currently under
review4). The provisions of the recommended deﬁnition include a requirement for review in the light of
experience and of scientiﬁc and technological developments. The European Commission is expected to
conclude this review in 2018. If this recommended deﬁnition (or any update of it) were to be
embedded in the food law, it would provide further information on whether or not a material should be
regarded as a nanomaterial in the context of any of the food regulations. According to that
recommended deﬁnition, ‘nanomaterial’ means a natural, incidental or manufactured material
containing particles in an unbound state or as an aggregate or as an agglomerate and where, for 50%
or more of the particles in the number–size distribution, one or more external dimensions is in the size
range 1–100 nm. In speciﬁc cases and where warranted by concerns for the environment, health,
safety or competitiveness the number–size distribution threshold of 50% may be replaced by a
threshold between 1 and 50%.
For the purposes of the recommended deﬁnition, ‘particle’ means a minute piece of matter with
deﬁned physical boundaries, ‘agglomerate’ means a collection of weakly bound particles or aggregates
where the resulting external surface area is similar to the sum of the surface areas of the individual
components, and ‘aggregate’ means a particle comprising of strongly bound or fused particles. In
addition, it is speciﬁed that fullerenes, graphene ﬂakes and single wall carbon nanotubes should be
considered as nanomaterials even though one or more external dimensions are below 1 nm.
The current recommended deﬁnition is used as the reference for determining whether a material
should be considered as a ‘nanomaterial’ for legislative and policy purposes in the EU. According to the
recommended deﬁnition the criterion is solely the size of the constituent particles of the material,
4 Commission Recommendation 2011/696/EU of 18 October 2011 on the deﬁnition of nanomaterial. OJ L 275, 20.10.2011, p.
38–40, under revision.
Guidance on nanotechnologies in the food and feed chain
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2018;16(7):5327
without regard to hazard, toxicokinetics or risk. Although this Recommendation is currently under
review, and has not yet been adopted under the relevant regulatory frameworks, the SC advises taking
this and any future reviews into consideration when assessing the safety of materials consisting of
small particles.
From a risk assessment perspective, it is essential to point out that size-dependent properties and
biological effects that are of potential concern for human health, speciﬁcally toxicokinetic behaviour
and particle–cell interactions, are not rigidly related to speciﬁc size thresholds. They depend on dose
and may continue to occur even when the particles constituting the nanomaterial have a size well
above 100 nm. Furthermore, whereas physical, chemical and biological properties of materials may
change with size, there is no scientiﬁc justiﬁcation for a single size limit associated with these changes
that can be applied to all nanomaterials (SCENIHR, 2010). Therefore, potential risks arising from
speciﬁc properties related to the nanoscale have to be assessed focusing on such properties and
potentially related hazards, which may be independent of the proportion of particles constituting the
material with a size below 100 nm. In line with the conclusions of SCENIHR (2010)5 and the EFSA
Scientiﬁc Committee (2011a), the EFSA Scientiﬁc Committee reiterates that not all nanomaterials have
new hazard properties compared with larger sized counterparts and that therefore a case-by-case
assessment is necessary.
This Guidance emphasises size-related properties associated with speciﬁc hazards and the need to
provide relevant nanospeciﬁc information in order to perform a risk assessment. In addition to the size
of the material, a number of other properties that may be associated with adverse health effects such
as chemical composition, morphology (in particular, aspect ratio), surface properties, crystallinity,
solubility and others) should also be taken into account.6 Particle properties that signiﬁcantly alter
levels/pathways of uptake and/or affect the mobility and persistence in the body are of high relevance.
Increased bioavailability of nanomaterial compared to the corresponding conventional form related to
particular surface properties resulting from, e.g. use of speciﬁc coatings and encapsulation, should be
ﬂagged for risk assessment according to the present Guidance.
1.2.3. Deﬁnition of engineered nanomaterial
Engineered nanomaterials are a subset of the ‘nanomaterial’ that is deﬁned in the European
Commission’s Recommendation of 2011. As outlined in the Novel Food Regulation (EU) No 2015/22837
and referring to Regulation (EU) No 1169/20118 on the Provision of Food Information to Consumers,
Engineered nanomaterial means ‘any intentionally produced material that has one or more dimensions
of the order of 100 nm or less or that is composed of discrete functional parts, either internally or at
the surface, many of which have one or more dimensions of the order of 100 nm or less, including
structures, agglomerates or aggregates, which may have a size above the order of 100 nm but retain
properties that are characteristic of the nanoscale. Properties that are characteristic of the nanoscale
include:
5 It should be noted that ‘nanomaterial’ is a categorisation of a material by the size of its constituent parts. It neither implies a
speciﬁc risk, nor does it necessarily mean that this material actually has new hazard properties compared to its constituent
parts or larger sized counterparts (SCENIHR, 2010).
6 Measurement of these and other relevant properties is also essential for an appropriate characterisation of the material
(Table 1).
7 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 (Text with EEA relevance). OJ L 327,
11.12.2015, p. 1–22.
8 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004 OJ L 304, 22.11.2011, p. 18–63.
• The European Commission recommended that a material with 50% or more of the particles in
the number size distribution in the nanoscale (1–100 nm) should be regarded a nanomaterial.
• Although this recommendation is currently under review, and has not yet been adopted
under the relevant regulatory frameworks, the Scientiﬁc Committee advises to take this and
any future reviews into consideration when assessing safety of materials consisting of
particles.
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i) those related to the large speciﬁc surface area of the materials considered; and/or
ii) speciﬁc physicochemical properties that are different from those of the corresponding
conventional material of the same chemical composition.’
According to the Novel Food regulation, ‘For consistency and coherence purposes, it is important to
ensure a single deﬁnition of engineered nanomaterial in the area of food law’.
The use nanomaterial as a pesticide and the use of the term ‘nanopesticide’ herein is explained
under the sector speciﬁc information of Appendix E.2.
1.3. Scope of this Guidance and when to apply it
This Guidance is aimed at all interested parties and, in particular, applicants and risk assessors such
as EFSA Units and Panels performing risk assessment for substances considered as nanomaterials and
falling under the food law. This means that this Guidance is applicable (at least partially) to the
following materials. The purpose of the scope Section 1.3 is to help applicants and risk assessors to
decide if the safety testing of the product requires the consideration of this guidance.
• For engineered nanomaterials that meet the criteria of the deﬁnition (see
section 1.2.3) according to the most recent revision of the Novel Food Regulation (EU
2015/2283) and Regulation (EU) No 1169/2011, i.e. nanomaterials that, amongst other
criteria, have particle sizes in the deﬁned nanoscale (1 nm to 100 nm). The SC considers
that the application of this Guidance is unconditional for EFSA and for all parties submitting
applications for the use of engineered nanomaterial under the food law.
• For materials that contain particles having a size above 100 nm which could retain
properties that are characteristic of the nanoscale (see Section 3.1), for example related to the
large speciﬁc surface area of the materials or different toxicokinetic behaviour (i.e. signiﬁcant
changes in absorption, distribution and/or metabolism) as compared to its non-nanomaterial.
This may be the case for materials resulting from production processes that are aimed at
reducing the average diameter of materials’ particles (e.g. micronisation). The Scientiﬁc
Committee considers that on a case-by-case risk assessment judgement this Guidance may be
applicable to parties submitting their assessments of such materials.
• For materials that are not engineered as nanomaterial but contain a fraction of
particles that is less than 50% in the number–size distribution (as per the
recommended European Commission deﬁnition, see Section 1.2.2), with one or
more external dimensions in the size range 1–100 nm.9 This is expected to be the case
of manufacturing processes for powdered or particulate food chemicals that typically result in
materials with a range of sizes (see details in Section 4.2.2). Even where the median size of
the particles is generally signiﬁcantly greater than 100 nm, a small fraction (< 50%) is always
expected to be present with at least one dimension below 100 nm. This Guidance is applicable
to parties submitting their assessments of such materials. The Scientiﬁc Committee considers
that the tests as described in this Guidance have to be performed with the representative
material as used in the agri/food/feed chain and as present on the market. For food additives,
for example, the material used for testing should be a ‘food additive EXXX’ as present on the
market, and that is also in compliance with European Commission speciﬁcations. The
applicants must ensure that the testing strategy is selected so that the data could be relevant
for the risk assessment of the fraction in the nanoscale. This may include the application of
this Guidance and the test strategies included herein.
• For nanomaterials having the same elemental composition but that occur in
different morphological shapes, sizes, crystalline forms and/or surface properties as a
consequence, for example, of different production processes, this Guidance is applicable to
each variant as a stand-alone case. Therefore, applicants must undertake a separate
physicochemical characterisation and speciﬁc risk assessment as described in this Guidance for
each distinct nanomaterial having a given elemental composition. The Applicant may also
explore whether a read-across approach can be applicable in these cases (see Section 6.3).
• Nanoscale entities made of natural materials that have been deliberately produced to
have nano-enabled/enhanced10 properties, or that have been modiﬁed for use in the
9 Even though the material contains a low percentage of particles (below the 50% threshold), the actual conditions of use may
result in a substantial exposure (depending on the content in the ﬁnal product) that may be relevant to risk assessment.
10 See ISO/TR 18401:2017.
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development of other nanoscale materials, e.g. for encapsulating (bioactive) compounds (see
Appendix E.6). These materials are within the scope of this guidance for risk assessment.
Other ‘natural’ nanoscale entities may be present in food/feed (e.g. macromolecules, colloids,
micelles, such as naturally occurring nanostructures in homogenised milk) and should not be
considered in the scope of this Guidance.
• Although the European Commission recommendation on a deﬁnition for nanomaterial is
currently under review, and has not yet been adopted under the relevant regulatory
frameworks, the SC advises to take this and any future reviews into consideration when
assessing safety of materials consisting of particles (see Section 1.2.2).
When a material under the scope of this guidance is being risk assessed, its degradation
products in the form of a nanomaterial (e.g. the core material after degradation of the coating), also
have to be considered at all the relevant steps, including the determination of characteristic of the
nanoscale which may affect toxicity (Section 3.1) and exposure assessment (Section 5).
• This Guidance is applicable to materials that meet the criteria of the deﬁnition of engineered
nanomaterial as outlined in Regulation (EU) No 2015/2283 and Regulation (EU) No 1169/
2011. Other materials consisting of particles with size range above 100 nm should also be
considered, if they could retain properties characteristic of the nanoscale, for example related
to the large speciﬁc surface area of the materials or different toxicokinetic behaviour.
• For materials that are not engineered as a nanomaterial but contain a fraction of the particles
that is less than 50% in the number size distribution with one or more external dimensions in
the size range 1–100 nm, the applicants must ensure that the testing strategy is selected so
that the data could be relevant to the risk assessment of the fraction in the nanoscale. This
may include the application of this Guidance and the test strategies included herein.
• Nanoscale entities made of natural materials that have been deliberately produced to have
nanoenabled properties, or that have been modiﬁed for use in the development of other
nanoscale materials, e.g. for encapsulating (bioactive) compounds are within the scope of this
guidance for risk assessment.
1.4. How to use this guidance?
The present guidance has taken a broader overview of the existing scientiﬁc knowledge relevant for
risk assessment of nanomaterials in food and feed. Guidance, as far as possible based on the current
state of knowledge, is summarised in dedicated boxes at the end of sections. However, whilst
highlighting the issues that require attention, it is expected that often a degree of expert judgement
will be needed and therefore a broader scientiﬁc background is also provided.
In general, the applicant is responsible for the best set-up for the tests and a description of the
rationale thereof. Working with a multidisciplinary team is therefore advised. This is not different as for
conventional chemicals.
In order to minimize animal testing, a tiered approach including in vitro tests, as well as directions
for read-across, have been provided.
The present guidance is cross-sectorial, and sector speciﬁc information has been provided in
Appendix E.
2. Data and methodologies
Primary references of particular relevance were identiﬁed by the EG members (up to 18 April 2018).
Also considered were publicly available guidance documents and reports relevant to risk assessment of
nanomaterial in agri/food/feed and produced by European Commission non-food Committees,
international authorities such as the FDA, WHO and JRC, ECHA and EMA. A draft of this Guidance
underwent a public consultation from 12 January to 4 March 2018. The comments received were
considered and have been incorporated where appropriate.
For construction of this Guidance, a problem formulation approach was followed for nanomaterials.
As a result, this Guidance highlights nanospeciﬁc issues only, and will be applied in conjunction to the
existing EFSA Guidances for conventional materials. Other principles of EFSA’s scientiﬁc assessments,
such as weight of evidence (EFSA Scientiﬁc Committee, 2017b), uncertainty (EFSA Scientiﬁc
Committee, 2018) and biological relevance (EFSA Scientiﬁc Committee, 2017c), have been followed
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while developing this Guidance. Also, the principle of the benchmark dose approach (EFSA Scientiﬁc
Committee, 2016) applies to nanomaterial risk assessments.
3. Risk assessment of nanomaterials: general outline
The risk of a nanomaterial is determined by its chemical composition, other physicochemical
properties, its interactions with tissues, and potential exposure levels. The schematic general outline
for risk assessment of nanomaterials is shown in Figure 1 and developed in each of the chapters cited
in the ﬁgure.
Physicochemical characterisation is needed to identify a material as a nanomaterial and decide
whether this Guidance applies (see Section 1.3).
The results from testing of the nanomaterial will give information for hazard characterisation that,
combined with the exposure assessment, will form the basis for the risk characterisation. A particular
case is represented by nanomaterials incorporated in FCMs: in this case, if convincing scientiﬁc
evidence and/or technically valid tests showing the absence of migration are provided, then further
testing may not be needed because, in the absence of exposure, no risk to consumers can be
expected.
Physicochemical characterisation; 
See Section 4; 
Is the material a nanomaterial? 
Yes No 
Yes 
Characteristic of the nanoscale; 
See Section 3.1; 
Does the material have properties that are characteristic of the nanoscale?  
Follow safety 
assessment 
according to 
the relevant 
EFSA 
Guidance for 
conventional 
materials
Yes No
In vitro digestion; 
See Section 6.2.1; 
Does the material quickly degrade in in vitro digestive tract conditions?
No
Assessment of stability in lysosomal fluid and in vitro testing; 
See Section 6.2.2 and 6.5; 
Is there a potential for the material to be biopersistent 
and/or hazardous? 
Hazard identification: in vivo testing 
See Sections 6.7 and 6.8.; 
Are there adverse effects in vivo?
Hazard characterisation 
See Sections 6
Risk characterisation 
See Sections 7
Yes
No
Exposure assessment
See Sections 5
No
Yes
Figure 1: Schematic outline for risk assessment of ingested11 nanomaterials for human and animal
health, focussing on hazard characterisation. A complementing outline for the exposure
part of the assessment is presented in Figure 2.
11 Other routes of exposure like dermal and inhalation are detailed in Appendix E for feed additives and nanopesticides.
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The applicants have to follow the relevant guidance for conventional material and check for
additional information requirements in this present Guidance when the evaluation concerns a
nanomaterial.
There are some general aspects to consider at an initial stage before testing a nanomaterial (the
problem formulation) that is proposed for use in the food/feed chain. If the available information
indicates absorption and distribution of the nanomaterial leading to internal exposure, altered reactivity
or biokinetics (compared with the non-nanomaterial), or persistence of the nanomaterial, these should
be considered as a trigger for in-depth testing.
3.1. Characteristic of the nanoscale which may affect toxicity
As mentioned in Section 1.3, characteristics of the nanoscale which may affect the toxicity of the
material, for example, relate to the large speciﬁc surface area of the materials or different toxicokinetic
behaviour (i.e. signiﬁcant changes in absorption, distribution and/or metabolism). Furthermore, the
following non-exhaustive list of indicators of potential toxicity should be considered when deciding on
an appropriate testing strategy:
1) speciﬁc morphology (e.g. rigid, long tubes or ﬁbres, high aspect ratio nanomaterials,
fullerenes, crystal structure, porosity), carrier materials with cores and shells of different
biopersistence (e.g. multifunctional nanomaterials) (see e.g. Figure 1 and Section 6.2.2 for
further information on biopersistence);
2) complex transformations (e.g. ageing, changes in surface properties, porosity) (see also
Section 4.2.2) or metabolites or de novo formed particles from ionic species (see
Section 6.2.1);
3) altered hydrophobicity/hydrophilicity;
4) persistence/high stability (e.g. in water, fat, or body ﬂuids, lack of degradation/dissolution);
5) increased reactivity compared to equivalent non-nanomaterial (e.g. catalytic, chemical,
biological);
6) targeted or controlled release by the nanomaterial;
7) nanomaterials having antimicrobial activity;
8) different or increased mobility of the nanomaterial in vivo compared to the conventional
non-nanomaterial, i.e. possibility of increased bioavailability and internal exposure (e.g.
transport via macrophages; transport through cell membranes, blood-brain barrier and/or
placenta, delivery systems) and mobilisation potential (e.g. inﬁltration, sorption, complex
formation);
9) interactions with biomolecules such as enzymes, DNA, receptors, potential ‘Trojan horse’12
effects (see Section 6.8.3 on immunotoxicity);
10) bioaccumulation;
11) quantum effects (e.g. altered optical, electronic, magnetic, mechanical or redox properties
in nanoscale materials).
Dekkers et al. (2016) concluded that the aspects of toxicokinetics and human hazard assessment
that are most likely to be inﬂuenced by the nanospeciﬁc properties of the material include:
degradation/dissolution, accumulation, genotoxicity and immunotoxicity (see also draft WHO (2017)
Principles and Methods to Assess the Risk of Immunotoxicity Associated with Exposure to
Nanomaterials, http://www.who.int/ipcs/Immunonano/en).
The metabolism and excretion parameters are important indicators of biopersistence. Persistence of
a substance/material is its ability to continue to remain in the body or the environment. Biopersistence
means that a substance/material is able to withstand those degradations that could lead to its
solubilisation, metabolic degradation/detoxiﬁcation, or clearance from a biological system. The
retention of a biopersistent nanomaterial or its degradation products in the form of a nanomaterial
(e.g. the core material after degradation of the coating) in the body can lead to its bioaccumulation.
Therefore, biopersistence and bioaccumulation of nanomaterials should be carefully considered.
The following should be considered as indicators of a potential for high external exposure:
1) high production volume for a nanomaterial for the ﬁeld of application,
2) existence of several ﬁelds of application of the same material,
12 Effects resulting from particle internalization with subsequent intracellular release of toxicants, either endogenous – e.g.
constituent metal ions – or exogenous – e.g. contaminants adsorbed on particle surface.
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3) high stability in products and/or persistence in the environment,
4) anticipated frequent/high volume use of the products containing the nanomaterial (see
Section 5 on exposure).
Other indicators that are considered to reduce the likelihood of adverse effects of the nanomaterial,
are based on speciﬁc exposure scenarios and/or on the loss of nanospeciﬁc properties. A complete loss
of nanospeciﬁc properties will allow the use of data on corresponding conventional material forms in
the sectorial risk assessment and the nanospeciﬁc risk assessment procedure would no longer be
required.
The following parameters may indicate a loss of nanoproperties or a low exposure to nanoparticles:
1) high dissolution rate13 (e.g. in water, food/feed matrix or body ﬂuids as described in
Section 6.2),
2) high rate of degradability (e.g. biological or photocatalytic) to non-nanosized degradation
products,
3) the presence of/as aggregates rather than agglomerates (e.g. determined by conditions of
production),
4) ﬁxed, permanent bonding in matrices (e.g. stability of matrix, type of bond, end-of-life
behaviour) or effective entrapment in FCMs (e.g. polymer nanocomposites).
Nanostructured modiﬁcations on surfaces, and nanostructures that do not release particles and are
not reactive are generally not expected to cause adverse effects (e.g. nanopores or lotus effect structures
that can be used in ﬁlters and processing equipment). In some instances, however, such applications
could give rise to release of nanomaterial that should be considered (e.g. impact of functional failure14).
In the case of particles entrapped in FCMs, mechanical release of particles by mechanical stress (bending
or elongation occurring in use, surface abrasion) should be considered as well.
The considerations and concepts presented above are further developed in the following Sections.
Characterisation and identiﬁcation of nanomaterial are covered in Section 4. Exposure assessment is
presented in Section 5. Hazard identiﬁcation and hazard characterisation and toxicity testing strategies
are covered in Section 6. Section 7 presents the risk characterisation. Uncertainty analysis is discussed
in Section 8.
More sector speciﬁc information (e.g. for feed additives and for pesticides) is provided in
Appendix E.
4. Physicochemical characterisation of nanomaterial
Clarifying the questions posed by the Terms of Reference and deciding whether they require risk
assessment of applications of nanoscience and nanotechnology to the food and feed chains is part of the
ﬁrst stage of scientiﬁc assessment. This is often referred to as problem formulation, and is a step
preceding the scientiﬁc assessment as a whole. Careful consideration will be needed early in the planning
process (in problem formulation) to ensure an adequate characterisation of nanomaterial, which is
essential for establishing its physicochemical identity both as a pure material and when in food and feed
products. It is also essential to identify changes in the material during storage, as a result of possible
interactions with the product matrix, and after ingestion. In addition, monitoring the behaviour of
nanomaterial in terms of biodistribution, speciation and quantiﬁcation is crucial for hazard assessment
(i.e. through toxicological and toxicokinetic studies). The physicochemical characteristics of a
nanomaterial are important as they can affect the outcome of the risk assessment (e.g. different sizes,
shapes, crystal structure (phase) and surface properties of nanomaterials of the same chemical
composition may show different toxicokinetic behaviours or toxicities). Nanosized particles of the same
elemental composition may be present with different shapes, sizes, crystal structures (phases) and/or
surface properties, for example as a consequence of a different production process. For each distinct
nanomaterial, the applicant must undertake a separate physicochemical characterisation and risk
assessment as described in this Guidance. It should also be noted that nanomaterials require speciﬁc
attention with view to the representativeness of sampling and proper dispersion state (SCENIHR, 2007).
As an essential requirement, all dossiers related to nanomaterials as described in Section 1.3 have
to be accompanied by thorough information on the particle size distribution and other parameters as
13 It should nevertheless be recognized that materials can generate, while dissolving, potentially more toxic smaller particles or
ions or molecules.
14 Functional failure is a topic of good manufacturing practice and must be technically avoided.
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described in Table 1 (in Section 4.2.1) of the material obtained through validated methods based on
suitable analytical techniques as detailed in the present Guidance (see Appendix C).
The physicochemical characterisation of the material under investigation is relevant to the:
1) decision as to whether the material has to be considered for nanospeciﬁc risk assessment
under this Guidance (see Section 4.1);
2) full determination of the physical and chemical identity of the pristine material (see
Section 4.2);
3) physicochemical characterisation of the material in test media used in toxicokinetic and
toxicological studies, which is needed before, during and after the studies (see Section 4.3);
4) physicochemical characterisation of the material in complex matrices e.g. product
formulations, which is needed for exposure assessment (see Section 4.3).
4.1. Framework for distinguishing nanomaterials and non-nanomaterials
The ﬁrst step is to consider whether a material falls under the scope of this Guidance according to
Section 1.3. Therefore, it is helpful to determine if a material meets the criteria of the European
Commission recommendation for a deﬁnition (under review) of nanomaterial. In many situations, this
information can be deduced from the existing data from the production process and accompanying
material characterisation. In other situations, it is necessary to measure the determining physical
properties, i.e. size and, where applicable, other nanospeciﬁc properties (e.g. surface area)
to decide whether a material falls within the scope of this Guidance. In such cases, it is essential to
select appropriate techniques in relation to the speciﬁc material under investigation.
The EU project NanoDeﬁne (www.nanodefine.eu15) has developed guidance for the selection of
appropriate techniques and interpretation of results. Respective publications, technical reports and
protocols are available from http://www.nanodefine.eu/index.php/nanodefine-publications. The project
addresses the recommended European Commission nanomaterial deﬁnition, i.e. size and size
distribution as well as volume speciﬁc surface area, where applicable. It provides a decision-ﬂow
scheme and is supported by an e-tool and methods manual. (see http://www.nanodefine.eu/index.
php/nanodefiner-e-tool). The decision as to whether the material has to be considered for nanospeciﬁc
risk assessment under this Guidance can be supported by using this ﬂow scheme.
The ﬂow scheme is based on a tiered approach. Tier 1 is based on screening methods, namely for
determination of volume speciﬁc surface area (VSSA, by the Brunauer Emmett Teller (BET) method as
described by Kreyling et al., 2010;.) for dry powders and of equivalent particle size with light scattering-
and particle mobility-based methods (e.g. dynamic light scattering (DLS), centrifugal liquid sedimentation
(CLS)) for dispersions. For VSSA criteria, further details are described in Wohlleben et al. (2017). Tier 2
relies on more sophisticated particle size analysis methods, e.g. electron microscopy. A schematic
overview of the decision tree as developed by NanoDeﬁne is provided in Appendix A. It should be noted
that in an initial step the already available material information (e.g. surface area and density) is
considered that may be applicable and result in a decision without further testing.
For materials with a median particle size above 100 nm, a second criterion, namely properties
characteristic of the nanoscale, may be relevant for risk assessment. Based on the provided
information, these materials should be assessed on a case-by-case basis as described in this Guidance.
However, size remains an essential criterion and the NanoDeﬁne decision tree and especially its
implementation in the NanoDeﬁner e-tool therefore remain helpful for the selection of appropriate
characterisation techniques expected to be used under this Guidance.
Any speciﬁc properties or effects of a nanomaterial are intrinsically linked to the stability of its
nanoscale features. Where a nanomaterial loses these, e.g. due to degradation by dissolution, it will
not be expected to behave any differently from its corresponding non-nanomaterial. For this reason,
safety concerns over orally ingested nanomaterials are related mainly to those that are able to survive
the digestive system, potentially resulting in (nano)particles being translocated to other parts of the
body (see in vitro digestion Section 6.2.1) or exert local adverse effects in the gastrointestinal tract.
Where a material is regarded as within the scope of this Guidance, a detailed physicochemical
characterisation is required, as described in the following Sections.
15 Consortium of 28 Partners form European research institutes and universities, metrology institutes, nanomaterial producers
and instrument manufacturers.
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4.2. Pristine material characterisation
4.2.1. Parameters
The characterisation of the material under investigation is essential to unambiguously deﬁne its
identity. Similar to conventional chemicals (e.g. food additives), names, identiﬁers and a number of
physicochemical parameters need to be measured. In addition, a broader range of parameters needs
to be addressed for nanomaterials, relating on the one hand to material identity, and to properties that
may be of biological/toxicological relevance on the other.
Owing to the current gaps in knowledge relating to properties, behaviour and effects of
nanomaterials, it is difﬁcult to identify a deﬁnitive shortlist of those parameters that can adequately
describe a nanomaterial in terms of both physicochemical and toxicological aspects. Different
international expert committees and working groups have considered certain parameters important for
safety assessment of nanomaterials. These are presented as a list of parameters to be reported in
Table 1. This list is not deﬁnitive, however, and has to be changed in future to include more, less or
different parameters that might be added with the advancement of scientiﬁc insights as well as
legislative developments.
The parameters in Table 1 have been derived from the reports published by the Scientiﬁc
Committee on Emerging and Newly Identiﬁed Health Risks (SCENIHR, 2009); the OECD Working Party
on Manufactured Nanomaterials in its exploratory project on ‘Safety testing of a representative set of
nanomaterials’ and the revised version of its ‘Guidance manual for the testing of manufactured
nanomaterials’ (OECD WPMN, 2009a, 2010); the International Organization for Standardization; the
EU’s Scientiﬁc Committee on Consumer Safety (SCCS, 2012); the ProSafe16 project (European Union
H2020 project ProSafe, 2015–2017); the ECHA Guidance on the preparation of registration dossiers
that cover nanoforms (ECHA, 2017b); the ECHA Appendix R.6-1 for nanomaterials applicable to the
Guidance on QSARs and Grouping of Chemicals (ECHA, 2016); and a recent publication by DeLoid
et al. (2017a).
In some instances, not all of the parameters listed in Table 1 (and Table B.1 in
Appendix B) may be relevant for a given material as determined by its composition, function,
purpose and/or intended use. In such cases, justiﬁcation should be provided for the characteristics
that are not determined or provided, or to explain why they were not deemed applicable to a
particular nanomaterial.
Currently, no generally accepted systematic nomenclature exists for nanomaterials. ISO TC 229 has
drafted a series on vocabulary and terminology of NMs (ISO 80004 series). The CODATA-VAMAS
Working Group on the Description of Nanomaterials has published a ‘Uniform Description System for
Materials on the Nanoscale’ (CODATA-VAMAS Working Group on the Description of Nanomaterials,
2016) that proposes in detail the information that should be supplied to describe a nanomaterial in the
best possible and most unambiguous way. The SC suggests that applicants follow the schemes
proposed by ISO and the CODATA-VAMAS Working Group when naming a nanomaterial.
In some instances, however, the material may be too complex to deﬁne precisely in terms of
chemical composition and stoichiometry. Examples could be complex iron oxide hydroxides or
polymers. Other examples include materials already authorised for use in FCMs such as a ‘butadiene,
ethyl acrylate, methyl methacrylate, styrene copolymer (either not crosslinked or crosslinked with
divinylbenzene or 1,3-butanediol dimethacrylate) in nanosized particles, (FCM substance Nos 998, 859
and 1043)’. In simpler materials (e.g. metal oxides), the stoichiometry in the surface layer may also
differ from the core of the particle. In these cases, the material should be described as exactly as
• The decision-ﬂow scheme developed by NanoDeﬁne project may be used to determine
whether or not a material is nanomaterial according to the recommended European
Commission deﬁnition, and to identify relevant methods and tools for characterisation.
• Where a material is regarded within the scope of this Guidance, detailed physicochemical
characterisation must be provided as an essential element of safety assessment.
16 The EU funded ProSafe project supported the aims of EU Member States in their EU and international efforts (OECD; http://
www.oecd.org/science/nanosafety/, and EU-US CORs; http://us-eu.org/communities-of-research/) regarding risk assessment,
management and governance focussing on regulatory oriented toxicology testing of nanomaterials, exposure monitoring, life
cycle assessment, and disposal and treatment of waste nanomaterials.
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possible. In any instance, the elemental composition must be given (e.g. the empirical formula) and
additional information on the starting material, the reaction process(es) and the intended composition
should be provided.
For nanomaterials consisting of multicomponent particles, the overall material should be described
together with the individual components. In the case of a nanomaterial consisting of a mixture of
different types of particles, each component should be described individually according to Table 1, and
the ratio of all components in the mixture should be provided. The structure of the particles should
also be described as exactly as possible. This includes information on the distribution of individual
components in the particle, e.g. homogeneous mixture, core/shell and coatings.17 Coating is a thin
layer of a component that covers completely or partially the surface of a particle and is strongly bound
(either chemically or physically) to the surface. Stabilisers (or dispersants) are substances that are
added to a dispersion of nanomaterial to prevent agglomeration, aggregation or sedimentation. They
are not seen as a part of the particle and should be reported under ‘formulation’. Substances strongly
bound to the particle surface for stabilisation purposes should be reported under ‘Surface (chemical)
composition’ or as coating (when covering the entire particle).
Changes in manufacturing process(es) can not only lead to signiﬁcant differences in the
physicochemical and morphological characteristics of nanomaterials between different batches, but
may also introduce new/different impurities and residual materials. Furthermore, for some materials,
fundamentally different production processes are in place (e.g. for pyrogenic vs. precipitated silica as
described in Fruijtier-P€olloth, 2012; sulfate or chloride process for converting titanium ores into TiO2)
that largely deﬁne the surface and crystallographic structure, and thus the particle properties. It is
therefore important to provide a description of the manufacturing process.
Table 1 is also meant to be applicable for multicomponent materials (e.g. core-shell or coated
particles). Table 1 is therefore structured into a Section for general and ensemble information on the
overall material and a Section on detailed chemical and physical information for its individual
components. In the case of a monocomponent particle (e.g. uncoated TiO2), information has to be
provided for component 1 only. Examples for component 2 information are details in Table 1B of
Appendix B. Some of the general parameters of Table 1 (and Table B.1 in Appendix B) might already
be required under the sectorial legislations. Appendix C provides a list of corresponding techniques for
each parameter.
Table 1: Descriptors and parameters on what data are to be provided for characterisation of pristine
material, together with hypothetical examples (not food related, not consistent, data for illustrative
purposes only). For clarity, the Table is divided in the different Sections: Table 1A for Information on the
overall material, Table 1B for Information on the chemical components, and Table 1C for extrinsic
properties
Table 1A: Information on the overall material
Item
Parameters
(incl. speciﬁcation
ranges)
Explanation Example
Name The name used in the submitted application. This
could for example be the name of the
nanomaterial
Ti-Max
Description
Short description of the
material
Provide a brief description of the material Nano grade titania coated with a
protective silica layer
Intended use Describe the foreseen use and function of the
material
UV protection to be incorporated in
food contact materials
17 For the purpose of this Guidance, a material is considered as a ‘coating’ where it is bound or adhered to the surface of a
nanomaterial in the form a continuous outside layer, or a ‘shell’ where it is in the form of a nanosized covering/casing in which
a (nano)material may be contained.
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Item
Parameters
(incl. speciﬁcation
ranges)
Explanation Example
Material composition
and purity
Relative amounts of
components and
impurities (in mass %)
Relative amount of the constituents in mass %, as
well as chemical identity of any impurities and
their relative amounts in mass % should be
provided
TiO2 97.1%  0.3%(a)
SiO2 2.8%  0.1%
purity: 99.9%
impurities: Fe2O3 0.1%  0.02%
Speciﬁcations composition:
TiO2 97.0%  0.5%
SiO2 3.0%  0.2%
Purity ≥ 99.7%
Elemental
composition
Empirical formula of the
complete material or
relative amounts of
element (in mass %)
The relative elemental composition of the particle
should be provided as the simplest positive integer
ratio of atoms present in the material.
Alternatively, the relative mass amounts of the
contained elements may be provided
Ti26SiO54
Ti 58.23% (m/m)
O 40.32% (m/m)
Si 1.31% (m/m)
Particle size
Agglomeration or
aggregation state
Mean and median
diameter [nm]
graphical diagrams of
size distribution
Data on primary and secondary (agglomerates and
aggregates) particle size, number-based size
distribution and mass-based size distribution of the
material should be provided as measured by more
than one independent technique, one being
electron microscopy (EM) if the measurement is
feasible (cfr. current publications on critical issues
of EM, e.g. drying, artefacts). If EM cannot be
applied, the use of a different imaging technique is
suggested. Information on the used
characterisation techniques and methods (e.g.
which techniques, instruments, settings, SOPs,
method performance characteristics, data
conversion) should be provided. Data should be
provided both as median particle diameter (x50 in
nm), with an indication of the width of the
distribution (e.g. standard deviation, in nm) and
with an estimate of the uncertainty of the median
diameter ( expanded uncertainty, conﬁdence
level 95%, in nm). Together with the size
distribution information on the lower and upper
cut-off limits for the calculation of the relative
amount of particles has to be provided.
Data obtained with a particle counting technique
(such as EM) should be provided as number-based
size distributions.
Data obtained with other techniques (such as
centrifugal liquid sedimentation (CLS) or dynamic
light scattering (DLS)) should be provided in the
original metrics as produced by the technique (e.g.
intensity, volume- or mass-based). In these cases,
a conversion to the number-based size distribution
must also be provided, including information on
the algorithms used for conversion and the
associated uncertainty.
Primary particles:
TEM data:
median diameter x50 = 85 nm
(uncertainty = 5 nm, 95%
conﬁdence level), width of
distribution: SD = 15 nm
mean diameter: 89 nm
(uncertainty = 6 nm, 95%
conﬁdence level), width of
distribution: SD = 13 nm
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CLS data:
median diameter x50 = 97 nm
(uncertainty = 19 nm, 95%
conﬁdence level), width of
distribution: SD = 8 nm)
mass-based arithmetic mean
diameter: 105 nm
(uncertainty = 10 nm, 95%
conﬁdence level), width of
distribution: SD = 13 nm)
Guidance on nanotechnologies in the food and feed chain
www.efsa.europa.eu/efsajournal 21 EFSA Journal 2018;16(7):5327
Item
Parameters
(incl. speciﬁcation
ranges)
Explanation Example
Most light scattering based techniques (incl. CLS
and DLS) provide light intensity-based
distributions, which can be converted into their
equivalent volume- or mass-based distributions
using Mie light scattering theory. As this step can
introduce considerable errors on the results due to
the unknown refractive index of nanoparticles, the
parameters used in the conversion must be
reported in detail. Reporting of the original light
intensity-based results can help to assess the
reliability of the results.
For each material, at least two graphs showing
particle size distributions shall be shown: one with
the relative number versus size (continuous graph
or histogram) and one with number-weighted sum
function (cumulative numbers)
[plus diagrams as above]
Aggregates:
[provide size data in the same
manner as for primary particles,
see above]
Speciﬁcations size: median
diameter 85 nm  5 nm
Particle shape
Description of the
shape, porosity, aspect
ratio, EM image of the
nanomaterial
Information should be provided on the particle
shape, aspect ratio and whether or not the
material is porous. This should also include
appropriate EM images to support the description.
For powders, information on porosity can be
obtained from gas adsorption measurements
Irregular particles, aspect ratio 1 to
3, non-porous
Structure
Description of the
structure, including
(relative) thickness of
structural elements
Spatial distribution of the components (e.g.
homogeneous mixture, core–shell, surface coating)
should be provided. A graphical sketch for non-
homogeneous particles should be provided to
demonstrate the schematic distribution if
applicable. The sketch should reﬂect schematically
the shape of the particles. Information should be
provided on any surface coatings or shells in terms
of coating or shell material and the proportion of
the coating or shell material in relation to the mass
of the nanomaterial
TiO2 particles with a surface
coating of silica. Thickness of the
coating 1.8 nm ( 16% (g/g))
TiO2
SiO2
Surface chemical
composition
Description of the
composition of the
groups or coatings on
the particle surface
Information on chemical characteristics of the
particle surface, e.g. the components bound to the
surface, the presence of functional groups (e.g.
carboxy, amino, hydroxy). Information should also
be provided on any surface contamination
Hydrophilic acidic silica surface, free
–OH groups
Production process
Name of the production
process of the material
The production process used to prepare the entire
nanomaterial (i.e. not of the individual
components in cases of multicomponent particles)
should be described as it can have a signiﬁcant
effect on the properties of the nanomaterial
SiO2 precipitation on dispersion of
wet-chemically synthesised TiO2
particles
Surface area
MSSA [m2/g]
VSSA [m2/cm3]
Where appropriate (for powder materials) data on
mass and volume speciﬁc surface area of the
material should be provided
The conditions under which the measurements
took place have to be reported
MSSA 15 m2/g (via BET according
to ISO 9277)
VSSA 65 m2/cm3 (via BET according
to ISO 9277 and assuming a
density value of 4.1 g/cm3)
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Item
Parameters
(incl. speciﬁcation
ranges)
Explanation Example
Surface charge
Zeta potential [mV]
Zeta potential values along with the conditions
under which measurements were made (e.g. pH,
ionic strength) should be provided
Zeta potential: 26 mV (deionised
water, pH 8), Isoelectrical point: pH
2.2, method: electrophoretic light
scattering according to ISO 13099-2
Appearance
Description
Describe the appearance, e.g. ‘white powder’ White powder
Melting point
m.p. [°C]
Provide the melting point of the nanomaterial 1,840°C
Boiling point
b.p. [°C]
Provide the boiling point of the nanomaterial 2,900°C
Density
Density [kg/m3]
Information on the density (specify type of density,
e.g. bulk, pour) of nanomaterial should be
provided
Bulk density: 4.1 g/cm3
Porosity
fraction of the volume
of voids over the total
volume [%]
Information on the porosity of nanomaterial should
be provided
Non-porous
Dustiness Provide the dustiness for powder material (e.g.
EN15051)
According to DIN EN 15051 B:
Wr: 280 mg/kg
Wi: 13,200 mg/kg
pH The pH value of a dispersion of the nanomaterial
should be provided along with description of the
conditions under which the measurement was
carried out
pH 5.8, 10 g/L, 20°C
Formulation
Formulation medium
Dispersing agents
(stabilisers)
Auxiliaries
Concentration of
nanomaterial in
dispersion
Description should be provided to indicate the
form in which a nanomaterial is present in a
formulation, e.g. powder, dispersion. Information
should also indicate other material(s) with which
the nanomaterial may have been mixed/
formulated. This should include information on any
dispersants/stabilisers and other auxiliaries (e.g.
preservatives, processing aids, etc.) used. The
concentration of the nanomaterial in the mixture
should be provided, in terms of both mass (g/kg)
and particle number (n/kg), as well as the mass of
the material as present in its ionic form
Dry powder
(a): The measurement uncertainty should be reported as detailed in Section 4.4.2.
Table 1B: Information on the chemical components(a)
Item
Parameters
(incl. speciﬁcation
ranges)
Explanation Example
Component 1
Chemical name
Systematic/IUPAC
name;
chemical name
Where available systematic/IUPAC name of the
substance that makes up component 1 of the
nanomaterial should be provided. Alternatively, the
chemical name that describes the chemical
composition of the component should be provided
based on the best available information –
e.g.’modiﬁed from XX’ where XX = the nearest
chemical name
Titanium dioxide
Titanium (IV) oxide
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Item
Parameters
(incl. speciﬁcation
ranges)
Explanation Example
Trade name,
common name,
other names,
synonyms
Names
Any common names, synonyms, trade names and
other names for the component should be
provided
Titania
CAS number
EINECS/EC number
E number
other registry
numbers
Registry numbers
related to the
constituent substance,
if available
CAS number, EINECS/EC number, E number or
other registry/database numbers related to the
component should be provided (where available)
CAS number: 13463-67-7, 1317-80-2
(Rutile)
ECHA Info card: 100.033.327
EINECS/EC number: 236-675-5
E number: E 171
Formula
Molecular and structural
formula (where
applicable) of the
constituent substance
Molecular and structural formula (where
applicable) of the constituent substance should be
provided
TiO2
Relative molecular
mass (molecular
weight) for
molecules or relative
atomic mass (atomic
weight) for elements
[g/mol]
Molecular weight or atomic weight (for elements)
(g/mol) should be provided for the component
79.866 g/mol
Elemental
composition
Empirical formula of
this component
The relative elemental composition of the
component should be provided as the simplest
positive integer ratio of atoms present in the
material
TiO2
Crystal form
Form and phase
Description of crystalline form (amorphous,
polycrystalline, crystalline including speciﬁcation of
phase) should be provided, including any
crystalline impurities
Crystalline, rutile phase
Purity of the
component
Relative amount of the
constituent in mass %;
and name(s) and
amount(s) of any
impurities in mass %
Relative amount of the constituent in mass %, as
well as chemical identity of any impurities and
their relative amounts in mass % should be
provided
Purity 99,9%
Impurities: Fe2O3 0,1%
Production process
component
Name of the production
process
The production process of the component should
be described as it can have a signiﬁcant effect on
the properties of the nanomaterial, e.g. pyrogenic
or precipitated silica, sulfate or chloride process for
TiO2.
Sulfate process
Component 2
In case of
multicomponent
particles:
Component 2, 3, etc.
In case of multicomponent nanomaterial the same
information as for component 1 should be
provided for all other components individually
The full data sheet for the example
including information on
component 2 (SiO2) can be found
in Appendix B
(a): A material may consist of different chemical components and each component should be addressed in the physicochemical
characterisation.
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4.2.2. Speciﬁcations and representativeness of the test material
In view of the potential signiﬁcant differences in the physicochemical characteristics of nominally the
same nanomaterial resulting from variations in the manufacturing process, or from being
produced by different manufacturers, or by ageing effects (e.g. agglomeration/aggregation,
sedimentation) a detailed and comprehensive proposed speciﬁcation for the pristine (as produced)
nanomaterial intended to be used in food/feed should be provided by the applicant. The proposed
speciﬁcation should provide the acceptable range for each physicochemical parameter in view of the
batch-to-batch variation and ageing effects. This information will be used by the risk assessor to
decide whether or not the batch(es) used in the toxicity texting could be considered representative for
risk assessment of the use in food/feed. More speciﬁc guidance on the number of batches and
batch-to-batch variation is provided in the relevant guidance for conventional materials (e.g. EFSA ANS
Panel, 2012). No more speciﬁc guidance on ageing (nor on homo/hetero agglomeration/aggregation) can
be provided as little is known about complex transformation and the analytical tools are to be developed.
As mentioned in Section 1.3, this Guidance also applies to materials that are not engineered as
nanomaterial but contain a fraction of particles, less than 50% in the number–size distribution, with
one or more external dimensions in the size range 1–100 nm. This is expected to be the case of
manufacturing processes for powdered or particulate food chemicals that typically result in materials
with a range of sizes. Even where the median size of the particles is generally signiﬁcantly greater than
100 nm, a small fraction is always expected to be present with at least one dimension below 100 nm.
For re-evaluations of authorised materials (i.e. food and feed additives), the test requirements
stipulated in current EFSA guidance documents and European Commission guidelines for the intended
use in the food/feed area apply in principle to food chemicals containing a fraction of particles with at
least one dimension below 100 nm and adequately conducted toxicity tests should detect hazards
associated with such food chemicals, including their nanoparticulate fraction. In such cases of
re-evaluation, however, it is also essential that thorough information on the size distribution of the
material is provided and the assessment should consider whether the material as a whole retains
Table 1C: Extrinsic (more media dependent) properties of the material as it is used on the market
Item
Parameters
(incl. speciﬁcation ranges)
Explanation Example
Stability
Stability of the nanomaterial
Provide information on the physical and chemical
stability of the nanomaterial and coatings (if
applicable). Conditions under which stability is
tested need to be reported and justiﬁed
Report on relevant
stability studies
Solubility (see glossary)
Solubility (proportion of solute in
solvent at room temperature) [g/L]
Degradation rate [g/(L*h)]
Data on solubility of the nanomaterial in relevant
media along with description of the media and the
conditions under which the measurements were
made should be provided. Note that solubility
should not be confused with dispersibility of poorly
soluble nanomaterials.
Data on degradation rate and the conditions under
which the measurements were made should be
provided for slowly dissolving nanomaterials
Poorly soluble in water
Dispersibility For poorly soluble dispersible nanomaterials,
information should be provided on dispersibility in
terms of a relative amount of the particles that
can be dispersed in a suspending medium. The
information should include stability of the
dispersion in the given medium and the conditions
applied (e.g. ionic strength and pH)
Best dispersibility in
water at pH 8.2, max.
50 g/L, stability of
dispersion of the
particles (DLS) at least
48 h
Reactivity where applicable
Chemical reactivity
Catalytic activity (incl. photo-)
Information should be given on chemical reactivity
of the nanomaterial as provided (including any
surface coating). Information on catalytic
(including photocatalytic) activity, and reactive
radical formation potential of the materials should
also be provided
Report on relevant
reactivity studies
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properties that require risk assessment according to this Guidance. For example, EU speciﬁcations for
TiO2 (E 171) should include a characterisation of particle size distribution present in TiO2 (E 171) used
as a food additive. The measuring methodology applied should comply with this Guidance.
4.2.3. Techniques and methods
Care should be taken in the selection of characterisation techniques, the evaluation of results and
their documentation. It is known that the results obtained from different particle size measurement
techniques may differ because they address slightly different physical parameters, e.g. hydrodynamic
diameter vs. geometric diameter (Domingos et al., 2009). In other words, particle size analysis
methods produce method-deﬁned or procedurally deﬁned size values. As a result, the best suited
technique depends on the physical and chemical properties of the nanomaterial, as well as on the
intended use of the size values. Moreover, particle size distribution data are usually reduced to an
average value. There are differences in the types of averaging between methods, which can amplify
the already existing differences between methods.
In a comparison of most currently available techniques, Babick et al. (2016) demonstrated that
signiﬁcant differences were observed in the results for a number of industrial materials. The observed
differences were mostly related to the technique-speciﬁc way of size determination since all other
inﬂuences on the result (e.g. data handling, sample preparation, differences in test materials) were
minimised by the study design. As an example, the use of some analytical methods, such DLS, may
not be optimal for measuring nanomaterials that have a low refractive index (such as nanosilica,
polymer encapsulates, etc.), because that can impact the intensity with which the light is scattered.
Therefore, although nanoparticles of less refractive materials would be detected by DLS, the limit of
detection (LOD) in terms of particle size would be high. This means that size measurements of such
materials by DLS will likely be skewed towards measuring larger sized particles, and particles and
agglomerates/aggregates in the lower range of the nanoscale might not be measured accurately. For
these reasons, it is required that the size parameter should always be measured by at least two
independent techniques, one being electron microscopy. If electron microscopy is not applicable (e.g.
for some organic nanomaterials), it is recommended to use another imaging technique instead of
electron microscopy.
Keeping the existing recommended deﬁnition of nanomaterial in view, it should be straightforward
to regard a particulate material as nanomaterial when it has been intentionally produced to have the
particle size distribution in the nanoscale (1–100 nm). However, it may not be easy to decide the
nanomaterial nature of a material if it has not been produced as such as a nanomaterial but contains a
fraction of the particles in the nanoscale. A typical example of this can be a micronised material
produced to have particle sizes in the micrometer range, but also contains a fraction of the particles in
the nanoscale. In the absence of an upper size cut-off threshold for particles to be included in the
determination of 50% in numbers in the current recommended deﬁnition, it is difﬁcult to decide
whether or not the whole material should be regarded a nanomaterial. This is where other
(supporting) criteria, such the use of VSSA, or conﬁrmatory analytical tests, have been proposed in the
decision scheme developed by NanoDeﬁne project. The scheme provides a structured way for deciding
whether or not a material should be regarded as nanomaterial, and under what conditions a suitable
analytical technique may be needed to conﬁrm or exclude it as a nanomaterial. In all borderline cases,
the use of imaging techniques based on electron microscopy has been recommended.
Several techniques are available for determination of the various parameters listed in Table 1. In
many instances, there is more than one suitable technique available, each with advantages and
disadvantages for speciﬁc materials and size ranges. In the literature, there are reviews assessing the
suitability of different techniques for a range of nanomaterials (Bowen, 2002; Hassell€ov et al., 2008;
Domingos et al., 2009; Linsinger et al., 2012; Peters et al., 2014b; Babick et al., 2016). An overview of
techniques commonly used for the characterisation of nanomaterial is given in Appendix C. The
selection of the appropriate technique is the responsibility of the assessor/applicant in charge and
depends on the parameter and the chemical nature of the material. For the size-related parameters, a
technique selection support is provided by the NanoDeﬁne e-tool and method manual (available from
http://www.nanodefine.eu/index.php/downloads/nanodefine-technical-reports).
Sampling and sample preparation are often crucial steps in the overall analytical process. They
usually contribute the largest uncertainty to the result. A critical issue in the sample preparation of
nanomaterial is the proper dispersion of particles. This issue is addressed in detail in Section 4.3.2.
General guidance for sampling also applies to the characterisation of nanomaterial. Special attention
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has to be paid to sampling, e.g. minimum sample size because of the particulate nature of the
analytes (Ersbøll et al., 2010)) and possible segregation and stratiﬁcation effects (Br€uning, 2017).
4.3. Characterisation and quantiﬁcation in matrix
Although detection and characterisation of a nanomaterial prior to use in food/feed and FCM
applications (i.e. pristine material) may be relatively straightforward, it is more challenging in biological
tissues and food products because of the presence of complex matrices, and the usually low
concentrations of the nanomaterial. In particular, biological matrices as well as food and feed also
contain a wide range of natural structures – including some in the nanoscale – that makes it difﬁcult to
separate, detect, and identify nanomaterial in these matrices.
The characterisation of nanomaterial in a matrix is relevant for various aspects of risk assessment,
including:
• hazard identiﬁcation and characterisation (in vitro, in vivo, in silico and absorption, distribution,
metabolism and excretion (ADME) studies); the relevant matrices may be: water, feed, in vitro
testing media, biological tissues and ﬂuids;
• exposure assessment (quantiﬁcation of nanomaterial in food/feed, migration from FCM); the
relevant matrices may be: feed, food, food supplements, FCMs, food simulants.
Furthermore, the detection and quantiﬁcation of nanomaterial in food, feed and FCM may be
necessary when enforcement measures are introduced, e.g. to monitor maximum permitted levels.
Some guidance on the detection and identiﬁcation of nano-objects in complex matrices is given by
CEN TC 352 (2018).
4.3.1. Characterisation in agri/food/feed products
It is currently difﬁcult to distinguish an intentionally added nanomaterial from background levels of
the same materials/substances in nanosized or non-nanosized particle form that may be present in
agri/food/feed products, especially when they are present at low levels. Appropriate methods (e.g.
stable isotope analysis, elemental ﬁngerprinting) can be applied to distinguish the intentionally added
nanomaterial from background levels of the same or similar materials of geogenic, biogenic or
anthropogenic origin.
When characterisation of nanomaterial in food/feed matrices is difﬁcult owing to the current limited
availability of analytical methods, possible food/feed matrix interactions of the nanomaterial may be
determined using food simulants (e.g. water, oil, ethanol, acetic acid or simulants representing the
characteristic composition of the target food, e.g. starch for carbohydrate-rich foods). However, the
use of a simulant creates an uncertainty, as extrapolation from the results obtained with the simulant
may not fully reﬂect the nanomaterial properties in a real food. With method development and
availability, such characterisation of nanomaterial can be expected to shift from food simulants to real
food/feed matrices.
• Detailed characterisation must be provided for each nanomaterial in pristine form (as
manufactured), including unambiguous description of the material’s identity and relevant
physicochemical properties as described in Table 1. Justiﬁcation must be provided for the
characteristics that are not determined or provided, or deemed not applicable to a particular
nanomaterial.
• The data must be relevant to the core nanomaterial and, where applicable, other substance
(s) that may have been used for surface modiﬁcation/coating.
• The techniques used for characterisation must be appropriate for the type of nanomaterial
(examples provided in Table 1B).
• Particle size parameters must always be measured by at least two independent methods
(one being electron microscopy). Other parameters should also be preferably measured by
more than one method. Special attention should be paid to protocols used for sampling,
sample preparation and dispersion of particles.
• A description of the manufacturing process must be provided along with data to indicate any
batch-to-batch variations, and/or due to material ageing. In cases of a signiﬁcant variation,
speciﬁcations should be provided for the acceptable range for each parameter.
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4.3.2. Characterisation in test media for in vitro and in vivo testing and in
biological matrices
For the toxicological assessment of nanomaterial, it is essential to know in which form the
nanomaterial is presented to the test systems. In addition, characterisation of nanomaterial in the test
system is relevant to determining the effect of the test medium/formulation (and its constituents) on
the characteristics and properties of the nanomaterial so that the validity of the toxicity test outcome
may be determined and to allow comparison with the nanomaterial in the food/feed matrix to which
exposure takes place.
For in vitro testing as well as for administration of nanomaterial in in vivo studies it is essential that the
nanomaterial is properly dispersed in the medium. Dispersion protocols have been developed and
published for a number of nanomaterial and purposes (Bihari et al., 2008; Jacobsen et al., 2010; Jensen
et al., 2011; Taurozzi et al., 2012a–e; Hartmann et al., 2015; Mast and De Temmerman, 2016; OECD
TG318 (OECD, 2017b)). More dispersion protocols are available via the websites of international
organisations (e.g. OECD – http://www.oecd.org/science/nanosafety/; European Commission-JRC –
https://ec.europa.eu/jrc/en/scientific-tool/jrc-nanomaterials-repository; US-FDA – https://
www.fda.gov/scienceresearch/specialtopics/nanotechnology/default.htm) and of their respective
research projects (e.g. NanoGenoTox – http://www.nanogenotox.eu; Nanopartikel – http://www.nanopa
rtikel.info; NanoDeﬁne – http://www.nanodefine.eu/; NANoREG – www.nanoreg.eu).
In the absence of standardised dispersion protocols, the dispersion efﬁciency of the applied
protocol and the stability of the dispersion should be tested and documented. Apart from their
tendency to agglomerate and aggregate (which should be addressed by a proper dispersion protocol
and use of dispersants that are compatible with the biological test system), nanomaterial may adhere
to the wall of glass ware, tubing, pipette tips, vials etc. see Section 6.9.2). Appropriate analytical
techniques depend on the type of nanomaterial and medium.
For in vitro studies, the nanomaterials may have to be characterised in the exposure medium at the
start and end of the experiment to conﬁrm actual presence in the test system and to observe potential
changes that the materials may undergo (Section 6.9.1). Characterisation in these cases should
include the number-based particle size distribution and concentration. Owing to the possible presence
of other particulate materials in the test medium (e.g. proteins) it is mandatory to use a chemically
speciﬁc method (e.g. single particle inductively coupled plasma mass spectrometry (spICP-MS) or
transmission electron microscopy–energy-dispersive X-ray spectroscopy (TEM–EDX)) for these
measurements. Non-speciﬁc methods such as DLS or CLS are not suited unless it can be demonstrated
that the material under investigation is the only (nano)particulate material in the test medium.
ADME studies (as described in Section 6.3) require the measurement of nanomaterial in body ﬂuids,
tissues and excreta. It is not only relevant to quantify the amount of nanomaterial present, but also to
specify in which form the nanomaterial is present in these compartments. This includes chemical
composition, size and shape, but may also refer to surface modiﬁcations and other parameters relevant
to the nanomaterial properties. Since many methods for nanomaterial analysis in biological matrices are
rather complex and laborious, a tiered approach can be considered for speciﬁc cases. For inorganic
nanomaterial that contains elements with very low background levels in the matrix the samples can ﬁrst
be screened by non-nanospeciﬁc methods for the total content of the respective elements, by e.g.
inductively coupled plasma mass spectrometry (ICP-MS), atomic emission spectrometry (AES), atomic
absorption spectroscopy (AAS), X-ray ﬂuorescence (XRF). Only positive samples have to be measured
with a nanospeciﬁc method, e.g. spICP-MS, scanning electron microscopy–energy-dispersive X-ray
spectroscopy (SEM–EDX), which may reduce the effort considerably. Recent studies have shown the
potential of some nanomaterials to accumulate very speciﬁcally, resulting in high concentrations in
speciﬁc cell types (Sadauskas et al., 2007; Powell et al., 2010; Loeschner et al., 2011; Landsiedel et al.,
2012; Kermanizadeh et al., 2015b). Homogenisation of the entire compartment (e.g. liver) may lead to a
dilution of the particles below the detection limit. In these cases, mapping techniques can be applied,
e.g. time-of-ﬂight secondary ion mass spectrometry (ToF-SIMS), laser ablation inductively coupled mass
spectrometry (LA-ICP-MS), chemical force microscopy (CFM), hyperspectral imaging, etc.
• Nanomaterials must be characterised in relevant food/feed matrix.
• In cases of technical limitations in the analysis of nanomaterials in food/feed matrices,
characterisation and study of matrix interactions may be carried out using food simulants.
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4.3.3. Solubility and degradation/dissolution rate
Information on solubility and degradation rate of the pristine material is requested as described in
Table 1, Section 4.2.1. In this guidance, degradation is considered a general term for the disintegration
of a nanomaterial, e.g. due to dissolution, enzymatic or chemical degradation. In addition, the
degradation rate in conditions representative of the human gastrointestinal tract and lysosomal ﬂuid is
considered key information in the present nanospeciﬁc Guidance because this is where nanomaterials
generally distribute to and where degradation can occur due to the acidic conditions and presence of
enzymes (see Figure 2 and more details in Sections 6.2.1 and 6.2.2). It is therefore important to
understand the fundamental differences between solubility and degradation/dissolution rate.
Solubility is the proportion of solute in solvent under equilibrium conditions (i.e. in a saturated
state, see also glossary). It is important to note the difference between dissolution (materials are
solubilised into their individual ionic or molecular species) and dispersion (colloidal suspension of
particles). Solubility is determined as the concentration of the dissolved material in a saturated solution
(i.e. undissolved material present as solid phase). The solubility is dependent on external parameters
such as solvent, temperature, pressure and pH. Care has to be taken when the concentration of the
dissolved species in the liquid phase is measured to distinguish between dissolved species and
dispersed particles. A separation of those species may be achieved by suitable ﬁltration or
centrifugation techniques. Limitations for very small particles and particles of a density similar to the
solvent have to be taken into account. Protocols and guidelines for the determination of the solubility
of nanomaterials have been proposed (Tantra et al., 2016).
High solubility is commonly understood if more than 1 mol/L solvent is dissolved.
The degradation/dissolution rate refers to the kinetics of dissolution. Nanomaterials may degrade/
dissolve faster than their bulk counterparts because of their high surface-to-volume ratio. The
dissolution rate is inﬂuenced by various factors, including solvent, temperature, pH, concentration, and
presence of substances interacting with the particle’s surface. It can be determined by kinetic
measurements such as time- dependent concentration changes (of either the nanoparticles or the
dissolved species) or changes in the particle size distribution (to smaller sizes). Dissolution is addressed
in detail in Section 6.2 (In vitro degradation tests).
4.3.4. Characterisation and quantiﬁcation of nanomaterial in FCM and after
transfer from FCM
Various applications of nanomaterial for use in FCM are described in published literature. In some
applications, the nanomaterial is applied into surface layers (e.g. in coatings); in others they are
embedded in the full FCM matrix (composites) or incorporated in active materials. Nanomaterials when
incorporated into an FCM matrix may structurally differ from the pristine nanomaterial. For instance,
mineral clays may exfoliate in the polymer matrix under the processing conditions. Therefore, in
addition to the characterisation of the nanomaterial used for manufacture of a FCM, the need arises
for characterisation of the nanomaterial when present in the FCM (on the surface, in the matrix) and
possibly when migrating from the FCM.
Nanomaterials on the surface or in the host polymer matrix can be characterised by their size and
shape (see Table 1), typically by using microscopy techniques (SEM, TEM). Other applied techniques for
this characterisation include Fourier transform infrared spectroscopy (FTIR) and X-ray diffraction (XRD).
To assess the exposure of the consumer to a nanomaterial from FCM, it is essential to determine
the potential migration of the nanomaterial from the FCM into the food matrix. This can be achieved
• Nanomaterials must be characterised in relevant biological matrices and the test media used
in in vitro and in vivo testing.
• The data must indicate the form in which a nanomaterial is presented to the test system;
proper dispersion of the nanomaterial in the medium; and any change in the nanomaterial
characteristics due to the test medium/formulation. This should include chemical
composition, size and shape, but may also refer to surface modiﬁcations and other
parameters relevant to the nanomaterial properties.
• Special attention should be paid to sample preparation and selection of characterisation
techniques for nanomaterials in body ﬂuids, tissues and excreta, and when measuring very
low levels (e.g. migrating nanomaterials from FCMs).
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by direct measurements on the nanomaterial in the food matrix, or in the food simulant used in
migration testing, or by migration modelling of the nanomaterial in the polymer matrix (Duncan and
Pillai, 2014; Noonan et al., 2014; Franz and Welle, 2017; Stormer et al., 2017).
Additionally, consideration should be given to potential release of the nanomaterial from the FCM
through mechanical stress or physical disintegration of a FCM polymer matrix. This can be achieved by
abrasion testing applying appropriate FCM material stress conditions (such as bending, stretching,
thermal stress) and suitable food simulants (able to disperse the nanomaterial) or abrasives (solids
generating friction with the FCM surface as used in scratch or tribological tests). It should be noted that
abrasion is not covered by ‘conventional’ migration testing or modelling and therefore case speciﬁc testing
is recommended. The migration patterns of nanomaterials from biodegradable polymer nanocomposites
(e.g. polylactic acid (PLA)) may be different from those in conventional (plastic) polymers when ofﬁcial EU
food simulants such as 95% ethanol are used. In these cases, the aggressiveness of the food simulant
towards the polymer may affect its integrity and the polymer chain-size distribution, and cause physical
release of the nanomaterial into the food simulant. In such cases, migration modelling does not apply and
testing may need to be performed. Migration/abrasion testing is also needed when nanomaterials have
been applied in a coating on an FCM surface (Golja et al., 2017).
To determine the amount of nanomaterial in food simulants after migration, it is possible to use a
tiered approach and ﬁrst apply a total-elemental-analysis method in conjunction with migration
modelling estimation (taking into account the concentrations, sizes and shapes of the nanomaterials in
the FCM). In this case, an appropriately sensitive detection technique (e.g. ICP-MS) should be selected
to minimise the possibility of missing (very) low levels of particles. If the test results and the models
estimates indicate the possibility of migration/release of the nanomaterial, more nanospeciﬁc technique
(s) should be employed to ascertain whether the migrating entities are in nanoparticle or in a
solubilised (non-nanomaterial) form.
Further information speciﬁc to the evaluation of substances used to manufacture FCM are available
in the EFSA CEF Panel opinion on ‘Recent developments in the risk assessment of chemicals in food
and their potential impact on the safety assessment of substances used in food contact materials’
(EFSA CEF Panel, 2016a). In general, it is recommended to check and consider the most recent
version of the EFSA Guidance(s) speciﬁc to FCM.
4.4. Quality assurance
4.4.1. Standardised methods
Preference should be given to standardised methods where available and applicable. While a number
of standard methods are available for particulate materials in pure solid state (e.g. powders), there are
hardly any standard methods available for the characterisation of nanomaterial in complex matrices.
Appendix C provides an overview of currently available standard methods at the time of issuing this
Guidance. It is recommended to search the ISO and CEN databases18 for the most up-to-date and
appropriate methods.
In cases where no standard methods are available, the applicant is responsible for providing
methods for the physicochemical characterisation and quantiﬁcation of the nanomaterial for which
approval is sought that are appropriate both for the pristine state and in matrices. The respective
methods have to have standard operation procedures (SOPs) as well as validation reports that are
provided with the dossier.
4.4.2. Method validation and performance criteria
As in other analytical ﬁelds, it has to be demonstrated that the methods used for the characterisation
of nanomaterials in their pristine form (as manufactured) and in commercial formulations, food/feed
matrices and in toxicity test systems are ﬁt for purpose and deliver reliable results. The ideal methods will
have gone through proper validation (both intra- and inter-laboratory) following existing international
guidelines (e.g. IUPAC, 2002); Commission Decision 2002/657/EC19), with adaptation if necessary. The
use of any validation protocols differing from internationally agreed protocols would need justifying. The
18 These are available from: https://www.iso.org/obp/ui/#home; https://www.iso.org/technical-committees.html; https://standa
rds.cen.eu/dyn/www/f?p=CENWEB:105::RESET::::
19 Commission Decision 2002/657/EC of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of
analytical methods and the interpretation of results (Text with EEA relevance) (notiﬁed under document number C(2002)
3044). OJ L 221, 17.8.2002, p. 8–36.
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validation would also include determination of the method performance parameters, such as speciﬁcity;
selectivity; robustness/ruggedness; recovery/trueness; repeatability, and reproducibility; detection/
quantiﬁcation limits for size, number and mass concentration; and measurement uncertainties. Assay
robustness for a nanomaterial could be established using similar principles for assessing assay robustness
for a non-nanomaterial. It would be worthwhile to include appropriate non-nanoscale controls for the
tested nanomaterials. Methods addressing the determination of particle number-weighted size
distribution or external dimension of the constituent particles in the nanoscale and beyond should be
assessed against general performance requirements as developed by NanoDeﬁne (Rauscher and Mech,
2018). Guidance for the validation of methods for the detection and quantiﬁcation of engineered
nanoparticles in food has been published (Linsinger et al., 2013) and is also applicable to other matrices.
The validation report documenting the results on these parameters should be part of the characterisation
report. The performance characteristics (including detection limit) should be within reasonable limits that
reﬂect the current state of the art and should be provided in a justiﬁcation with references to similar
techniques in this area. It has to be shown that the performance meets the requirement, e.g. in terms of
sensitivity (detection limits) and precision.
4.4.3. Reference materials
Reference materials are essential for controlling and comparing the performance of analytical
methods used for nanomaterial characterisation and in their validation. Only a few certiﬁed reference
materials are currently available, however, for which certiﬁcation usually covers only one property (e.g.
particle size, surface area). The Federal Institute for Materials Research and Testing (BAM) online,
www.nanorefmat.bam.de/en/ has inventories of the currently available nanomaterial reference materials.
More reference materials are currently under development and can be expected to become
available over time. In addition to the certiﬁed reference materials, the European Commission JRC has
recently made available a repository of industrial nanomaterials to be used as representative test
materials for safety testing (https://ec.europa.eu/jrc/en/scientific-tool/jrc-nanomaterials-repository).
These nanomaterials were used for testing by several EU-funded projects (e.g. MARINA,20
NANoREG21) as well as the OECD WPMN and can be used as test materials by any research
laboratories to generate comparable toxicological results (Totaro et al., 2016). In the absence of
certiﬁed reference materials, self-generated and properly characterised and documented test materials
may also be used. The ISO has issued a technical speciﬁcation for the preparation of reference
nanomaterials that should be taken into account for these cases (ISO, 2013).
5. Oral Exposure Assessment
Anticipated uses, use levels and potential oral exposure to the nanomaterial should be outlined as
demonstrated in Figure 2 and the paragraphs below. Some types of application could lead to other
routes of exposure, such as dermal or inhalation. Examples of these include the use as feed additives
or as pesticide. The nano speciﬁc aspects (including all relevant routes of exposure) that have to be
considered in risk assessment of these types of application have been detailed in the Appendix E.
20 FP7 MARINA project developed reference methods for managing the risk of engineered nanoparticles and engineered
nanomaterials. MARINA was a project of a consortium of 47 national institutions of Member States and industries association.
21 FP7 NANoREG project was a project with over 89 partners from the EU, Brazil and the Republic of Korea in which scientists,
industry and policy makers collaborated.
• The methods used for physicochemical characterisation must be appropriate for the type of
nanomaterial.
• Standardised methods should be used where available. Other ﬁt-for-purpose methods may
be used with provision of supporting documentation for validation and standard operation
procedures.
• Method performance parameters must meet the requirements, e.g. in terms of sensitivity
(detection limits) and precision.
• Certiﬁed reference materials should be used to control and compare the performance of the
analytical method used. In the absence of certiﬁed reference materials, self-generated and
properly characterised and documented test materials may also be used.
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When direct exposure of humans or animals is possible, such as from novel foods, food/feed
additives, use of nanomaterial as pesticide (see Appendix E.2) it should be assessed if the
nanomaterial or its dissolution/degradation products in the form of a nanomaterial remain present as
particles in the food/feed matrix. If no nanomaterial remains present in food/feed, there is no
exposure to nanomaterial and risk assessment should follow relevant EFSA guidance for conventional
materials. If yes, it should be assessed if the nanomaterial or nanosized degradation products remain
present as particles under the in vitro simulated conditions of the gastrointestinal tract. Figure 2
illustrates the steps of subsequent exposure assessment.
If there is no data on the quantiﬁcation of the nanomaterial in the food/feed matrix (Section 4.3.3)
or on the degradation under the simulated conditions of the gastrointestinal tract (Section 6.2), it has
to be assumed that the exposure is to the nanomaterial initially added to the food/feed. It should
therefore be assumed that all added nanomaterial is present, ingested and absorbed as the nanosized
particle. This represents the worst-case scenario.
Indirect exposure includes migration or transfer from FCM and transfer by carry-over of the
nanomaterial from feed, via animals to food from a pesticide to a crop or as a contaminant. It should
be assessed if indirect exposure occurs via particles or solutes (ions, molecules). For FCM, this means
that the elution towards food/feed or food simulant22 should be considered. The same considerations
as to whether particulate or non-particulate species are transferred need to be taken into account in
the case of carry-over from feed, via animals to food, from a pesticide to crop or as contaminant. For
FCMs, the extent of transfer should be measured by an appropriate technique with detection limits
according to the state of the art (see Section 4.3.3), and in consideration of the particles in the
relevant size distribution.23 Occurrence of nanomaterials as contaminants may be what happens in
cases of nanomaterials being persistent in the environment (see Section 3). When any transfer of
nanomaterial into food/feed/food simulants can occur, the principles of this Guidance apply. Unlike
non-nanomaterial (chemical) migrants from FCMs (Br€uschweiler, 2014; EFSA and WHO, 2016), an
acceptable threshold for the migration of nanomaterials from FCM has not yet been established owing
to the paucity of data (from producers) that would be necessary to establish safe limits. In the context
of this Guidance, evidence indicating no release of nanomaterial (or release exclusively as non-
nanomaterial), should be sufﬁcient to waive further nanospeciﬁc testing of food/feed products. It is
equally important to note that, irrespective of the presence of a nanomaterial or nanosized
degradation products in the FCM, the release of molecules/ions should be assessed in accordance with
the relevant EFSA guidance for conventional FCM.
When exposure to the nanomaterial or its degradation products in the form of a nanomaterial can
occur, the dietary intake should be estimated. The principles of exposure assessment of nanomaterials
(via food and feed) will be the same as in exposure assessment of non-nanomaterials (Kroes et al., 2002;
EFSA Scientiﬁc Committee, 2006, 2009a). Thus, guidances apply that provide speciﬁc information on the
determination of consumer exposure. General issues like food/feed sampling, variability within composite
samples and variation in concentrations between samples are not different from the exposure
assessment for the micro/macroscale or for non-nanomaterials, and need to be addressed in the risk
assessment.
The anticipated average and high exposures to nanomaterial food/feed for various population
groups must be estimated based on the available consumption data. Probabilistic methods may be
useful to determine ranges of plausible values rather than point estimates. If possible, particular
subgroups of the population with an expected high exposure – through anticipated frequent use of the
same type of food item, for example – should be identiﬁed, and this should be considered in the risk
assessment. There is limited information on the consumption (amounts and frequency) of food
supplements. Data on import and production quantities of the nanomaterial could provide additional
information for the exposure assessment. Any assumptions made in the exposure assessment should
be described. The exposure estimates should take into consideration the ﬁndings of the presence of
nanomaterial in food/feed, food simulant and/or in vitro digestive tract conditions.
22 See Table 1 of consolidated Commission Regulation (EU) No 10/2011 on plastic materials and articles intended to come into
contact with food: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R1416&from=EN
23 Examples of nanomaterials evaluated positively on the basis of absence of a signiﬁcant migration in particulate form include
carbon black, titanium nitride (EFSA CEF Panel, 2012a), zinc oxide (EFSA CEF Panel, 2015a, 2016b), nanoclays (EFSA CEF
Panel, 2012b, 2015b), silanated silicon dioxide (EFSA CEF Panel, 2014a), nanosized polymeric substances (EFSA CEF Panel,
2014b).
Guidance on nanotechnologies in the food and feed chain
www.efsa.europa.eu/efsajournal 32 EFSA Journal 2018;16(7):5327
Direct exposure via food/feed (potential) Indirect exposure, i.e. after 
release from FCM or via carry-over
Go to Risk Characterisation
See Section 7.  
Information on the characteristics of the pristine nanomaterial and 
the amount added to food/feed item or FCM
Does the material fully 
degrade in the food/feed 
matrix?(a)
Does the material quickly and fully (b) degrade in digestive 
tract conditions? 
No
Yes
Yes
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Exposure estimation in various population groups based on 
consumption data, average and high exposure, and the 
presence of nanomaterial and any nanosized degradation 
products in food/feed, food simulant and/or in vitro digestive 
tract conditions. 
Type of nanomaterial application
(e.g. ingredient/additive/pesticide/food contact material) 
Quantification and characterisation (particle size 
distributions) of the nanomaterial and any nanosized 
degradation products in food/feed, food simulant and/or in 
vitro digestive tract conditions. 
There is nanomaterial present 
Is there migration/transfer of 
nanomaterial to food/feed (a)
No
Yes
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(a): If it cannot be measured whether a nanomaterial is present in e.g. food/feed matrix, food simulant or
simulated digestive tract, it should be assumed it is. See Section 6.2.1 and Appendix D for details on in vitro
gastrointestinal digestion.
(b): The assessment of degradation products that are still in the form of a nanomaterial should continue as
presented in this Guidance.
Figure 2: Steps in oral exposure assessment. The arrows going out (left and right) indicate that
nanospeciﬁc considerations are not needed, and risk assessment for the non-nanomaterials
can follow the standard approach (i.e. the relevant EFSA Guidances for conventional
materials)
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6. Hazard identiﬁcation and hazard characterisation
The test requirements stipulated in current EFSA guidance documents and European Commission
guidelines for different intended food/feed uses also apply in principle to nanomaterials. This
Section outlines additional hazard identiﬁcation and characterisation aspects to be considered that may
arise because of the speciﬁc characteristics and properties of the nanomaterial or any degradation
product in the form of a nanomaterial. Appropriate in vitro and in vivo studies on the nanomaterial
should be undertaken to identify hazards and obtain dose-response data to characterise these hazards.
Limited data are available on toxicological hazards of nanomaterials following oral exposure
(Fr€ohlich and Roblegg, 2012; Bouwmeester et al., 2014; Hadrup and Lam, 2014; Rossi et al., 2014;
Heringa et al., 2016). The majority of the currently available information on toxicity of nanomaterial, as
when EFSA’s previous opinions were published (EFSA Scientiﬁc Committee, 2009a, 2011a,b), is from
in vitro studies or in vivo studies using routes of exposure other than oral (e.g. inhalation). The key
point for hazard identiﬁcation is that nanomaterials may show typical’small particle’ behaviour, and
thereby can exhibit biological properties different from the corresponding non-nanomaterial (if
applicable, see glossary). Therefore, they have to be assessed according to this Guidance. On the
other hand, risk assessment for quickly degrading nanomaterial may follow the relevant existing
guidance for conventional materials.
General considerations for testing nanomaterial are covered in Section 6.9 and need to be taken
into account. It is important to highlight that, even around or within the nanoscale, there may be
considerable ﬂuctuation in the toxicity of a given nanomaterial due to variations in particle size. For
instance, in the case of silver, 10 nm has been identiﬁed as a size threshold where a substantial
increase in toxicity occurs both in vitro and in vivo compared with slightly larger nanoparticles (Ivask
et al., 2014; Recordati et al., 2016). It is therefore crucial that there is complete correlation
between the material as produced and as tested, and that the size and properties of the
manufactured material used in the speciﬁc application lie within the narrow range covered by the risk
assessment. In this light, batch-to-batch variation is of special concern and strict criteria should be
followed to ensure the manufactured material consistently presents constant physicochemical
parameters (i.e. those considered in the risk assessment).
• Exposure assessment should take account of the anticipated uses in line with the type of
nanomaterial application (Figure 3). Particular sections of the population with an expected
high exposure should be identiﬁed. Any assumptions used in the exposure assessment
should be clearly described.
• A primary consideration for exposure assessment should be the presence of nanomaterial (or
nanosized degradation products) in food/feed, food simulant and/or in vitro digestive tract
conditions. Where a nanomaterial or nanosized degradation products are no longer present,
risk assessment should be carried out according to the relevant EFSA guidance for
conventional materials.
• For assessment of indirect exposure (e.g. migration from FCM; transfer via carry-over from
animal feed or from a pesticide to crop), one should determine whether the exposure is to
(nano)particles or solutes (ions, molecules).
• Unlike conventional (non-nanomaterial) migrants from FCMs, the scientiﬁc knowledge is
considered to be too limited to propose a threshold for the migration of nanomaterials. An
argument for safety may be made on a case-by-case basis if migration of a nanomaterial in
particulate form is only in trace amounts.
• Where it is not possible to determine the nanosized particles in complex matrices, it should
be assumed as a worst-case that all nanomaterial added to a food/feed product is present as
the nanomaterial and is ingested and absorbed.
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6.1. Stepwise framework for nano-related hazard identiﬁcation and
characterisation in food/feed
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Step 3 Targeted in-depth investigations 
See Section 6.8: E.g. additional toxicokinetic 
study (optionally in human studies), 
reproductive and developmental toxicity, 
additional immunotox, neurotox, 
carcinogenicity/mutagenicity, endocrine 
effects, gut microbiome
Do these results warrant further testing? 
Indications for slow elimination or accumulation and distribution to specific tissues 
may warrant further testing. 
Step 0 In vitro digestion
See Section 6.2.1 in vitro gastrointestinal digestion
Does the nanomaterial degrade quickly and fully under gastrointestinal tract conditions?
Yes 
No 
Go to Risk Characterisation 
See Section 7
Yes 
No: two parallel steps need to be taken (1a and 1b) 
Step 1b Generate new in vitro data  
See Sections 6.2.2: Including dissolution 
under lysosomal conditions, Section 6.4 in 
vitro genotoxicity and Section 6.5 in vitro
cell toxicity. 
Step 1a Review existing information(b)
See Sections 3, 4, 6.3: Review all existing 
physicochemical and toxicological 
information as well as information relevant to 
grouping/read-across. 
Step 2a Pilot in vivo study 
See Section 6.6: A pilot study for dose 
finding and assessment of absorption, 
tissue distribution and accumulation and 
elimination phases (≈ 14 days) is 
recommendable.
Step 2b In vivo studies 
In vivo genotoxicity(c) 
See Section 6.4 
+ 
Modified 90-day oral toxicity study 
+ Satellite group for assessment of 
absorption, tissue distribution and 
accumulation (≈ 14 days, 90 days, elimination 
phase),  
See Section 6.7: Including an assessment of 
key gastrointestinal sites, organs normally 
investigated with emphasis on liver, brain, 
testis and spleen by histopathology and 
relevant endpoints.  
Is the nanomaterial non-persistent AND no indication of potential toxicity is observed(a))
Yes 
An argument for waiving of in vivo studies(a) 
with nanospecific considerations might be put 
forward. To be assessed by EFSA on a case-
by-case basis.No
(a)
(d)
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The SC notes that this Guidance complements the existing relevant EFSA Guidances for
conventional materials (see Introduction). Hence, it is noted that some of those Guidance have a
parallel tiered approach and the sequence is: Tier 1 -> Step 2, Tier 2 -> Step 3, Tier 3 -> Step 3. This
is because for nanomaterials a determination of whether nanospeciﬁc properties exist (i.e. Steps 0 and
1, which do not exist in the already described tiered approach for food additives and novel foods)
should be made prior to testing.
In Step 0, the rate of degradation of the nanomaterial to the non-nanomaterial under conditions
representative of the gastrointestinal tract is investigated. Nanomaterials that quickly degrade, (i.e.
have a high degradation rate; see Section 6.2) can be expected not to show nanorelated behaviours,
and thus an appropriate standard risk assessment approach would be applied including read-across to
the solute. If the material does not quickly degrade, one should continue to Step 1.
The aim of Step 1a is to gather any available information from existing literature that meets
quality criteria (i.e. that has adequate characterisation data on the nanomaterial tested) and obtain
information from a set of in vitro studies (see Section 6.5) that can identify speciﬁc issues that need to
be addressed in the 90-day oral study in Step 2b, or that provide weight of evidence information for
decision making in risk assessment. References and bibliographic lists must be provided in the format
required by EFSA Guidances (e.g. the existing guidance for conventional materials).
This can include both existing information on the speciﬁc nanomaterial, as well as on similar
materials i.e. those which only deviate to a limited extent in one or more physicochemical parameters
as described in Table 1. Information on carcinogenic, mutagenic, reprotoxic (CMR) properties of one or
more of the components of the material should always be considered.
The in vitro studies in Step 1b comprise degradation tests under simulated lysosomal conditions
(see Section 6.2.2), in vitro genotoxicity tests (see Section 6.4) and a battery of tests including any
relevant in vitro toxicity tests (see Section 6.5). Use of speciﬁc cell lines highlights further information
required from investigations in vivo and inﬂuences the design of these studies. Where there is
evidence of a lack of persistence based on degradation rate under simulated lysosomal and
gastrointestinal conditions, and no indication of potential toxicity from existing information and the
in vitro test battery, an argument may be put forward that further nanospeciﬁc testing as outlined in
the present stepwise approach (e.g. continuation to Step 2) is not necessary. However, it is anticipated
that for most cases that have entered Step 1, testing under Step 2 will be required. This is because
conclusive evidence for toxicity (including local effects for any relevant route of exposure) based on
in vitro testing alone, is not expected. Direct testing under Step 2 is acceptable to demonstrate if the
nanomaterial represents a hazard or not.
In Step 1b, the in vitro genotoxic potential of nanomaterials will be investigated according to the
tests indicated in Section 6.4. Nanomaterials that resulted negative in in vitro genotoxicity assays are
considered non genotoxic and further in vivo genotoxicity test is not usually required. Nanomaterials
that were positive in a least one in vitro genotoxicity assay have to be considered a potential hazard
whose genotoxic capability requires further investigation in in vivo (Step 2). If genotoxicity cannot be
tested in vitro, as a rule in vivo genotoxicity testing is necessary (see Section 6.4).
The results from the in vitro testing of the nanomaterial should be reviewed and other relevant
information considered, such as on chemical reactivity (which might predispose to site of contact
effects), bioavailability, metabolism, toxicokinetics, and any target organ speciﬁcity.
(a): If yes, an argument can be put forward that further nanospeciﬁc testing is not necessary. However, it is
anticipated that for most cases that have entered Step 1, testing under Step 2 will be required. This is because
conclusive evidence for toxicity (including local effects for any relevant route of exposure) based on in vitro testing
alone, is not expected. Hence, the decision to not perform any toxicity study has also implication for uncertainty
reporting (see Section 8.3). Direct testing under Step 2 is acceptable to demonstrate if the nanomaterial represents
a hazard or not. Furthermore, for many Regulatory frameworks, e.g. for food additives, there is a requirement for a
90-day test. In these cases, this study has to be designed according to the stipulations of nanospeciﬁc issues as
described in this Guidance for performing the tests of Steps 2 and 3.
(b): Review of existing information should continue throughout the entire process of hazard identiﬁcation and risk
assessment.
(c): Step 1 genotoxcity testing is mandatory for all nanomaterial. A positive result in Step 1 requires follow-up in Step 2.
(d): Some nanomaterials have been related to inﬂammation, immunotoxicity, genotoxicity, reproductive organ effects
and/or neurotoxicity (Dekkers et al., 2016; Bencsik et al., 2017; Higashisaka et al., 2017; Prosafe white paper, 2017).
Indications for respective effects during step 1 and 2 assessment should be further investigated in Step 3.
Figure 3: Framework for step-wise hazard identiﬁcation and characterisation
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Step 2a consists of a Pilot in vivo study (See Section 6.6) which is recommendable for dose ﬁnding
and assessment of absorption, tissue distribution and accumulation, elimination phase ( 14 days), for
example by measurement of tissue concentrations at the end of study. Subsequently, Step 2b consists
of a modiﬁed 90-day toxicity test (OECD TG 408 with extended parameters from OECD TG 407 (2008),
e.g. for behavioural and endocrine disruptive effects) (preliminary reference: OECD TG 408 (2017a))
(see Section 6.7). For many Regulatory frameworks e.g. for food additives, there is a requirement for
a 90-day study. In these cases, this study has to be designed according to the stipulations of
nanospeciﬁc issues as described in this guidance for performing the tests of Steps 2 and 3. This study
can be omitted only when there is robust justiﬁcation (to be evaluated by EFSA) of non-absorption,
and the absence of local effects for any relevant route of exposure. In the Step 2 modiﬁed 90-day
study, speciﬁc attention should be paid to (indications on) effects on key gastrointestinal sites, organs
normally investigated with emphasis on liver, brain, testis and spleen by histopathology and relevant
endpoints. The results from this study can be used to identify a reference point (such as lower
boundary of the BMD conﬁdence interval (BMDL) or a no-observed-adverse-effect-level (NOAEL), See
Section 6.7). This study should allow for the identiﬁcation of nanomaterials with the potential to cause
immunological, proliferative, neurotoxic, reproductive organ effects or endocrine-mediated effects that
may warrant further in-depth investigation in Step 3 as appropriate. Performing a pilot study including
some toxicokinetic assessment is recommended for targeting of the hazard parameters in Step 2 and
for dose ranging in Step 3 and onwards, and also to avoid the administration of highly toxic doses. In
vivo studies should be combined where possible to minimise the use of test animals.
6.2. In vitro degradation tests
6.2.1. In vitro gastrointestinal digestion
Assessment of the degradation rate of nanomaterials in conditions representative of the human
gastrointestinal tract is considered a key ﬁrst step in the stepwise approach (Figure 3). If a high
degradation rate can be demonstrated, as detailed later this paragraph, the standard safety
assessment procedure for conventional materials can be followed.
A suite of in vitro digestion models have been described in the literature that assess the release or
degradation/dissolution of non-nanomaterials (Dressman et al., 1998; Krul et al., 2000; Oomen et al.,
2002; Brandon et al., 2006; Minekus et al., 2014; Lichtenstein et al., 2015; K€astner et al., 2016). In
vitro digestion models have been applied to determine the release of various orally ingested
compounds, e.g. contaminants from soil (Oomen et al., 2003; Van de Wiele et al., 2007), food
• A stepwise approach (Figure 3) should be adopted for hazard identiﬁcation and
characterisation to avoid unnecessary testing of nanomaterials.
• In the ﬁrst instance (Step 0), the rate of degradation of the nanomaterial to non-
nanomaterial form under conditions representative of the gastrointestinal tract should be
investigated. Quickly and fully dissolving nanomaterials may be subjected to standard (non-
nanomaterial) assessment, instead of further nanospeciﬁc testing.
• In Step 1, all available information should be gathered and a set of in vitro studies carried out
to identify hazards and any need for further testing in Step 2. If the information indicates that
the nanomaterial is not persistent and not (geno)toxic (investigated with the relevant tissue
and a comet test in case of secondary genotoxicity due to inﬂammatory effects in the gut as
mentioned in Section 6.4), an argument may be made to waive further nanospeciﬁc testing in
Step 2. However, safety assessment for conventional (non-nano)materials will still be needed.
• In Step 2, a modiﬁed 90-day oral toxicity test (OECD TG 408 with extended parameters from
OECD TG 407) should be carried out for identiﬁcation of the nanomaterials with potential to
cause immunological, proliferative, neurotoxic, reproductive organ or endocrine-mediated
effects as appropriate.
• The results of the modiﬁed 90-day toxicity test should determine whether further in-depth
investigations would be needed in Step 3 (e.g. human kinetic data from volunteer studies,
additional toxicokinetic study, reproductive and developmental toxicity, additional
immunotoxicity, neurotoxicity, carcinogenicity/mutagenicity, endocrine effects, gut
microbiome).
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contaminants (Versantvoort et al., 2005; Dall’Asta et al., 2010), food mutagens (Krul et al., 2000), food
components (Blanquet-Diot et al., 2009; Tydeman et al., 2010), contaminants in toys (Brandon et al.,
2006) and drugs (Dressman et al., 1998; Kostewicz et al., 2002; Blanquet et al., 2004). These models
simulate the conditions of the gastrointestinal tract (including mouth, stomach and gut). The
differences between these models relate to the extent to which physiology is simulated, e.g. from very
simple to rather sophisticated by using static or dynamic conditions, and with or without enzymes, bile
salts etc. In addition, the physiology that is simulated may vary between models: fasted versus fed
conditions, baby versus adult.
An in vitro digestion method suitable for food under fed conditions (as opposed to fasted) has been
described by Minekus et al. (2014) that is harmonised by the COST Infogest network.24 The effects of
differences in pH, mineral type, ionic strength, digestion time and, enzyme activity were also
discussed. The method consists of a short simulation of mouth conditions, followed by a gastric phase
at pH 3 for 2 h and an intestinal phase at pH 7 for 2 h. The composition of the digestion ﬂuids was
exactly described. While this method is not speciﬁed for nanomaterials, nor is it an ofﬁcially
standardised method, this it is considered a key approach also to be used for nanomaterial in food, i.e.
for simulating physiological conditions in the gastrointestinal tract after food consumption.
For fasted conditions, several in vitro digestion methods have been described and compared by
Koch et al. (2013). These methods can be explored further for applicability in this context.
Recently, some experience has been gained with the application of in vitro digestion models to
nanomaterials. NANoREG D5.0225 shows that the degree of aggregation/agglomeration (see Table 1)
of several nanomaterials (Ag, SiO2 and ZnO) in artiﬁcial saliva, gastric juice and intestinal juice varies
over these stages. Nanoparticles were still present in the intestinal stage, although considerable
degradation was observed for Ag and ZnO (up to 45% was degraded after mouth, stomach and 2 h of
intestinal digestion under the speciﬁed conditions). Degradation measurement in such complex
matrices was challenging, and a single, robust and rapid test method for all types of materials in all
types of matrices could not be developed. Possible techniques include spICP-MS, and ICP-MS/AES
based methods in combination with a separation technique like ultraﬁltration (NANoREG D5.02).
Furthermore, Peters et al. (2012) and Walczak et al. (2013) investigated respectively SiO2 and Ag
particle distribution in artiﬁcial mouth, gastric and intestinal conditions. Here also, the degree of
aggregation/agglomeration varied between the different compartments of mouth, stomach and
intestine. Sieg et al. (2017) describe that the aluminium nanoparticles remained unchanged in saliva,
and strongly agglomerated in the gastric phase showing also an increased ion release. The levels of
aluminium ions decrease in the intestinal ﬂuid and particles de-agglomerated. Altogether, dissolution of
nanoparticles was limited. DeLoid et al. (2017b) found that iron(III)oxide (Fe2O3) nanoparticles in an
oil-in-water emulsion showed different size distribution in an in vitro digestion model with or without
Fe2O3, in the mouth, stomach and intestinal phase. This size distribution comprised all particles,
unspeciﬁed to chemical composition. There appeared to be minimal dissolution of the Fe2O3 particles
in all three stages of digestion.
Remarkably, intestinal digestion of soluble silver ions (from AgNO3) and ionic aluminium also
resulted in the formation of particles (of 20–30 nm) composed of silver, sulfur and chlorine (Walczak
et al., 2013) and aluminium (Sieg et al., 2017).
There is a lack of validation and standardisation of in vitro digestion models for nanomaterials. At
present, no comparison for nanomaterials has been made between in vitro degradation/dissolution
data from such digestion models and in vivo data. Lefebvre et al. (2015) concluded that in vitro
digestion models are generally applicable to nanomaterials, as the basis of the models is mimicking the
conditions of the gastrointestinal tract. Important properties affecting degradation/dissolution are
expected to include physical forces, temperature, pH, presence of enzymes, salts and bile, and
presence of food (Bellmann et al., 2015). Therefore, a rationale for the used in vitro digestion model
used in the stepwise approach should be provided in view of the representativeness of the physiologic
state for exposure, and whether the model is expected to represent worst-case, realistic or favourable
conditions for in vitro degradation of the speciﬁc nanomaterial. For example, fasted conditions may be
less representative of the use of nanomaterials in food products, whereas low pH conditions in the
stomach – as may occur in fasted conditions – may promote the degradation of most metals and metal
24 See https://www.cost-infogest.eu/
25 http://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoREG_D5_02_DR_
Report_on_the_development_of_a_solubility_testing_procedure.org. NanoReg was a cooperation between 71 Partners form
a consortium of European RTD performers, metrology institutes and nanomaterials and instrument manufacturers.
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oxides. Therefore, a careful choice between fed or fasted conditions should be made for the test
system in view of anticipated conditions and the worst-case situation, depending on the characteristics
of the nanomaterial and the application. In some cases, it may be relevant to investigate the
degradation rate under both physiological conditions. Further scientiﬁc research on the impact of food
components on the degradation of nanomaterials is recommended (Lichtenstein et al., 2015). The
in vitro digestion model should also be critically assessed for its reliability and reproducibility. To
increase the reliability of the degradation information from the model, the degradation rate should be
determined by including different time points (at least four time points in duplicate at about 5, 15, 30
and 60 min) in the intestinal phase. The study should be performed at three different concentrations
as this may affect the degradation, and the middle concentration should be representative of human
exposure. This can be calculated by the estimated daily intake that, depending on the anticipated use,
is ingested at once or throughout the day assuming that the daily volume of secretions into the
gastrointestinal tract is 4–5 L. Furthermore, the particle number–size distribution and concentration
should be analytically determined with a chemically speciﬁc method (i.e. verifying the chemical identity
of the measured particles, e.g. spICP-MS or TEM-EDX). The concentration of the solute and, if present,
other degradation products, should also be determined.
Some materials may degrade completely in the conditions of the stomach and then precipitate in
the intestinal conditions as salts or nano- or microsized particles (Walczak et al., 2013). The dissolved
fraction should not be separated from the rest during in vitro digestion as this may promote the
dissolution. It has also been shown that SiO2 particles can form large non-nanosized agglomerates in
the conditions of the stomach that may disagglomerate in the intestine stage (Peters et al., 2012). This
indicates that the absence of small particles in stomach conditions is insufﬁcient to conclude that
there will be no exposure to the nanoparticles. Therefore, only information on the dissolution rate in
the intestinal conditions is considered relevant and should be provided. This means that the simulation
of the stomach conditions still need to precede the intestinal conditions, but no data on the dissolution
rate in the stomach phase are required.
The measured concentrations of solute, degradation products and particles should be compared
with the start situation at the beginning of the in vitro digestion, in saliva or in the matrix as
introduced into the in vitro digestion model. Analytical limitations such as detection limits should be
taken into consideration (see Section 4.3).
A nanomaterial is considered to degrade quickly/have a high degradation rate if the degradation
rate proﬁle in the intestinal phase shows a clear decrease in the presence of particles over
time (no plateau), and that 12% or less of the material (mass-based26) – compared with the
particulate concentration at the beginning of the in vitro digestion – is present as particles after
30 min of intestinal digestion. This is indicative that the rest of the material should be fully degraded
to non-nanomaterial (e.g. ionic) under gastrointestinal conditions (as mentioned in Figure 3). Details of
the rationale and discussion of the uncertainty for this cut-off value can be found in Appendix D. The
cut-off value assumes a ﬁrst-order half-life in the intestinal phase of 10 min. It is considered feasible
to measure this value analytically, and the time required to reach the intestinal epithelium and be
taken up by cells is of the same order of magnitude. In such cases, a nanospeciﬁc risk assessment
would not always be required. However, in case of complete digestion in gastrointestinal ﬂuids,
localised exposure (e.g. in the upper gastrointestinal tract) needs to be considered (Holpuch et al.,
2010). When applicable to the material, a comparison to an ionic control should be included to identify
de novo particle formation from these ions.
It should be noted that the cut-off for a high degradation rate is based a pragmatic choice based
on limited science (see Appendix D) and may need modiﬁcation with increasing knowledge.
If it cannot be demonstrated that the material quickly degrades, one should continue to Step 1 of
Figure 3.
26 While number based would be preferred, mass based evaluation would be accepted for pragmatic reasons.
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6.2.2. Stability in lysosomal ﬂuid
Once in the body, some nanomaterials may not be easily cleared and may accumulate over time.
Assessment of the stability in lysosomal conditions is important to screen the potential of
nanomaterials for biopersistence and intracellular accumulation (Utembe et al., 2015). Lysosomal
conditions are considered as model as this is where nanomaterials generally distribute to and where
degradation can occur due to the acidic conditions and presence of enzymes.
Release of ions due to degradation in lysosomal ﬂuid can be an indication of toxicity due to these
ions and should be considered in further testing.
Artiﬁcial lysosomal ﬂuid simulates the inorganic environment within lysosomes (hydrolytic enzymes
are typically not included) and is buffered at pH 4.5–5.0 (see e.g. Stopford et al., 2003; Stefaniak
et al., 2005; Henderson et al., 2014; Pelfre^ne et al., 2017).
To assess the stability in lysosomal ﬂuid, pristine materials should be submitted to in vitro simulated
lysosomal degradation and the degradation rate in lysosomal ﬂuid has to be determined by considering
different time points (at least four) in duplicate at three different concentrations. Time points for
sampling and concentrations have to be properly selected and justiﬁed; time points are normally
expected to be in the range of hours and extend up to, e.g. 72 or 96 h. Degradation and particle size
of nanomaterials after lysosomal treatment should be characterised using the same approach
described for in vitro gastrointestinal digestion, where a half-life of about 24 h is considered indicative
of a high degradation rate given that degradation in lysosomal conditions should provide a predictive
estimate for potential accumulation in cases of where frequent exposure is expected. This half-life
would result in 12% or less of the material (mass-based) being present at 72 h compared to the
particulate concentration at the beginning of the degradation test (ﬁrst-order kinetics). As with in vitro
gastrointestinal digestion, no evidence of a plateau should be visible.
6.3. Read-across
A particular issue identiﬁed in the risk assessment of nanomaterials is the fact that a given material
can be developed in several forms with different sizes, crystalline forms, morphological shapes, and/or
• The use of the in vitro digestion model should be justiﬁed for relevance to the physiologic
state (fasted or fed) for exposure, and whether it represents worst-case, realistic or
favourable conditions for in vitro dissolution of the speciﬁc nanomaterial. It is recommended
that worst case conditions (fed or fasted) should be used for the in vitro digestion model.
• The reliability and reproducibility of the model should be assessed and documented.
• The concentration of particles (in mass and numbers), solute, degradation products and the
particle size distribution should be determined analytically (using at least an EM-technique).
• Information on the dissolution rate for each nanomaterial should be obtained from:
 At least four time points for the intestinal phase (of up to 4 h) to allow the
determination of a dissolution rate.
 A minimum of duplicate samples at each time point should be used. At least three different concentrations with a middle concentration that is calculated
to be representative for human exposure should be used.
• A nanomaterial is considered to dissolve quickly/have a high dissolution rate if 12% or less of
the material (mass based) is present as particles after 30 min of intestinal digestion
compared to the particulate concentration at the beginning of the in vitro digestion.
• The in vitro dissolution rate proﬁle for each nanomaterial in simulated lysosomal ﬂuid should
be provided. Information on the dissolution rate should be obtained in duplicate from at least
four different time points up to 72–96 h and at three different concentrations tested.
• A half-life of ca. 24 h is considered indicative of high dissolution rate in lysosomal ﬂuid. This
would result in 12% or less of the material (mass based) remaining at 72 h compared to the
particulate concentration at the beginning of the dissolution test.
• The information together with the dissolution rate in simulated gastrointestinal conditions
would indicate the likelihood of persistence and bioaccumulation of the material.
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surface characteristics. Adequate physicochemical and toxicological data are often not available for
each individual variant to allow case-by-case assessment and generation of such data would require a
considerable time and resources. This is where a scientiﬁcally based framework for grouping and
read-across can facilitate risk assessment within both industry and regulatory settings. Read-across
here refers to the use of data from one or more (nano)materials (the source (nano)materials) to
another nanomaterial of the same chemical composition (the target nanomaterial) to ﬁll a data gap. A
number of frameworks for nanomaterials have been proposed, based on approaches already
established for conventional chemicals (Arts et al., 2014, 2015, 2016; Oomen et al., 2015; ECHA,
2016; ECHA/JRC/RIVM, 2016; OECD, 2016a,b). The scientiﬁc justiﬁcation for read-across should
demonstrate that the physicochemical characteristics of source and target (nano)materials are similar
enough to allow the prediction of the toxicological effect of the target nanomaterial. At present,
however, the scientiﬁc basis for allowing substantiation based on existing data for read-across is
limited. This is because, unlike conventional chemicals, the current database on physicochemical and
toxicological parameters of nanomaterials is too limited.
It is, nevertheless, relevant to assess if the existing data on a nanomaterial can be useful for
grouping/read-across of other variants of the nanomaterial with the same chemical composition, and
to identify what would be needed to substantiate the use of existing data for a grouping/read-across
approach. A scientiﬁc reference paper by ECHA, JRC and RIVM (2016) on grouping of nanomaterials
has recently been developed into an ECHA Guidance in the form of an appendix to Registration,
Evaluation, Authorisation and Restriction of Chemicals (REACH) Chapter R.6 on Information
Requirements and Chemical Safety Assessment (IR&CSA) on Quantitative structure–activity
relationships (QSARs) and Grouping, intended to inform those preparing registration dossiers for
nanomaterials (ECHA, 2016). This document aims to provide an approach on how to justify the use of
hazard data between nanoforms and the non-nanoform(s) and within groups of nanoforms of the
same substance. First, the target material should be similar in physicochemical characteristics to the
source material(s). Subsequently, the outline proposes substantiation that would require toxicokinetic
considerations (e.g. does the nanoform of a target nanomaterial differ from the source material(s) in
terms of reaching the target site) and hazard considerations (e.g. does the target nanoform of a
nanomaterial differ from the source material(s) in terms of hazard potential and proﬁle). Hence, an
argument should be built based on the limited number of differences in physicochemical properties
between source and target materials and how they can affect exposure, toxicokinetics and hazard and
substantiated with additional physicochemical, in vitro and/or in vivo data as needed. The
consequences of the potential differences in exposure, toxicokinetics and hazard should be considered
in view of the applicability of existing data from one or more source (nano)materials for the risk
assessment of the target nanomaterial, for example by justiﬁcation that the source (nano)materials
exhibit toxicokinetic behaviour and hazards that are more worst case than the target nanomaterial.
Owing to the current data gaps, the applicability of read-across to nanomaterials is limited and it is
likely that in a majority of cases, experimental data (in vitro, in vivo) would be needed for the
substantiation. In time, such data may become available that can be used as source material(s) to
compare the toxicokinetic behaviour and hazard potential to substantiate the use of a grouping/read-
across approach. Application of read-across would require data and information on the relationship
between physicochemical properties and the toxicokinetic behaviour and hazard potential of different
variants of the nanomaterial with the same chemical composition. This implies that any nanomaterials
considered for grouping/read-across should ﬁrstly be well characterised regarding physicochemical
parameters. It is therefore also recommended that toxicological studies be conducted in a systematic
manner to decipher the relationship(s) between changes in one or a few physicochemical properties
and the toxicokinetic proﬁle and hazard potential of variants of the nanomaterial with the same
chemical composition. It would facilitate the interpretation of ﬁndings if only one parameter (or at
most a small number) were changed systematically allowing the critical ones to be identiﬁed.
At the moment, there is considerable uncertainty (e.g. limited usability due to lack of data) on the
value of read-across for risk assessment of nanomaterials. Owing to the current data gaps, the
applicability of read-across to nanomaterials is limited and it is likely that experimental data (in vitro,
in vivo) for read-across substantiation would be needed in a majority of cases. With time such data, or
data speciﬁcally for a speciﬁc read-across case, may become available. Once available such data can
then be used to compare the toxicokinetic behaviour and hazard potential for justiﬁcation of the use of
a grouping/read-across approach in the setting of nanomaterials in the food and feed chain. Whether
a read-across justiﬁcation is acceptable for waiving further (in vivo) testing is to be judged by EFSA on
a case-by-case basis.
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6.4. In vitro and in vivo genotoxicity testing
Genotoxicity testing of nanomaterials should follow the general indications of the EFSA genotoxicity
testing strategies (EFSA Scientiﬁc Committee, 2011b, 2017d) taking into account the speciﬁc properties
of nanomaterials. Speciﬁc issues related to genotoxicity testing of nanomaterials have been highlighted
by the OECD Expert Meeting on Genotoxicity of Manufactured Nanomaterials (OECD, 2014b) and
included in the SCCS (2016) notes of guidance (SCCS/1564/15) and in ECHA (2017a). Catalan et al.
(2017) described a theoretical approach for weighed assessment of the mutagenic potential of
nanomaterials.
Materials, nano and non-nano, may induce genotoxic damage by direct interaction with DNA, by
disturbing the process of mitosis, or by producing reactive oxygen species (ROS) (reviewed by Gonzalez
et al., 2010; Magdolenova et al., 2014; Kermanizadeh et al., 2015a,b). As a consequence, various types
of genetic alterations may result and a battery of tests covering different genotoxic mechanisms is
needed to assay the genotoxic potential of nanomaterials. Furthermore, in vitro genotoxicity testing of
nanomaterials should always include an assessment of cellular uptake (Magdolenova et al., 2014;
Dekkers et al., 2016). Speciﬁc recommendations on how to conduct the genotoxicity tests for
nanomaterials are also described by Pfuhler et al. (2013) and Doak et al. (2012).
In selecting a suitable battery of in vitro genotoxicity tests, the three critical genotoxicity endpoints
(gene mutation, structural and numerical chromosome aberrations) should be considered. The following
in vitro tests are required for assessment of genotoxicity in the context of the present Guidance:
1) A test for induction of gene mutations – A bacterial reverse mutation (Ames) assay is usually
recommended for the detection of gene mutations. However, since nanomaterials may not
be able to penetrate the bacterial cell wall and because bacterial cells, unlike mammalian
cells, do not have the ability to internalise (Doak et al., 2012), the OECD Expert Meeting on
‘Genotoxicity of Manufactured Nanomaterials’ concluded that the Ames test (OECD TG 471
(1997b)) is not a recommended method for investigating the genotoxicity of nanomaterials
(OECD, 2014b). In this respect, the use of mammalian cell models is considered more
suitable: both the in vitro mammalian cell gene mutation tests using the Hprt and xprt
genes (OECD TG 476 (2016b)) and the in vitro mammalian cell gene mutation tests using
the thymidine kinase gene (OECD TG 490 (2016e)) are appropriate. In speciﬁc
circumstances (e.g. indirect genotoxic effects due to extracellular induction of reactive
oxygen species), an Ames test might still be informative.
2) A test for structural and numerical chromosome damage, i.e. the in vitro mammalian cell
micronucleus test (OECD TG 487 (2016c)) – To take into account the possibly low particle
penetration into the cell nucleus and to facilitate the contact of nanomaterials with DNA
after nuclear membrane dissolution during mitosis, a long-duration treatment, covering two
cell cycles, is advisable (Catalan et al., 2012). If cytochalasin B is used in the test, its
addition to cell cultures after nanomaterial treatment must be delayed because of its ability
to inhibit endocytosis and reduce nanomaterial cell uptake (Gonzalez et al., 2011; Doak
et al., 2012; Magdolenova et al., 2012; Pfuhler et al., 2013). According to the OECD TG 487
(2016c), micronucleus detection by ﬂow cytometry is acceptable, provided the potential
interference of nanomaterials with the dyes applied in the analysis is taken into account (Li
et al., 2017). Several mammalian cell models have been used for nanomaterial genotoxicity
assessment that show comparable or differential sensitivity (European Comission Joint
Action, 2008–2013, Nanogenotox;27 European Union Seveht Framework Program, 2007–
2013, Nanoreg;28 Cowie et al., 2015). Cell lines representative of the gastrointestinal tract
• A case for read-across of data from one (nano)material to another nanomaterial to ﬁll a data
gap may be made on the basis that the two (or more) variants of the nanomaterial of the
same chemical composition have comparable physicochemical and toxicokinetic proﬁles.
• A case for read-across may also be made on the basis that the source (nano)material
exhibits a more worst case than the target nanomaterial.
27 Nanogenotox was a Joint Action of European Commission and a consortium of national institutions of Member States which
was funded by European Commission’s health programme (46%), while partners and some ministries of the participating
Member States (Belgium, France, Germany, and Netherlands) provide the remaining. www.nanogenotox.eu
28 http://www.nanoreg.eu/
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or the expected target tissue should be considered as ﬁrst choice. In selecting the most
appropriate mammalian system for in vitro genotoxic hazard identiﬁcation, the uptake
capability should be considered as a critical feature because the internalisation of a
nanomaterial is a crucial step in understanding its behaviour and toxicity (Magdolenova
et al., 2014; Dekkers et al., 2016).
Most poorly soluble nanomaterials are not metabolised and the metabolic activation system (S9)
may interfere with the assay reducing the nanomaterial bioavailability. Organic nanomaterials or some
inorganic nanomaterials coated with organic functional groups may however exert their genotoxic
effects in the presence of the metabolic activation system (Shariﬁ et al., 2012). The use of S9 in the
tests should therefore be evaluated case by case.
The in vitro comet assay, though not yet validated, may provide complementary information and
contribute to an understanding of the nanomaterial genotoxicity mechanisms. The modiﬁed comet
assay for detection of oxidative DNA lesions can be recommended as many nanomaterials have been
shown to induce oxidative stress or at least a concomitant measurement of oxidative stress (ROS,
antioxidants). If in vivo assays are necessary, the comet assay also allows them to be better designed
(Møller et al., 2015; Collins et al., 2017). Possible interference by residual intracellular nanomaterials
during the assay procedure, producing artefactual positive results, must be evaluated (Ferraro et al.,
2016; George et al., 2017) and explained. The in vivo comet assay should not be combined to repeat-
dose oral studies without using satellite groups because of the need to sample at Tmax which is not
possible in the general toxicity autopsy procedures.
The interpretation of the results from the in vitro genotoxicity studies would be supported by an
assessment of cellular uptake (and nuclear uptake, if feasible) of nanoparticles. However, an absence
of observed cellular uptake does not mean that the material will have no genotoxic potential, since it
can also indirectly induce secondary mechanisms of genotoxicity (without cellular uptake).
If at least one of the in vitro tests indicates genotoxic activity, or if it is not appropriate to test the
nanomaterial in vitro (e.g. if the dispersion medium is not compatible with the in vitro system), this
normally requires follow-up by in vivo testing (Eastmond et al., 2009; EFSA Scientiﬁc Committee,
2011b, 2017d), unless it can be adequately demonstrated by other means that the positive in vitro
ﬁndings are not relevant for the in vivo situation. It has to be noticed that inﬂammatory effects
induced by nanomaterials can generate reactive radical species, potentially triggering secondary
genotoxicity that cannot be detected by in vitro systems. In this case an in vivo comet assay, which
can also provide information on mode of action (and when combined with other tests), is
recommended for inclusion in a repeated-dose oral toxicity study (Pfuhler et al., 2013).
The choice of the appropriate in vivo genotoxicity test(s) requires expert judgement, based on all
available information. It should be related to the genotoxic endpoint(s) identiﬁed as positive in vitro
and performed on appropriate target organ(s) or tissue(s). As outlined in the EFSA Genotoxicity testing
strategies (EFSA Scientiﬁc Committee, 2011a, 2017d), in vivo genotoxicity testing should be performed
in a step wise approach depending on the outcome of the in vitro tests. Accordingly, the following
in vivo tests testing may be suitable:
• an in vivo micronucleus test (OECD test guideline 474). Demonstration of target tissue
exposure is required following the considerations as provided in EFSA Scientiﬁc Committee,
2017d.
• an in vivo mammalian alkaline comet assay (OECD test guideline 489)
• a Transgenic rodent somatic and germ cell gene mutation assay (OECD test guideline 488
(OECD, 2013))
Based on expert judgement, a combination of these tests applied to the same individual animals
may be advisable.
Evidence, either from the test itself or from other toxicokinetic (see Section 6.6) or repeated-dose
toxicological studies (see Section 6.7), that the target tissue(s) (for instance bone marrow in the
in vivo micronucleus test) have been exposed to the nanomaterial and/or its metabolites is essential
for interpretation of negative results (EFSA Scientiﬁc Committee, 2017d).
A number of activities are currently ongoing to harmonise, update, reﬁne and eventually validate
genotoxicity tests of conventional materials for their application to nanomaterials. Such developments
and any updates in the genotoxicity tests (OECD, 2016c) have to be considered before embarking on
genotoxicity testing for the purposes of this guidance.
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6.5. In vitro toxicity testing
In vitro tests in Step 1 may also provide insights into a nanomaterial’s hazard and its mode of
action upon e.g. internal exposure (see Section 6.10). The in vitro toxicity tests may add to the weight
of evidence approach (see Section 7). Although the Scientiﬁc Committee cannot provide more
guidance on which assays or endpoints to use, it notes the following information.
Considering oral intake as the main in vivo route of administration, several in vitro approaches may
be applied to generate additional hazard identiﬁcation information (Drasler et al., 2017). In vitro
models based on primary cells or cell lines and on monoculture or coculture systems are available to
represent the gastrointestinal tract. Coculture-based systems (including 3D in vitro models), compared
to monocultures, can provide conditions more closely mimicking in vivo; e.g. human colorectal
epithelial cells (CaCo-2) combined with immune cells and mucus-secreting cells (Gamboa and Leong,
2013). Primary human cells, such as primary human oesophageal epithelial cells either in monoculture
or (better) in coculture, may therefore be used to represent the gastrointestinal tract. Two or three
different cell types need to be tested. Yet, the disadvantage of primary cells is a substantial batch to
batch variations as well as they are more difﬁcult to obtain and to culture. Besides the gastrointestinal
cellular models, it is also important to test immune cells such as macrophages (e.g. primary human
monocyte-derived macrophages or human monocytic cell line THP-1). As nanomaterials are prone to
translocate through the gastrointestinal barrier, they might enter the circulatory system and reach, e.g.
liver, spleen and kidney. It is therefore recommended to include the respective representative cell
types (e.g. hepatocytes) in the testing strategy. In addition, the commercially available whole blood
cytokine release kit can serve for characterisation of immunotoxic reactions, including
immunostimulation and immunosuppression of immune responses (Langezaal et al., 2001, 2002) even
though it is not directly representative for testing gut-associated immune responses.
Detailed cell characterisation (i.e. cell source, passage number, cell growth, morphology and
differentiation before and during the test performance) and precise description of cell culture method
need to be reported in order to verify the method’s reliability. Exposure and post-exposure times need
to be well deﬁned and justiﬁed with respect to the individual tested parameters. For mono- or
co-culture systems grown on membrane inserts, conﬂuence and viability must be checked for the
appropriate level of resistance by transepithelial electrical resistance (TEER) measurements before
cytotoxicity assay. For the reporting of any non-OECD approved in vitro assay, it is required that the
Guidance OECD 211 is followed (OECD, 2014c).
Speciﬁc endpoints can be considered to investigate the effects of nanomaterial on, e.g. impaired
cell viability/cytotoxicity, oxidative stress responses, (pro-) inﬂammatory responses (as part of
immunotoxicity), and integrity of the gastrointestinal barrier.
• Genotoxicity testing of nanomaterials should follow the general indications of the EFSA
genotoxicity testing strategy (EFSA Scientiﬁc Committee, 2011a) taking into account the
speciﬁc properties of nanomaterials.
• In vitro genotoxicity testing of nanomaterials should always include an assessment of cellular
uptake, especially to substantiate negative test results.
• In selecting a suitable battery of in vitro genotoxicity tests, the three critical genotoxicity
endpoints (gene mutation, structural and numerical chromosome aberrations) should be
addressed.
• The bacterial reverse mutation (Ames) assay is not considered suitable for nanomaterials due
to limitations in the penetration of particles through the bacterial cell wall and the lack of
internalisation in bacteria.
• The use of S9 in the tests should be evaluated on a case by case basis.
• Where at least one of the in vitro tests indicates genotoxic activity, or if it is not appropriate
to test the nanomaterial in vitro, a follow-up in vivo study should be carried out, unless it
can be demonstrated by other means that the positive in vitro ﬁndings are not relevant for
in vivo situation.
• Expert judgement should be used to select one or more of the available in vivo tests e.g.
in vivo micronucleus test (OECD TG 474); in vivo mammalian alkaline comet assay (OECD TG
489); Transgenic rodent somatic and germ cell gene mutation assay (OECD TG 488)
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A number of parameters can be considered for investigation of cytotoxicity in in vitro models,
including membrane rupture by the lactate dehydrogenase (LDH) leakage assay or impaired cellular
metabolism using e.g. MTTor MTS reduction assays. Proinﬂammatory responses in vitro can be measured
via enzyme-linked immunosorbent assays (ELISA) for speciﬁc proinﬂammatory cytokines (Elsabahy and
Wooley, 2013) and/or immune markers. There are also other convenient screening methods available
that allow for the simultaneous detection of multiple pro- and anti-inﬂammatory mediators (Multiplex
analysis based cytokine proﬁling; Bhattacharya et al., 2017). Additionally, oral-route speciﬁc endpoints
might be considered, for example the effect of nanomaterials on hepatic function by measuring metabolic
activity of hepatocytes in vitro (e.g. via modiﬁcation of the expression level or the activity of enzymes
involved in the xenobiotic metabolism such as the cytochromes P450). It is also important to consider any
potential interference of nanomaterials with in vitro test systems (see section 6.9.1) (Cornu et al., 2018).
Nanomaterial translocation through the gastrointestinal barrier in vitro may serve only as supporting
data for further in vivo investigations. In vitro translocation models are grown on Transwell  system
membranes. These membranes may hamper translocation by adherence of nanomaterials (resulting
from a possible inability to pass through the membranes or from nanomaterial attachment).
Depending on the type of application (e.g. animal feed, pesticide), in vitro tests may also be used to
determine dermal absorption and skin sensitisation potential of the nanomaterial. These involve standard
in vitro tests as required for bulk (non-nanomaterial) substances (see Appendix E for animal feed and
pesticides) but must be carried out in consideration of the nanospeciﬁc aspects as detailed in Section 6.9.
If in vitro results indicate compromised epithelial barrier integrity, release of (pro-)inﬂammatory
mediators, effects on immune cells or immune response, appropriate targeting in in vivo studies should
be considered (see Sections 6.7 and 6.8). As mentioned in Section 6.1 for most cases that have
entered Step 1, it is anticipated that testing under Step 2 will be required. In some cases, however,
when the in vitro methods do not indicate effects and in vitro degradation in lysosomal and
gastrointestinal conditions is fast, an argument may be made for waiving in vivo studies. Such an
argument is to be assessed by EFSA on a case-by-case basis. Outcomes of in vitro tests may serve as
basic evidence of a possible nanomaterial hazard and can contribute to the design and interpretation
of in vivo studies by identifying their modes of action.
The dosimetry aspect, i.e. assessment of the dose delivered to the cells and the internalised dose is
important for a sound interpretation of the in vitro cytotoxicity data. Besides information on particle
mass per incubation volume or particle mass per cell culture dish surface, also data on incubation
volume, cell culture dish size, cell number, etc., should be provided (consult also the Section 6.9.1).
6.6. Toxicokinetics (ADME)
Toxicokinetics (ADME) is important in human health risk assessment and greater application of
toxicokinetics could offer more efﬁciency, use fewer test animals and provide better data. For risk
assessment of nanomaterials, as well as for substantiation of read-across to other materials, e.g.
non-nanomaterial or a similar nanomaterial, toxicokinetic information is crucial. This is because
nanomaterials may show different toxicokinetic behaviours (i.e. signiﬁcant changes in absorption,
• In vitro toxicity data may be used as additional weight of evidence and/or to target further
in vitro testing.
 Speciﬁc endpoints relevant for in vitro testing are: cytotoxicity/cell viability, induction
of oxidative stress, (pro-)inﬂammation and gastrointestinal barrier integrity
impairment.
 Use of cocultures is often preferred over the monocultures when testing on a more
complex system is desired, yet depending on the objective; standard monocultures
are also informative, easier to standardize and can be useful for screening purposes.
 Complete dosimetry information should be provided (e.g. particle mass per incubation
volume or particle mass per cell culture dish surface, incubation volume, cell culture
dish size, cell number).
• Where in vitro methods indicate lack of toxic effects, and in vitro dissolution of the
nanomaterial in lysosomal and gastrointestinal conditions is fast, an argument can be put
forward to EFSA for waiving in vivo studies on a case-by-case basis.
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distribution and/or metabolism and excretion) compared with larger sized materials and solutes with
the same chemical composition (Hagens et al., 2007; Higashisaka et al., 2017).
Their size-related properties, shape or surface characteristics can affect the toxicokinetic behaviour.
For example, particle uptake by intestinal epithelial cells is size dependent (Powell et al., 2010; Fr€ohlich
and Roblegg, 2012; Howe et al., 2014; Macierzanka et al., 2014). It seems that 20–40 nm
nanomaterials are easily taken up by intestinal cells (enterocytes). M-cells in Peyer’s patches can
rapidly (within minutes) internalise not only a signiﬁcant number of nanoparticles (20–100 nm), but
also few large particles (0.5–2 lm) (Howe et al., 2014). Based on the available information, Powell
et al. (2010) suggest that the mechanism of intestinal uptake is likely to be size dependent, and there
may well be an optimum size for gut uptake, tentatively around 50 nm, with perhaps a range of
20–250 nm. This size dependent behaviour can also be inﬂuenced by coating.
The toxicokinetic (ADME) investigations to be followed are presented in a stepwise assessment.
In Step 1, the existing information is gathered, on the speciﬁc nanomaterials as well as similar
materials (such as the non-nanomaterial). This includes existing information on the toxicokinetic
behaviour. In particular, information on the absorption/bioavailability, distribution pattern and clearance
is considered relevant, as physicochemical properties of nanomaterials are known to be able to affect
these. In addition, in vitro tests with the nanomaterial are performed in Step 1 (see Figure 3). Since
nanomaterials may not be easily cleared, they may accumulate over time (Geraets et al., 2014;
Kermanizadeh et al., 2015a,b; Kreyling et al., 2017).
It is therefore considered important to assess the degradation of nanomaterial in lysosomal ﬂuid,
considered as model as this is where nanomaterials generally distribute to and where degradation can
occur due to the acidic conditions and presence of enzymes. Information on the degradation rate under
simulated lysosomal conditions in combination with the degradation rate in simulated gastrointestinal
conditions (as obtained in Step 0) provides insight into the likelihood of persistence and
bioaccumulation of the material. An argument may be put forward that further testing (e.g. Step 2) is
not necessary only in cases of non-persistence based the degradation rate under simulated lysosomal
and gastrointestinal conditions with no indication of potential toxicity based on existing information and
the in vitro test battery.
When there is a soluble non-nanocounterpart of the material, it is important to report any
differences in toxicokinetics between the nanomaterial and the corresponding soluble substance. In
addition, in the case of a bulk material containing a range of particle sizes, it is recommended to do
(when possible) the in vitro testing in Steps 0 and 1 for both the nano and non-nanomaterial to gain
insight into potential differences in behaviour and nanospeciﬁc hazards that would lead to the next tier
of testing. The presence of nanosized particles indicates that nanospeciﬁc considerations are relevant.
Information gathered in Step 1 should be used to ﬁne-tune Step 2. For example, the design of the 90-
day study and the satellite groups of Step 2b will beneﬁt from pilot studies for dose ﬁnding and
assessment of absorption, tissue distribution and accumulation, elimination phase (Step 2a  14 days).
Demonstration of absorption of nanomaterial can be challenging in a 14-day study. In this case, the
applicant goes to Step 2b directly. Also, a limited rate of degradation in gastrointestinal and lysosomal
ﬂuids suggests that the material may be persistent in tissues in particulate form and that information
from longer time period may be needed to assess the clearance after the last dosing. The degradation
rate may also indicate whether toxicity is due to release of ions or molecules at the sites of distribution.
Step 2b consists of a modiﬁed 90-day oral toxicity test (OECD TG 408 with extended parameters
from the OECD TG 407 (2008)) (preliminary reference OECD TG 408 (2017a)). Studies on
toxicokinetics in animals should be conducted using internationally agreed test guidelines, such as
OECD TG 417 (2010). This guideline describes general methodologies for performing ADME studies. It
provides minimum criteria for acceptance of studies but makes clear that studies should be designed
on a case by case basis. Moreover, the OECD Expert Meeting on ‘Toxicokinetics of manufactured
nanomaterials’ concluded that OECD TG 417 needs to be revised it in order to make it appropriate for
nanomaterials (OECD, 2016d).
The difﬁculties of undertaking ADME studies on nanomaterials should not be underestimated. There
may be particular difﬁculties in measuring the amounts of nanomaterial in blood, tissues and excreta,
and in establishing the form in which they are present in the body (see Section 4.3.2). Nanomaterial
surface transformations affecting, e.g. the dynamics of adherence of proteins and other biomolecules
can have a profound effect on ADME.
For ADME studies, it is essential that a measurement system is available for detecting either the
nanomaterial or its elemental composition in organs, tissues and other biological samples. Alternatively,
labelling of the nanomaterial may be used, either directly (radioactive or stable isotopes) or indirectly
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(ﬂuorescent dyes or radiolabels). ICP-MS has the limitation that the chemical element is determined
rather than the presence of the nanomaterial itself (i.e. more than the nanosized fraction may be
detected), but combining it with suitable separation techniques or turning to spICP-MS and/or
analytical electron microscopy (Tassinari et al., 2014) could overcome this. Radioactive isotopes have
been used for certain metal nanomaterial (Geiser and Kreyling, 2010; Kreyling et al., 2017).
Fluorescence labelling or labelling with radiolabelled chemicals has the disadvantage that the label may
be released from the nanomaterial. In such a case, the distribution of the label may not be indicative
of the presence of the nanomaterial (Geiser and Kreyling, 2010). The choice of the labelling and
detection technique should be based on the composition of the nanomaterial, e.g. metal nanomaterials
vs lipid-like nanomaterials. In addition, the impact of the labelling system on the properties and activity
of the nanomaterial should be considered. For example, coupling certain ﬂuorescent dyes may change
the hydrophobicity/hydrophilicity of the nanomaterial.
A satellite group should be added to the 90-day oral toxicity study to investigate if and to what
extent the nanomaterial could accumulate. In the satellite group, the tissue distribution of the
nanomaterial should be determined after a short-dosing period (i.e. 2 weeks) and at the end of the
90-day study. Preferably, the tissue distribution after an elimination period should also be determined,
for example for animals that were dosed for the short 2-week period. Nanomaterials are generally
quickly – often within minutes – taken up by tissues (Landsiedel et al., 2012). Blood or plasma
concentration–time information therefore usually has limited value, and only a small number of data
points are necessary. In such cases, a rough estimate of toxicokinetic plasma parameters (t1/2, area
under the curve (AUC), bioavailability, Cmax and Tmax) would be sufﬁcient. Because nanomaterials are
taken up by the mononuclear phagocyte system (MPS), they typically distribute to liver and spleen,
and to a lesser extent to tissues such as the kidney, bone marrow and lung. Nanomaterial retention
within the gut wall is also an important determinant, particularly when discriminating between
retention in epithelial cells vs immune-competent M-cells in Peyer’s patches. In the gastrointestinal
tract, gut-associated lymph tissue (GALT), particularly in Peyer’s patches and mesenteric lymph nodes,
is of importance for potential nanomaterial accumulation and immune responses.
The difference in organ concentration between days 0, 14 and 90, as well as the rate of elimination
should be used to assess the likelihood for accumulation, given the anticipated exposure pattern in
humans. Any signiﬁcant increase in tissue concentration between days 14 and 90, or slow release during
the elimination period, should be discussed in this light, and triggers further assessment in Step 3.
The relationship between dose and tissue concentrations should be assessed, as oral absorption
and other toxicokinetic processes may be dose dependent, e.g. as a result of aggregation of the
nanomaterial at high doses. The amount distributed to tissues should be considered in estimating the
absorption of the nanomaterial. Mass balance studies are recommended.
Performing a pilot study including some toxicokinetic assessment is recommended for targeting of
the hazard assessment and for dose ranging to avoid the administration of highly toxic doses in Step 2
and onwards.
A negative control – a group that is not exposed – is used to assess e.g. background exposure.
For the purpose of comparison and potential use in read across, in the absence of existing data, it
is advisable to include a control with the conventional non-nanomaterial.
Little is known about route-to-route extrapolation for nanomaterials. In principle, therefore, oral
studies should be performed, since this will be in many cases the relevant exposure route for food/
feed applications.29
In Step 3, there may be a need for additional toxicokinetic studies to evaluate the effect of
repeated dose administration and whether this leads to steady-state conditions or accumulation of the
nanomaterial. In such circumstances, it is possible that the kinetics observed in experimental animals
may need to be validated in human studies. This reﬁnes the risk assessment and may also be required
where there is evidence that age, physiological state, disease state, etc., could modify the toxicokinetic
behaviour.
Toxicokinetic modelling can be employed to estimate/extrapolate the fate of nanomaterials in
animals and humans to other exposure scenario’s, e.g. other duration or dose, or to other species, e.g.
animal to man.
In summary, assessment of the toxicokinetics of nanomaterials has to include the following:
29 For dermal and inhalation routes of exposure to nanomaterial in food or feed, see Appendix E.
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 Step 1 comprises assessment of existing information on the speciﬁc nanomaterial as well as
similar nanomaterials and non-nanomaterials (bulk) form. This step also includes
determination of the degradation rate in lysosomal conditions. Taken together with
information on in vitro toxicity and degradation rate in simulated gastrointestinal conditions
(Step 0), an argument can be put forward that further testing is not necessary in some cases.
Information gathered in Step 1 should be used to ﬁne tune Step 2.
 Step 2 consists of toxicokinetic studies linked with a 90-day oral toxicity study in rodents.
Information on tissue distribution should be obtained before dosing, after a short-dosing
period, i.e. 2 weeks, and at the end of the 90-day toxicity study. Preferably, tissue distribution
after an elimination period would also be determined. The extent to which nanomaterials can
accumulate in tissues should be investigated. Any signiﬁcant increase in tissue concentration
between days 14 and 90, or slow release during the elimination period triggers further
assessment in Step 3.
 Step 3 toxicokinetic studies can be designed to investigate to what extent accumulation of the
nanomaterial occurs with long-term exposure and determine whether there are species
differences in toxicokinetic behaviour between animals and humans or because of other
physiological or disease factors. These studies permit reﬁnement of the risk assessment by
decreasing the uncertainty.
6.7. In vivo repeated-dose 90-day oral toxicity study
For ingested nanomaterial, the minimum requirement is the modiﬁed 90-day toxicity test (OECD TG
408 with extended parameters from the OECD TG 407 (2008)) (preliminary reference (OECD TG 408
(2017a)). The modiﬁed 90-day study should allow for the identiﬁcation of nanomaterials with the
potential to cause neurotoxic, immunological, reproductive organ or endocrine-mediated
effects that either provide sufﬁcient information for risk assessment or require further in-depth
investigation. After systemic translocation (as identiﬁed in the ADME study), most nanomaterials are
likely to end up in the MPS tissues, therefore, in repeated-dose studies, speciﬁc attention should be paid
to cardiovascular and inﬂammatory parameters as well as to sites/organs involved in or part of the MPS.
Preliminary range-ﬁnding studies conducted for shorter periods can indicate target organs and help
in selection of appropriate doses for 90-day studies. When range-ﬁnding studies have been conducted,
the results should be submitted in the dossier. Studies of shorter duration than 90-days are generally
not sufﬁcient, by themselves, for evaluation of potential subchronic toxicity.
In the cases for which Step 2a Toxicokinetics testing indicates a lack of systemic availability, still any
local adverse effects on the gastrointestinal tract have to be considered which will be covered by
the gastrointestinal histopathology in the 90-day study (Step 2b).
The results from the 90-day toxicity study should also be used to determine whether sufﬁcient
information for risk assessment is available or whether additional testing is required (e.g. for chronic
effects, in-depth reproductive and developmental toxicity, or speciﬁc studies on
immunological, neurological end points or endocrine activity). If no triggers for additional
• All available information must be collated along with data from in vitro tests from Step 1 to
identify any changes in the toxicokinetic behaviour, bioavailability, and persistence and
bioaccumulation of the nanomaterial compared to non-nanomaterial equivalent.
• Performing a pilot study that includes some toxicokinetic assessment is recommended for
targeting of the hazard assessment, and for dose ranging to avoid administration of highly
toxic doses in Step 2 and onwards.
• A satellite group should be added to the 90-day oral toxicity study to investigate if and to
what extent the nanomaterial could accumulate. Tissue distribution should be included in the
distribution studies.
• An appropriate measurement system should be used to detect the nanomaterial or its
elemental composition in organs, tissues and other biological samples. Labelling of the
nanomaterial may be used where possible.
• Distribution of the nanomaterial to speciﬁc tissues should trigger further assessment on e.g.
neurotoxicity and reproductive toxicity in Step 3. If in-depth investigations in Step 3 are
necessary, the kinetics observed in experimental animals may need to be validated by studies
in human studies.
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testing are identiﬁed, then the 90-day study can be used to identify a reference point for risk
assessment according to the type of food chemical (e.g. food additives, feed additives, enzymes,
ﬂavourings, novel foods and nanomaterials that are incorporated into products that come into contact
with food (e.g. FCMs and articles)).
6.8. Higher tier toxicity testing
Evidence of absorption of the material and ﬁndings in the 90-day toxicity study are triggers for
proceeding to Step 3. This step features specialised studies on the endpoints presented in the
subsections below. The purpose of investigations into mechanisms and modes of action is to determine
the relevance for man of effects observed in the test species as part of a mode of action framework
analysis by the evaluator (Meek et al., 2013).
Information on the levels of nanomaterials present in key tissues in animals of Step 3 studies can
be useful in the risk characterisation, as this provides direct information on the internal exposure.
Nanomaterials may be absorbed to a very small extent from the gastrointestinal tract, whereas at the
same time they may accumulate in tissues in time, making the amount of nanomaterial reaching
tissues and potentially causing systemic toxicity difﬁcult to predict. Hence, measuring the level of
nanomaterials in a few relevant tissues, for example by analysis of a part of the tissue at the end of
Step 3 studies, can be used for better interpretation of the study and interpretation of the study result
in relation to exposure and other studies.
6.8.1. Chronic toxicity and carcinogenicity
Chronic toxicity and carcinogenicity studies are performed in a single species, generally the rat.
Either separate studies (OECD TGs 452 (2009d) and OECD TGs 451 (2009c), respectively) or
preferably the combined study (OECD TG 453 (2009e)) can be carried out. Carcinogenicity study in a
second species would only be triggered by the results in the preferred species (equivocal results or
species speciﬁc ﬁndings) or by observations from specialised studies to investigate the mode of action
or mechanism of toxicity or carcinogenicity observed.
6.8.2. Reproductive and developmental toxicity
There are indications in the literature suggesting that systemic exposure to speciﬁc nanomaterials
may result in adverse effects on reproduction and development (Brohi et al., 2017). In this review,
• For ingested nanomaterials, the minimum requirement is the modiﬁed 90-day toxicity test
(OECD TG 408 with extended parameters from the OECD TG 407 (2008).
• Speciﬁc attention should be paid in repeated-dose studies to cardiovascular and
inﬂammatory parameters as well as to sites/organs involved in or part of the MPS.
• A satellite group should be added to the 90-day oral toxicity study to investigate
toxicokinetics (Section 6.6).
• Where results indicate a lack of systemic availability, local effects on the gastrointestinal tract
must be considered.
• The results from the 90-day study should be used to determine whether sufﬁcient
information for risk assessment is available or whether additional testing is required (e.g. for
chronic effects, in depth reproductive and developmental toxicity, or speciﬁc studies on
immunological, neurological end points or endocrine activity).
• The results from the Step 2 modiﬁed 90-day oral toxicity study can be used to identify a
reference point (such as BMDL and NOAEL). The results in conjunction with evidence of
absorption of the material will determine the need for proceeding to Step 3.
• Step 3 features studies on chronic toxicity and carcinogenicity in a single species, generally
rat, and may also include, where triggered by the ﬁndings, further testing for reproductive
and developmental toxicity, immunotoxicity and allergenicity, neurotoxicity or endocrine-
mediated effects.
• Information on the levels of nanomaterials present in key tissues in animals used in step 3
studies should also be considered in risk characterisation.
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ROS generation and inﬂammation, direct interaction with the male and female reproductive systems,
alterations of ovarian gene expression and steroidogenesis, adverse effects on fetal morphology,
organogenesis and development have been related to reproductive and developmental toxicity induced
by speciﬁc nanomaterials. Some nanomaterials, depending on their physicochemical properties, were
reported to be able to penetrate the blood–testis barrier and the placental barrier (Brohi et al., 2017).
The data from Step 2 subchronic toxicity testing are relevant when considering the need for
reproductive and developmental testing in Step 3.
The repeated dose 90-day oral toxicity study (OECD TG 408 (2017a)) offers only limited
information on reproductive toxicity and none on developmental toxicity; it can inform about effects on
the reproductive organs and, if assessed, the oestrous cycle, but it does not assess fertility and the
whole reproductive cycle from in utero exposure onwards, through sexual maturity to conception,
gestation, prenatal and postnatal development. Decisions on whether tests are necessary for
reproductive and developmental toxicity need to be considered in light of the toxicity data and
toxicokinetics information available. If the Step 2 toxicokinetic study shows that the test
material is systemically available in the test species (normally rodents) or suspected to be
systemically available in humans, Step 3 testing for reproductive and developmental
toxicity is required. For materials that do not appear to be systemically available, indications of
effects on reproductive organs or parameters in the 90-day oral toxicity will also trigger Step 3 testing
for reproductive and developmental toxicity. In the case where absorption appears to be very low,
Step 3 reproductive and developmental toxicity studies may still be needed if the tissue distribution
data from the 90-day oral toxicity study indicate that the test material is able to reach reproductive
organs and distribute there.
Step 3 testing for reproductive and developmental toxicity comprises a prenatal developmental
toxicity study (OECD TG 414 (2001)) and an extended one-generation reproductive toxicity study
(EOGRTS) (OECD TG 443 (2012a)). Cohorts for the preliminary assessment of additional more speciﬁc
endpoints should be routinely incorporated in the EOGRTS. Where it already exists, a multigeneration
study, instead of an EOGRTS, would be acceptable, provided that sufﬁcient information on possible
neurotoxicity and immunotoxicity is available (for example from an extended 90-day study, OECD TG
408 (2017a)).
The EOGRTS in the rat will provide information evaluating speciﬁc life stages not covered by the
other toxicity studies: fertility and reproductive function, and short to long-term developmental effects
from exposure during pregnancy, lactation and prepubertal phases, as well as effects on juvenile and
adult offspring will be assessed, by efﬁciently integrating several endpoints covering the whole
reproductive cycle (from gametogenesis through to maturation of the following generation) as well as
preliminary assessment of additional more-speciﬁc endpoints (i.e. developmental neurotoxicity and
developmental immunotoxicity). According to OECD Guidelines (TG 443 (2012a)), the selected
parameters to be measured in the EOGRTS fall into the following categories:
 reproductive endpoints
 developmental (prenatal and postnatal) endpoints
 speciﬁc endpoints (developmental neurotoxicity, immunotoxicity and endocrine disruption).
With the additional parameters evaluated in the F1 generation in the EOGRTS, it is expected that
the F2, with their limited parameter assessments, would seldom affect the hazard characterisation for
risk assessment (Piersma et al., 2011). When predicted human exposures are considered adequately
characterised, however, this may be factored into the decision to require the assessment of an F2
generation.
In devising appropriate Step 3 additional testing, a case-by-case approach should be adopted with
careful consideration given to all available data as well as animal welfare issues. Step 3 testing is
triggered by results in Step 2 studies and might be comprised of additional studies for. e.g. endocrine,
developmental neurotoxicity (OECD TG 426 (2007)), and mode-of-action studies that could include
both guideline studies and experimental studies designed on a case-by-case basis.
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6.8.3. Immunotoxicity and Allergenicity
Immunotoxicity may manifest in the form of adverse effects on the structure and function of the
immune system itself, or an adverse consequence (such as an allergic or autoimmune reaction) that
may arise from the immune response. Most inorganic and small-molecule organic substances in
conventional (non-nanomaterial) forms are not immunogenic, but may act as haptens and become
immunogenic after binding to proteins. In addition, they may act as adjuvants for other immunogens.
For example, aluminium compounds have been used as adjuvants in vaccines. Nanomaterial forms of
these compounds may present different immunological behaviour compared with conventional
materials.
In addition to being potentially immunogenic/antigenic themselves, nanoparticles may also act as
‘Trojan horses’ for other immunogens/antigens by binding them on to the particle surfaces and
carrying them to immune cells (see Section 3). The state of current knowledge on the immunotoxicity
of nanomaterials, and guidance on methods to evaluate this, will be described in a WHO publication,
which has undergone public consultation in 2017 (DRAFT WHO, 2017 ‘Draft Environmental Health
Criteria Document: Principles and Methods to Assess the Risk of Immunotoxicity Associated with
Exposure to Nanomaterials’, once the ﬁnal document is published, an additional reference will be
provided as a corrigendum).
The tiered approach to testing outlined in this present Guidance includes, at Step 2, a 90-day study
in rats (OECD TG 408 (2017a)). This involves investigation of the effect of the nanomaterial on a
number of parameters that may be indicative of an immunotoxic or immunomodulatory effect. These
include: changes in spleen and thymus weights relative to body weight in the absence of overt toxicity,
histopathological changes in these and other organs of the immune system (e.g. bone marrow, lymph
nodes, Peyer’s patches); changes in total serum protein, albumin:globulin ratio and in the
haematological proﬁle of the animals, i.e. the total and differential white blood cell counts.
The effects may be extended or, alternatively, seen for the ﬁrst time in Step 3 studies, notably the
EOGRTS (OECD TG 443 (2012a)), but also in chronic toxicity/carcinogenicity studies conducted
according to OECD TGs 452 (2009d), OECD 451 (2009c) or OECD 453 (2009e). In the EOGRTS, a
cohort of animals is speciﬁcally dedicated to assessing the potential impact of exposure on the
developing immune system. In subchronic and chronic studies, haematological and clinical chemistry
data are generally provided, together with phenotypic analysis of spleen cells (T-, B-, NK cells) and
bone marrow cellularity. The EOGRTS provides additional information on the primary immunoglobulin
M (IgM) antibody response to a T-cell-dependent antigen such as sheep red blood cells (SRBC) or
keyhole limpet hemocyanin (KLH).
Evaluation of the potential of a nanomaterial to adversely affect the immune system may be based
on an integrated assessment of the results obtained from these toxicity studies (Steps 2 and 3). If
these results indicate that the nanomaterial has such a potential, additional Step 4 studies should be
considered, on a case-by-case basis. These will normally be designed to investigate the underlying
mechanisms of the effects seen, and/or their biological signiﬁcance. Step 4 studies may include
specialised functional, mechanistic, and disease model studies. There are no OECD guidelines for these
extended specialised studies, but these should be based on IPCS.
• Whether tests for reproductive and developmental toxicity are necessary should be decided
in the light of the toxicity data and toxicokinetics information.
• Step 3 testing for reproductive and developmental toxicity will be required if the Step 2
toxicokinetic study shows that the test material is systemically available in the test species
(normally rodents) or suspected to be systemically available in humans – especially if the test
material is able to reach reproductive organs.
• Testing for reproductive and developmental toxicity should comprise a prenatal
developmental toxicity study (OECD TG 414) and EOGRTS (OECD TG 443) that addresses
reproductive developmental (prenatal and postnatal) and other speciﬁc endpoints
(developmental neurotoxicity, immunotoxicity and endocrine disruption)
• Where a multigeneration study is already available, it would be acceptable instead of an
EOGRTS, provided that sufﬁcient information on possible neurotoxicity and immunotoxicity is
available from, e.g. an extended 90-day study (OECD TG 408).
• In devising appropriate Step 3 additional testing, a case-by-case approach should be
adopted with careful consideration to animal welfare and all available data.
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At present, there are no data or validated studies in laboratory animals that would allow
assessment of the potential of a substance to cause allergic reactions in susceptible individuals
following oral exposure. Where the nanomaterial is a potential allergen (e.g. a protein or a peptide) or
contains residues of proteins or other known potential allergenic molecules, the principles discussed in
the EFSA Guidance on the Allergenicity of GMOs should be followed in evaluating allergenic
components. These principles for the determination of allergenicity include the investigation of
structural aspects of the protein or peptide, in silico (or bioinformatics) approaches, immunoglobulin E
(IgE) binding and cell-based methods, analytical proﬁling techniques and animal models (EFSA GMO
Panel, 2010; EFSA NDA Panel, 2014). Since no single experimental method yields decisive evidence for
allergenicity and allergic responses, a weight-of-evidence approach taking into account all the
information obtained from various test methods is recommended.
6.8.4. Neurotoxicity
Indications of potential neurotoxic effects of a test substance are obtained from the modiﬁed
90-day toxicity study (Step 2b). This study involves investigation of the effect of the nanomaterial on a
number of parameters that may be indicative of a neurotoxic effect. These include changes in clinical
signs, functional observational battery and motor activity, brain weight relative to body weight in the
absence of overt toxicity, and histopathological changes in this organ. Other information, such as read-
across considerations or physicochemical properties that are indicative of neurotoxic potential should
also be considered. Where indications of potential neurotoxicity are seen at Step 2, further
neurotoxicity testing (OECD TG 424 (1997a)) should be considered. Such testing should be carried out
on a case-by-case basis and is intended to conﬁrm or further characterise (and quantify) the potential
neurotoxic response induced by the nanomaterial. Information from other studies should also be
considered in designing these studies to minimise confounding effects secondary to general toxicity.
Further specialised studies can also be performed to elucidate mechanisms to improve extrapolation
from animals to humans when completing the risk assessment.
• Potential immunotoxicity should be investigated where data relating to the likely route(s) of
exposure indicate either systemic availability of the nanoparticles, or a potential for local
contact with the immune cells. This should receive particular emphasis if the nanomaterial is
(entirely or partly) composed of peptides/proteins, or may have an immunogenic/antigenic
moiety adsorbed/attached to the particle surface.
• The potential of nanoparticles to act as a ‘Trojan horse’ for carrying other immunogens/
antigens on to particle surfaces to immune cells should also be investigated.
• A thorough consideration of the manufacturing process and formulation steps is necessary
because of potential changes in the secondary, tertiary or quaternary structure of proteins.
• Consideration should be given to the parameters investigated in the Step 2 90-day study that
may be indicative of an immunotoxic or immunomodulatory effect. Such effects should also
be focused on in Step 3 studies (EOGRTS as well as chronic toxicity/carcinogenicity studies).
• If the results indicate adverse effects on the immune system, additional Step 4 studies
should be considered, on a case-by-case basis.
• Where the nanomaterial is a potential allergen (e.g. a protein or a peptide), or
contains/carries residues of allergenic entities, the principles discussed in the EFSA Guidance
on Allergenicity of GMOs (2017) should be followed to evaluate the allergenic components.
• Indications of the potential neurotoxic effects should be deduced from the modiﬁed 90-day
study (Step 2b). Other information, such as results of in vitro screening tests, read-across
considerations or physicochemical properties, that are indicative of neurotoxic potential,
should also be considered.
• Where indications of potential neurotoxicity are noted at Step 2, further neurotoxicity testing
(OECD TG 424) should be considered on a case-by-case basis.
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6.8.5. Endocrine activity
Evidence exists that several types of nanoparticles may adversely affect the endocrine system, and
in particular the male and female reproductive systems (Iavicoli et al., 2013; Larson et al., 2014).
Hormone alterations also appear to play a role in other toxic effects of nanoparticles with sex-related
patterns (Tassinari et al., 2014; Ammendolia et al., 2017). However, the role of endocrine-related
modes of action in the toxic effects of nanomaterials is largely unknown and unexplored, and warrants
further investigation.
The starting point for investigating endocrine disruptive properties is the design of the modiﬁed
90-day toxicity test (OECD TG 408 with extended parameters from the OECD TG 407 (2008)) (preliminary
reference (OECD TG 408 (2017a)). The additional parameters place more emphasis on endocrine-related
endpoints (e.g. determination of thyroid hormones, gross necropsy and histopathology of tissues that are
indicators of endocrine-related effects) and (as an option) assessment of oestrous cycles.
For further testing, the EFSA Scientiﬁc Opinion of 2013 (EFSA Scientiﬁc Committee, 2013) describes
scientiﬁc criteria for the identiﬁcation of endocrine disruptors (EDs) and the appropriateness of existing
test methods for assessing effects mediated by these substances on human health and the
environment (mainly based on OECD TG 150 (2012b)). To distinguish between EDs and other groups
of substances with different modes of action, it was concluded that an ED is deﬁned by three criteria:
the presence of (i) an adverse effect in an intact organism or a (sub)population; (ii) an endocrine
activity; and (iii) a plausible causal relationship between the two.
6.8.6. Gut microbiome
Currently, there are limited data on the interaction of nanoparticles with the gut microbiome (e.g.
Frohlich and Frohlich, 2016; Bouwmeester et al., 2018), but further research is ongoing. For
nanomaterials with antibacterial properties (Hadrup et al., 2012), the possibility of interactions and on
the composition of the microbiome and the mucus should be considered, especially for unabsorbed
nanoparticles (Fr€ohlich and Roblegg, 2012; Mercier-Bonin et al., 2016).
The consequences of interactions with the gut microbiota on systemic or local tissues or
physiological processes (whether direct or indirect) should be identiﬁable in the examinations that are
part of the modiﬁed 90-day toxicity study. Currently, there are neither speciﬁc tests for this nor a clear
understanding of the signiﬁcance of changes in composition of the microbiome or their effects on
health and further research would be valuable.
6.9. Considerations when testing nanomaterial
Appropriate in vitro and in vivo studies may be undertaken to identify and characterise hazards.
Some of the currently available testing methods may also need adapting to take account of the
speciﬁc properties of nanomaterials. The following paragraphs provide general considerations for
testing nanomaterials, whereas the Sections 6.9.1 and 6.9.2 provide speciﬁc information for in vitro or
in vivo testing respectively.
In both in vitro and in vivo testing, it is recommended to check the structure/properties of the
nanomaterial in the test medium (e.g. particle agglomeration/aggregation).
For hazard characterisation, mass is a convenient metric to express the concentration/doses
used for in vitro and in vivo (oral) studies. Mass is not always the best dose metric to describe the
• The design of the modiﬁed 90-day study (Step 2b) should provide a starting point for
investigation of endocrine-disrupting properties, with additional parameters on endocrine-
related endpoints, and optional assessment of oestrous cycles.
• Further testing should follow the scientiﬁc criteria provided in the EFSA opinion (2013) for
the identiﬁcation of endocrine disruptors and the appropriateness of existing test methods.
• Consequences of interactions of nanomaterials with the gut microbiota on systemic or local
tissues or physiological processes (whether direct or indirect) should be identiﬁed through
observations made during the modiﬁed 90-day study.
• Studies on the composition of the microbiome and the mucus might be required for
nanomaterial – especially for those that have antimicrobial effects.
Guidance on nanotechnologies in the food and feed chain
www.efsa.europa.eu/efsajournal 53 EFSA Journal 2018;16(7):5327
response but is usually the only practicable one in the laboratory. By having the number–size distribution
and density, the concentration/dose can be transformed as necessary. Other metrics such as speciﬁc
surface area can also be derived from the nanomaterial characterisation and might be considered.
Although, studies with abnormally high30 concentrations/doses have been published, the SC
notes that this should be avoided. The use of high concentrations or doses enhances the risk of
altering the size distribution of the material, by agglomeration and, as a result, lowers absorption and
toxicity. Unrealistically high dosing of particles can also lead to outcomes that may not be related to
the inherent toxicity of the material, but rather to the high amount of material administered. The
choice of dose levels should therefore be carefully considered and a justiﬁcation of the selected doses
provided. In addition, the physicochemical characteristics of the test material at the higher doses
should be checked to detect whether any substantial alteration occurs (in particular, the formation of
secondary particles like agglomerates).
Critical to the interpretation of studies (especially those with negative results) is the demonstration
that cells (in vitro) and tissues (in vivo) were exposed to the nanomaterial, i.e. that the
nanomaterials actually came into contact with the cells/tissues. While this provides considerable technical
challenges due to the limitations of current methodologies, the lack of such evidence does represent a
signiﬁcant uncertainty in reaching a deﬁnitive conclusion. In addition, whenever technically feasible, it
should be determined whether nanomaterial distribution occurs in speciﬁc compartments of tissues or
cells, which might modulate their biological effects.
In evaluating and interpreting results from studies on nanomaterials, there should be consideration
of whether a plausible mode of action can be envisaged. Whenever feasible, an experimental group
exposed to the corresponding non-nanomaterial (if available) should be included (in both in vivo and
in vitro studies).
Where possible, an experimental control group exposed to the corresponding non-nanomaterial
should also be included both in in vivo and in vitro studies.
The SC is aware that corona formation on particle surfaces occurs in test systems. Physical and
chemical interactions with proteins and/or other biomolecules (e.g. phospholipids, sugars, nucleic
acids, etc.) are always present and may play a role in nanomaterial fate and/or toxicity. However,
corona formation is still difﬁcult to measure. Corona formation can affect the state of agglomeration
and sedimentation as well as the overall biological identity of nanomaterials (Cedervall et al., 2007;
Lundqvist et al., 2008). The formation of the corona is a dynamic process, with the composition
changing over time, governed by the abundance of proteins in the blood plasma and their binding
afﬁnities. Certain components of the corona (e.g. opsonins) might activate the mononuclear
phagocytic system (macrophages) and induce a subsequent nanomaterial clearance from the
organism. In view of the present limitations in measurement and interpretation, information on corona
formation and its characterisation is not mandatory, but may be taken into consideration.
• The test material should be checked to ensure that there is no substantial alteration in
physicochemical characteristics under test conditions (e.g. particle agglomeration/
aggregation).
• Mass-based dose metric is applicable to nanomaterials, but it is advisable to also consider
other metrics such as particle number and speciﬁc surface area.
• Exposure of the tests system to the test material must be demonstrated, especially for
negative results to be considered valid.
• A justiﬁcation on the selected doses should be provided.
• Consideration should be given to whether a plausible mode of action can be deduced.
• Where possible, an experimental group exposed to the corresponding non-nanomaterial
should also be included in both in vivo and in vitro studies.
30 Drasler et al. (2017) noted that in mechanistic studies, unrealistically high nanomaterial concentrations (used both in in vivo
rodent and – even to a higher extent – in in vitro assays) are sometimes required for determination of both the effect and
no-effect levels of nanomaterials. However, for assessment of potential nanomaterials hazard to humans, nanomaterial
concentrations should be selected based on realistic human exposure measurements, and based on principles of toxicological
study design.
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6.9.1. Speciﬁc issues for in vitro studies
Although ‘validated’ in vitro methods speciﬁcally for nanomaterials are not currently available, the
results of ‘valid’ methods may be considered for hazard identiﬁcation (See Glossary for both terms).
In vitro studies with nanomaterials require extra attention to the suitability of the test methods for
the purpose, e.g. test reagents used for standardised toxicity tests might react with the nanomaterial
or the read-out signal of the test.
Additional quality controls should include (where available), negative and positive reference
nanomaterials, assay reagent controls (such as the dye) and the non-nanomaterial controls.
It also has to be shown that the target cells were exposed to the nanomaterial along with the
determination of the number-based size distribution and concentration of nanomaterials at the
start (and end if applicable) of in vitro testing. These should be measured in the exposure medium
using an appropriate method (see Section 4.3.2). Models based on DLS and density have been
proposed to estimate how much nanomaterial is reaching the cell system (DeLoid et al., 2017a). Other
models exist and can also be used to assess if the cells are truly exposed (e.g. Hinderliter et al., 2010).
For nanomaterials, the nominal concentration/dose may not be representative of the concentration/
dose reaching the cells. Therefore, the assessment of the dose delivered to the cell system (Rischitor
et al., 2016) and the internalised dose (the fraction of nanomaterials internalised by the cells) is highly
recommended to allow better interpretation of the results and for comparison with or extrapolation to
in vivo situations. In in vitro tests a series of concentrations should be used, keeping in mind the
response–concentration range, and their choice justiﬁed. Exclusive use of high concentrations that lead
to extensive agglomeration/aggregation should be avoided as well as conditions leading to
sedimentation of the material.
At least two independent in vitro assays (see Section 6.5) per individual endpoint need
to be selected.
The possible interference of nanomaterials with in vitro test systems also has to be taken into
account, e.g. with assay components (reagents, proteins, nutrients), and with optical read-out system
(e.g. dyes) (Kroll et al., 2012; Guadagnini et al., 2015). Case-by-case background controls, e.g.
cell-free medium, all the reagents and the nanomaterials, should also be included and processed in the
result interpretation. These background corrections should also take into account any changes in
the dispersion status of the nanomaterial during and after the test, because this might inﬂuence their
degree of interference with a test system based on optical measurements.
Speciﬁc issues with in vitro digestion are addressed in Section 6.4.
6.9.2. Speciﬁc issues for in vivo studies
Nanomaterials are potentially unstable when dispersed. In oral toxicity studies, the test material
can be administered by adding it to the animal feed, the drinking water or by gavage. For
proper administration the nanomaterial should be homogeneously blended into the feed matrix or
stably and uniformly dispersed in the drinking water or gavage vehicle. The stability and
physicochemical characteristics of the nanomaterial in the vehicle should always be
determined (see Section 4.3). Possible interactions with the administration vehicle, either the food
matrix or water, need to be determined in advance before in vivo administration. This may require
dispersions for testing to be prepared freshly and used immediately after preparation.
Complete delivery of the dose should be checked because a nanomaterial may, for example, adsorb
• Quality controls should include (where available) negative and positive reference
nanomaterials, assay reagent controls, and the non-nanomaterial controls.
• Exposure of the target cells to the nanomaterial must be demonstrated, along with the
number based size distribution and concentration of nanomaterials at the start (and end if
applicable) of in vitro testing.
• Assessment of the dose delivered to the cell system and that internalised is highly
recommended to allow better interpretation of the results and for comparison or
extrapolation to in vivo situations
• At least two independent in vitro methods per individual endpoint should be performed.
• It is important to consider possible nanomaterial interference with the assay reagents and to
implement necessary background and reference material control experiments.
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to the walls of the drinking vessel or the gavage syringe and therefore may no longer be available (i.e.
there is no exposure) (Kreyling et al., 2017).
Application by gavage ensures that the nanomaterial is dispersed, characterised and administered
under well-deﬁned conditions. It is known that this method of administration can give a fairly precise
dose of nanomaterial delivered to the animal and a well-characterised degree of dispersion (Kreyling
et al., 2017).
On the other hand, application by gavage is not likely to be representative of the lower
concentrations delivered over time when the nanomaterial is administered via drinking water or feed,
two ways that more closely simulate human dietary exposure. Gavage provides a bolus of
nanomaterial at a given time. Absorption kinetics following bolus gavage administration differs from
kinetics following continuous administration leading to a greater likelihood of effects associated with
the peak concentration rather than total exposure. In addition, when exposure to the nanomaterial is
expected to happen via solid foods, the lack of co-ingestion of dietary components (with which a
nanomaterial can interact) is another limitation of gavage. However, at the current state of knowledge,
bolus gavage administration of the nanomaterial still might be the method of choice for
identiﬁcation and characterisation of hazards associated with the nanomaterial; this is because of the
certainty of the administered dose and thus the dose–response relationship for possible adverse
effects. In speciﬁc cases, and especially when exposure occurs mainly through solid and liquid foods,
additional groups with dietary or drinking water administration have to be included to
determine whether hazards associated with the nanomaterial are observed under more realistic
exposure scenarios.
6.10. Integrated testing strategies
The SC notes the continuing development of integrated testing strategies (ITS) for non-
nanomaterials and welcomes the promotion of alternative methods to acquire the information required
in this Guidance, at the precondition that sufﬁcient information is provided to assess the safety the
material.
Alternative methods could fulﬁl the goal to reﬁne, reduce or (partly) replace (the 3Rs) current
traditional toxicological approaches (see European Partnership for Alternative Approaches to Animal
Testing since 2005; National Research Council, 2007; van Leeuwen et al., 2007). ITS comprise
methods that can efﬁciently generate toxicological data for both hazard identiﬁcation and risk
assessment, combining in vitro tests, thresholds of toxicological concern, computational methods,
read-across and chemical categories and exposure assessment, hereby aiming to reduce costs and
minimise the need for experimental animals.
In 2012, the OECD launched the building of a toxicological knowledge framework based on
mechanistic reasoning to support chemical risk assessment: The Adverse Outcome Pathway (AOP)
programme. The OECD’s AOP knowledge-based tools, continually developed and reﬁned, are web-
based platforms bringing together available knowledge on how chemicals can induce adverse
effects.31 Similarly, a view on future risk assessment was provided by the EU Scientiﬁc Committees
SCHER, SCENIHR and SCCS, focussing on organic chemicals. These committees indicate that there
is a need/trend to change the basis of human health risk assessment from the one based on standard
tests to one that is centred on mode of action. To enable the most effective use of resources and to
limit the unnecessary use of animals, a tiered approach to the assessment of hazards from exposure to
individual stressors is proposed.
For nanomaterials, the need to efﬁciently obtain risk assessment information is high, considering that
not only chemical composition but also various physicochemical properties may affect nanomaterial
• Oral administration may be carried out through feed, drinking water or by gavage.
• Dispersions for testing should be prepared fresh and used immediately after preparation.
• Complete delivery of the dose should be ensured by avoiding the test material sticking to the
walls of the drinking vessel or in the gavage syringe.
• In speciﬁc cases, especially when exposure occurs mainly via solid and liquid foods,
additional groups with dietary administration should be included.
31 See (http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-screening-and-toxicogenomics.htm).
This is currently being developed for non-nanomaterials, but the future development for nanomaterials would be welcomed.
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exposure, toxicokinetic behaviour and hazard. General outlines on testing strategies and ITS have been
developed (Dekkers et al., 2016; ProSafe, 2017; Oomen et al., 2018), but a harmonised and detailed
approach is not yet available.
While acknowledging that there are still many knowledge gaps in the understanding of
nanomaterial toxicity, Gerloff et al. (2017) discussed the AOP approach in nanotoxicology. AOPs can
provide a mechanistic framework to assess speciﬁc adverse outcomes. Information obtained via omics
methodologies may also inform or enrich AOPs (Nymark et al., 2018). EFSA is continuing the
investigate the role of omics technologies in risk assessments.
OECD now also explores Integrated Approach to Testing and Assessment (IATAS) and
promotes the use of AOPs to build risk assessment, while assessing all the existing data.
These developments in efﬁcient testing strategies and AOPs for nanomaterials are highly
acknowledged, though they need further development and veriﬁcation before incorporation into
guidance documents can be considered.
Studies on the mode of action (MOA) may be used to investigate the relevance to humans of
ﬁndings in animals. These studies can examine the mode of action for carcinogenic effects or other
endpoints such as endocrine disruption, and should use the appropriate MOA frameworks when
assessing the data (Boobis et al., 2006, 2008; IPCS, 2006; Meek et al., 2013).
7. Risk characterisation
The risk characterisation of nanomaterials considers the same steps as for conventional non-
nanomaterial. This step combines hazard characterisation with exposure assessment. Risk
characterisation is essentially an iterative process and should result in a quantitative assessment,
and if not possible qualitative.
The output from the risk characterisation is the overall assessment of the safety of the
nanomaterial in its intended use together with the parameters under which the assessment is valid and
the uncertainties associated with the assessment.
Several approaches to generating the information required for risk assessment are described in this
Guidance. At every stage in determining whether sufﬁcient information has been generated, a weight
of evidence process should be applied according to the EFSA Guidance to make a decision on
whether an adequate risk assessment can be undertaken. If this is not considered possible, the default
presumption is that a sequence of further tests should be undertaken. For an overview of existing
weight of evidence approaches and their implementation, reference is made to the Guidance
Document on Weight of Evidence (EFSA Scientiﬁc Committee, 2017b).
Risk characterisation of a nanomaterial considers the same elements as for conventional chemical
substances – i.e. data and information relating to physicochemical properties, exposure, and
toxicological effects. Where the data have been derived from appropriately conducted studies using
validated methods and considering nanospeciﬁc issues where relevant, there may be no reason to use
higher uncertainty factors for a nanomaterial than for a conventional material. However, where
data are either insufﬁcient or have been derived from inadequate tests for nanomaterials, applying
additional uncertainty factors may be considered for safety assessment.
• ITS comprise methods that can generate toxicological data for both hazard identiﬁcation and
risk assessment through combination of in vitro tests, thresholds of toxicological concern,
computational methods, read-across and chemical categories and exposure assessment.
• For nanomaterials, only general outlines ITS have been proposed so far and a harmonized
and detailed approach still needs to be developed and veriﬁed.
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8. Uncertainty analysis
To meet the general requirements for transparency, all EFSA scientiﬁc assessments must include
consideration of uncertainty. The Guidance on Uncertainty in EFSA Scientiﬁc Assessment is applicable
to all areas of EFSA and all types of scientiﬁc assessment (EFSA Scientiﬁc Committee, 2018). The
Scientiﬁc Committee had also adopted a Scientiﬁc Opinion in 2009 that deals with general principles to
be applied in the identiﬁcation of data sources, criteria for inclusion/exclusion of data, conﬁdentiality of
data, assumptions and uncertainties (EFSA Scientiﬁc Committee, 2009c).
That opinion makes a number of general recommendations on how to handle uncertainties in risk
assessment that should also be addressed in nanomaterial risk assessment. The Scientiﬁc Committee
has also adopted a Guidance related to uncertainties in dietary exposure assessment that includes
practical approaches on how to handle uncertainties in risk assessment that will also be applicable in
nanomaterial risk assessment (EFSA Scientiﬁc Committee, 2006).
These principles and recommendations are also applicable to risk assessment of nanomaterials.
8.1. Uncertainty in the scope
Uncertainty about the legal framework remains and can be reported. Until the European
Commission recommended deﬁnition of nanomaterial is ﬁnalised in food law (e.g. specifying the size
range of 1 nm to 100 nm and the threshold (of 50%)), it will remain unclear whether or not a given
material is covered under a particular regulation. As a consequence, it remains unclear as to which
materials shall be subject to nanospeciﬁc risk assessment as outlined in this Guidance. The Scientiﬁc
Committee therefore advises that this Guidance is taken into account where a material exhibits
size-related properties, even if it does not strictly fall within the deﬁned size range or threshold.
8.2. Measurement uncertainties in the physicochemical characterisation
of nanomaterial
Uncertainties in the measurement results arise within the analytical process of nanomaterial
characterisation, i.e. sampling, sample preparation, instrumental analysis, data handling and evaluation
of results, similar to conventional analytes. Measurement uncertainties should be reported as combined
uncertainties for the entire process. They can be derived in the course of the validation process (see
Section 4.4.2). The measurement uncertainty can be estimated as
uc ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2r
n
þ s
2
d
d
þ u2t
s
uc is the combined uncertainty, sr is the repeatability standard deviation, n is the number of replicates
performed for the measurement, sd is the between-day standard deviation, d is the number of days,
over which the n replicates were spread, and ut is the uncertainty of the recovery determination
(Linsinger et al., 2013). Guidance for the determination and expression of measurement uncertainty is
widely available, e.g. from ISO (2008).
• The output from the risk characterisation should be in the form of an overall assessment of the
safety of the nanomaterial in its intended use, together with the description of the parameters
under which the assessment is valid and the uncertainties associated with the assessment.
• At every stage where information is assessed, a weight of evidence process should be
applied to decide whether an adequate risk assessment can be undertaken. Risk assessment
can be performed at any stage where the totality of the available information is adequate,
and no further testing is necessary.
• Where the data have been derived from appropriately conducted studies using validated
methods and considering nanospeciﬁc issues, there should not be a reason for the use of
any higher uncertainty factors for a nanomaterial than those used for a conventional
material. However, where data are either insufﬁcient, or have been derived from inadequate
tests for nanomaterials, application of additional uncertainty factors may be considered for
safety assessment.
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While calculation of measurement uncertainty is the same for nanomaterial and conventional
analytes the contribution of the individual sources may be different in quantity and there may be
additional sources in nanomaterial characterisation. For example, the particle size distribution may not
only be affected by instrument uncertainties, but also by agglomeration effects.
Accuracy of the available characterisation methods is dependent on the target nanomaterial, the
matrix, sample preparation procedures and calibration of the analytical equipment against appropriate
reference materials (e.g. calibration standards). The results obtained by various measurement
techniques may nevertheless differ because of their method-deﬁned nature (Domingos et al., 2009).
It is therefore essential to specify the procedures used (e.g. type of sample preparation, technique
applied for size measurement) and to provide information on their analytical performance (validation
study) and the combined measurement uncertainty. The speciﬁcities of individual characterisation
techniques and the measurement uncertainty of the applied analytical process have to be taken into
account to decide if a material is or is not regarded as a nanomaterial. The expanded measurement
uncertainty U (U = uc 9 k) should be applied in order to avoid potential risks. A coverage factor k = 3
should be used that corresponds to greater than 99% conﬁdence.
8.3. Uncertainties in exposure assessment
Exposure assessment is an integrated part of scientiﬁc assessments performed by EFSA. There are
established procedures for exposure assessment in different areas of EFSA’s work. Every dietary
exposure assessment is affected by scientiﬁc uncertainties and it is important for assessors to
characterise the extent of uncertainty so it may be taken into account by risk managers.
When it is not possible to characterise the form in which the nanomaterial substance is present in
food and/or feed applications, uncertainty in exposure assessment will be increased. This uncertainty
could be reduced by characterisation of the nanomaterial in the food/feed or liquid food/feed products
according to intended or existing applications.
Exposure assessments should systematically examine potential sources and types of uncertainty.
The assessment of uncertainties in exposure assessment should follow principles in the EFSA Guidance
of the Scientiﬁc Committee related to uncertainties in dietary exposure assessment (EFSA Scientiﬁc
Committee, 2006), and updated recently (EFSA Scientiﬁc Committee, 2018).
In case the tested nanomaterial is readily biodegradable, the decision to not perform any in vivo
toxicity study speciﬁc for nanoparticles, may result in uncertainty due to the possibility of local effects.
Such local effects may be deriving from an exposure to nanoparticles particularly in the mouth and in
the upper gastrointestinal tracts, especially when the nanomaterial is ingested following dispersion in
the food product.
8.4. Uncertainties in the hazard characterisation of the nanomaterial
Limited information is available in relation to aspects of nanomaterial toxicokinetics and toxicology,
including optimal testing methods. Existing toxicity testing methods (e.g. OECD test guidelines) may
need methodological modiﬁcations (e.g. regarding sample preparation and characterisation). Speciﬁc
uncertainties arise due to limited experience of testing nanomaterial in currently applied standard
testing protocols and test animals. There may also be additional toxic effects caused by nanomaterials
that are not readily detectable with current standard protocols. Additional endpoints (e.g.
cardiovascular or immune function endpoints) not routinely addressed may need to be considered in
addition to traditional endpoints. Currently there are no in vitro methods validated for use in hazard
assessments of nanomaterials.
It is still not fully understood how and to what extent biochemical reactions occur at the molecular
level of the nanomaterial surface with biological ﬂuids, cell membranes and cell compartments, e.g.
which and how many of the atomic/molecular clusters on the nanomaterial surface area are causing
what kind of biochemical or catalytic reactions, such as electron exchange. With the generation of such
knowledge, the reactivity of a given nanomaterial will be better understood and potential effects may
be predicted.
Assays for allergy testing of food components are currently not available. For nanomaterials, a
comparison with existing allergic proteins does not seem appropriate. However, the identiﬁcation of
proteins of the food matrix adhering/bound to the nanomaterial surface might give some insight into
the potential of nanomaterials for promoting allergy induction. Post-marketing monitoring may also
provide useful information.
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Information emerging from studies on nanomaterial in the future may point to other modiﬁcations
in test protocols.
8.5. Uncertainties in the risk characterisation
As for conventional non-nanosized particles of substances in food/feed, risk assessment should
preferably be quantitative, but at present, only a qualitative nanomaterial risk assessment may be
possible in some circumstances.
Lack of or inadequate characterisation of the nanomaterial test substance is a source of uncertainty
in studies for hazard identiﬁcation and characterisation in which identiﬁed NOAELs or calculated BMDLs
are used to derive health-based guidance values (HBGVs) subsequently used in risk characterisation.
Uncertainty will increase when the available data on characterisation of the nanomaterial test
substance used in studies for hazard identiﬁcation and characterisation are insufﬁcient to conclude that
the tested nanomaterial and its form are comparable to those present in food products or commercial
feed. Depending on the circumstances, the risk characterisation may under- or over-represent the risks.
These uncertainties could be reduced by use of a test nanomaterial that is sufﬁciently characterised (see
Section 4), and the form in which it is present in the feed or liquid matrices in animal studies would
closely mimic the form in anticipated (as described in an application dossier) or existing food/feed
products, the exposure to which has to be assessed in order to perform risk characterisation.
As with conventional risk assessment, the HBGV derived from the hazard characterisation can be
used to estimate safe human food and animal feed intakes by the application of uncertainty factors.
These uncertainty factors allow for inter- and intra-species differences in toxicokinetics and
toxicodynamics. If not indicated otherwise by consideration of the data, the conventional default
uncertainty factors of 10 for inter- and 10 for intraspecies differences should be applied, as currently
there are no indications for a need to modify these factors.
The absence of data essential for the risk assessment should be indicated, and the quality of the
existing data and that provided should be reported in accordance with EFSA Guidances on weight of
evidence and biological relevance (EFSA Scientiﬁc Committee, 2017b,c). Uncertainties in risk
assessment should be stated and their impact on risk assessment analysed in accordance with EFSA
guidance on uncertainty in risk assessment (EFSA Scientiﬁc Committee, 2018). In the absence of
essential data, the risk assessor will not be able to conclude on the risk assessment. It should be clear
from the assessment how the available body of information has been taken into account when the risk
assessment is completed in accordance with the EFSA Guidance on transparency in the scientiﬁc
aspects of risk assessment (EFSA Scientiﬁc Committee, 2009c).
• EFSA Scientiﬁc Committee (2018) provided general principles and general recommendations
for the identiﬁcation of uncertainties in dietary exposure assessment, and in regard to data
sources, criteria for data inclusion/exclusion, conﬁdentiality, assumptions and uncertainties.
These principles and recommendations are also applicable to risk assessment of
nanomaterials.
• The terms for the expression of risks and associated uncertainties should be as precise,
understandable and transparent as possible. Any uncertainties inherent in the different risk
assessment steps should be highlighted and quantiﬁed as appropriate.
• Uncertainties should be reported.
• Similar to conventional analytes, the uncertainties in the measurement results for
nanomaterials should be described in relation to the analytical process used for
characterisation, i.e. sampling, sample preparation, instrumental analysis, data handling and
evaluation of results.
• It is essential to specify the procedures used and to provide information on the analytical
performance and combined measurement uncertainty.
• Uncertainties relating to any limited information on toxicokinetics and toxicology, including
test methods must be highlighted. Uncertainties arising from the lack of validated in vitro
assays for nanomaterials should also be highlighted.
• Potential sources and types of uncertainty in exposure assessment should be systematically
examined.
• If not indicated otherwise by consideration of the data, the conventional default uncertainty
factors of 10 for inter- and 10 for intra-species differences should be applied for nanomaterials.
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9. Conclusions and Recommendations
• The use of a nanomaterial in food/feed and related applications will need to be assessed for
safety to fulﬁl requirements of the relevant EU food laws, and in accordance with the
provisions of this Guidance.
• Irrespective of the presence of a nanomaterial, the existing requirements for safety
assessment according to EFSA Guidances for conventional non-nanomaterials under relevant
regulations must be followed.
• The existing risk assessment paradigm for chemicals is also applicable to nanomaterials.
However, testing of nanomaterials needs consideration of certain nanospeciﬁc aspects that
have been highlighted in this Guidance.
• The Guidance proposes a structured pathway for carrying out safety assessment of
nanomaterial in food/feed and related applications, and provides practical suggestions for the
types of testing needed and the methods that can be used for this purpose.
• The Guidance also highlights certain gaps where further research is needed to facilitate
adequate safety assessment of materials that consist of small-sized particles.
 Although a deﬁnition of engineered nanomaterial currently exists under the Regulation
on Novel Food and Regulation on Food Information to Consumers a possible revision of
the existing deﬁnition in the light of the European Commission Recommendation may
provide more clarity on the type of materials to be covered.
 Currently, there is no agreed deﬁnition of the term ‘nanopesticides’ (see Appendix E).
Clariﬁcation is needed to identify any relevant active substances and formulations that
may be required to undergo nanospeciﬁc safety assessment.
 More work is needed on analytical methods and techniques that can be used for
characterisation of nanomaterials in complex matrices.
 Further investigations are required on methods for measuring reactivity of
nanomaterials.
 More work on validation of relevant in vitro methods, including in vitro degradation, is
needed to ascertain their applicability to nanomaterials.
 More work is needed to strengthen the conceptual application of grouping and read-
across and other in silico (computational) modelling approaches for use in risk
assessment of nanomaterials.
 The limited availability of reference materials should be addressed because reference
materials are essential for ensuring quality and reliability of data.
 For nanomaterial pesticides, speciﬁc recommended Guidance is provided in Appendix E.
The Scientiﬁc Committee strongly suggests that regulatory authorities take note of this
recommended Guidance. It is suggested that during the next update of the legal data
requirements consideration is given to Appendix E.2.
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Abbreviations
AAS atomic absorption spectroscopy
ADME absorption, distribution, metabolism and excretion
AES atomic emission spectroscopy
AFM atomic force microscopy
ANS Panel on Food Additives and Nutrient Sources Added to Food
AOP adverse outcome pathway
AUC area under the plasma concentration-time curve
BET Brunauer Emmett Teller method
BMD benchmark dose
BMDL lower boundary of the BMD conﬁdence interval
CAS Chemical Abstracts Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CEN European Committee for Standardization
CFM chemical force microscopy
CLS centrifugal liquid sedimentation
CMR carcinogenic, mutagenic, reprotoxic
CODATA-VAMAS Committee on Data for Science and Technology - Versailles Project on Advanced
Materials and Standards
CONTAM Panel on Contaminants in the Food Chain
DESI desorption electrospray ionisation
DG ENV Directorate-General for Environment
DIN German Institute for Standardization
DLS dynamic light scattering
DMA/IMS differential mobility analysis/ion mobility spectroscopy
ECHA European Chemicals Agency
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EDs endocrine disruptors
EEA European Economic Area
EINECS European Inventory of Existing Commercial chemical Substances
ELISA enzyme-linked immunosorbent assays
EM–EDX electron microscopy–energy-dispersive X-ray spectroscopy
EM technique electron microscopy technique
EMA European Medicines Agency
EOGRTS extended one-generation reproduction toxicity study
ESI electrospray ionisation
ESZ electrical sensing zone
EU FP7 European Union Seventh Framework Programme
FCM food contact material/s
FEEDAP Panel on Additives and Products or Substances used in Animal Feed
FFF ﬁeld ﬂow fractionation
FTIR Fourier transform infrared spectroscopy
GALT gut-associated lymphoid tissue
GI gastrointestinal
HBGVs health-based guidance values
IATAS Integrated Approach to Testing and Assessment
ICP-MS inductively coupled plasma mass spectrometry
ICP-AES inductively coupled plasma atomic emission spectrometry
ICR ion cyclotron resonance
IgE immunoglobulin E
IgM immunoglobulin M
IPCS International Programme on Chemical Safety
IR&CSA Information Requirements and Chemical Safety Assessment
ISO/CEN International Organization for Standardization/European Committee
for Standardization
ITS Integrated testing strategies
IUPAC International Union of Pure and Applied Chemistry
JRC Joint Research Centre
KLH keyhole limpet hemocyanin
LA-ICP-MS laser ablation inductively coupled mass spectrometry
LDH lactate dehydrogenase
LOD limit of detection
MALDI matrix-assisted laser desorption/ionisation
MALS multiangle light scattering
MOA mode of action
MSSA mass speciﬁc surface area
NDA Panel on Dietetic Products, Nutrition and Allergies
NMIs National Meat Inspection Service
NOAEL no-observed-adverse-effect-level
OECD Organisation for Economic Co-operation and Development
OES optical emission spectroscopy
pH potential of hydrogen
PPR Plant Protection Products and their Residues
PLA polylactic acid
QqQ triple quadrupole
QSARs quantitative structure –activity relationships
REACH Registration, Evaluation, Authorisation and Restriction of Chemicals
RIVM Dutch National Institute for Public Health and the Environment
RA risk assessment
ROS reactive oxygen species
SAXS small angle x-ray scattering
SC Scientiﬁc Committee
SCCS Scientiﬁc Committee on Consumer Safety
SCENIHR Scientiﬁc Committee on Emerging and Newly Identiﬁed Health Risks
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SCHER Scientiﬁc Committee on Health and Environmental Risks
SCOEL Scientiﬁc Committee on Occupational Exposure Limits
SEM scanning electron microscopy
SMPS scanning mobility particle sizer
SOPs Standard Operating Procedures
spICP-MS single particle inductively coupled plasma mass spectrometry
SRBC sheep red blood cells
SSA speciﬁc surface area
STXM scanning transmission X-ray microscopy
TEER transepithelial electrical resistance
TEM transmission electron microscopy
TEM–EDX transmission electron microscopy–energy-dispersive X-ray spectroscopy
TG Test guideline
ToF-SIMS time-of-ﬂight secondary ion mass spectrometry
US-EPA United States Environmental Protection Agency
US-FDA United States Food and Drug Administration
VSSA volume speciﬁc surface area
WG Working group
WHO World Health Organization
WPMN Working Party on Manufactured Nanomaterials
XPS X-ray photoelectron spectroscopy
XRD X-ray diffraction
XRF X-ray ﬂuorescence
Glossary
ADME Absorption, distribution, metabolism and excretion (elimination).
Agglomerate ‘Agglomerate’ refers to a collection of weakly bound particles or
aggregates where the resulting external surface area is similar to the
sum of the surface areas of the individual components.
Aggregate ‘Aggregate’ means a particle comprised of strongly bound or fused
particles.
Chemically speciﬁc method An analytical method verifying the chemical identity of the measured
particles (e.g. spICP-MS or TEM-EDX).
Conventional material See non-nanomaterial.
Degradation Degradation as used herein is the process by which a nanomaterial is
transformed to degradation products in the form of another nanomaterial
(examples include photodegradation, oxidative degradation, etc.) or to
solutes with the loss of nano features. A relevant example is the oxidative
degradation of silver nanoparticles with the release of Ag+ ions (i.e.
dissolved form of silver).
Dissolution Dissolution as used herein is the process by which a soluble nanomaterial
in an aqueous medium or biological environment is converted to the
constituent ions or molecules with the loss of nano features.
Dispersion A system in which discrete particles are distributed in a continuous phase
(e.g. a liquid) of a different composition. A poorly soluble nanomaterial
introduced into a liquid forms a ‘dispersion’, where the liquid and the
nanosized particles coexist.
Fullerene A fullerene is a molecule composed entirely of carbon, in the form of a
hollow sphere, ellipsoid, or tube. Spherical fullerenes are also called
buckyballs, from buckminsterfullerene (a 60 carbon atom sphere).
High aspect ratio
nanomaterials (HARN)
The aspect ratio of a shape is the ratio of its longer dimension to its
shorter dimension. The length of a HARN is considerably longer than its
width. Examples of HARN include materials such as carbon nanotubes
(CNT) and metal nanowires.
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Incidental presence Alternative but not preferred terms are accidently present,
unintentionally present, unintended presence, traces, etc.
In vivo In vivo means in living organisms. For clarity, ‘in situ ex vivo’ means in
place, but in pathology that may also be seen as in vivo.
Lotus effect A property of highly hydrophobic surfaces that creates a ‘self-cleaning’
effect.
Manufactured
nanomaterial (ISO)
Nanomaterial intentionally produced for commercial purposes to have
speciﬁc properties or a speciﬁc composition.
Micronisation The process of reducing the average diameter of solid material particles
by mechanical or other means. While the process usually aims to reduce
the average particle diameters to the micrometer range, formation of
particles in the nanoscale may also result.
Nanomaterial (EC) Recommended deﬁnition is under review (see Section 1.2.2).
Nanomaterial (ISO) Material with any external dimension on the nanoscale or having internal
structure or surface structure on the nanoscale.
Nanoproperties Examples include (but are not restricted to): size on the nanoscale, large
surface area, high surface reactivity, quantum effects, possibility to
translocate over biological membranes not observed in larger non-
nanosized particles etc.
Nanoscale A size measurement generally considered to refer to the size range
1–100 nm (e.g. L€ovenstam et al., 2010; SCENIHR, 2010). From a metric
interpretation, nanoscale encompasses the range from 1–999 nm. The
size range below 1 nm is measured in picometers, and the size range
above 999 nm is measured in micrometers.
Nanoscience (ISO) Study, discovery and understanding of matter on the nanoscale (where
size- and structure-dependent properties and phenomena can emerge
that are distinct from those associated with individual atoms or molecules,
or with bulk materials.
Nanotechnology (ISO) Application of scientiﬁc knowledge to manipulate and control matter on
the nanoscale to make use of size- and structure-dependent properties
and phenomena, as distinct from those associated with individual atoms
or molecules, or with bulk materials.
Non-nanomaterial A material that is either in ionic, molecular or particulate form having a
size above the nanoscale. In this guidance, the term non-nanomaterial is
used for the conventional material in connection with the corresponding
nanomaterial of the same chemical composition.
Nanosized degradation
product
Is a degradation product in the form of a nanomaterial, meaning not in
ionic or molecular form.
Pour density A function of the degree of compaction during pelletisation.
Primary particle For the purposes of this guidance, the term ‘primary particle’ is used for
(i) individual particles which are not aggregates or agglomerates and (ii)
constituent particles of aggregates/agglomerates which are not
aggregates or agglomerates themselves. Agglomerates and aggregates
are also termed secondary particles.
Solubility (OECD, ECHA) The solubility of a substance in water is speciﬁed by the saturation mass
concentration of the substance in water at a given temperature (kg/m3
or g/L) (OECD, 1995; ECHA, 2017c), see also glossary on ‘solution’.
Solubility in relevant media requires description of the media and the
conditions under which the measurements were made.
Solution In a solution the solute does not exist as a solid, but is fully dissolved.
Valid methods In toxicological testing, a method that has not necessarily gone through
the complete validation process, but for which sufﬁcient scientiﬁc data
exist demonstrating its relevance and reliability (Based on Rogiers, 2003).
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Validated method A method for which the relevance and reliability are established for a
particular purpose (in most cases according to the criteria established by
EURL-ECVAM, taking into account that a prediction model needs to be
present from the start of the validation procedure). (Based on Balls and
Fentem, 1997; and Worth and Balls, 2001). These methods are taken up
in Regulation (EC) No 440/2008 and/or published as OECD Technical
Guidelines.
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Appendix A – NanoDeﬁne decision-ﬂow scheme
Tier 2: Screening method measurements
VSSA
Nano? non-nano?
Plausibility check?
Material
properes
Requirements
Purpose
Methods
characteri-
saon
Exisng data
NanoNon-Nano
Nano/non-nano ?
Plausibility check?
Tier 2: Conﬁrmatory method opons,
if required
Samples preparaon opons
Samples preparaon opon
Tier 1: Screening method measurements
Go to Tier 2
VSSA
Criterion
Mobility-based techniqueVSSA
Mobility
based
Dispersion
Criteria
Tier 2: Conﬁrmatory method measurements
Tier 1: Screening method opons
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Appendix B – Demonstration fact sheet for component 2
Table B.1: Descriptors and parameters for component 2 in Table 1 (of Section 4.2.1)
Information on the chemical component 2
Component 1
Chemical name
Systematic/IUPAC name;
chemical name
Where available systematic/IUPAC name of the substance
that makes up component 1 of the nanomaterial should be
provided. Alternatively, the chemical name that describes
the chemical composition of the component should be
provided based on the best available information – e.g.
‘modiﬁed from XX’ where XX = the nearest chemical name.
Silicon dioxide
Silicon (IV) oxide
Trade name, common
name, other names,
synonyms
Names
Any common names, synonyms, trade names and other
names for the component should be provided
Silica, synthetic
amorphous silica
CAS number
EINECS/EC number
E number
other registry numbers
Registry numbers related to
the constituent substance, if
available
CAS number, EINECS/EC number, E number or other
registry/database numbers related to the component
should be provided (where available).
CAS number:
7631-86-9
ECHA Info card:
100.028.678
EC number:
231-545-4
E number: E 551
Formula
Molecular and structural
formula (where applicable) of
the constituent substance
Molecular and structural formula (where applicable) of the
constituent substance should be provided
SiO2
Molecular weight or
atomic weight (for
elements)
[g/mol]
Molecular weight or atomic weight (for elements) [g/mol]
should be provided for the component.
60.08 g/mol
Elemental composition
Empirical formula of this
component
The relative elemental composition of the component
should be provided as the simplest positive integer ratio of
atoms present in the material.
SiO2
Crystal form
Form and phase
Description of crystalline form (amorphous, polycrystalline,
crystalline including speciﬁcation of phase) should be
provided, including any crystalline impurities
amorphous
Purity of the component
Relative amount of the
constituent in mass %; and
name(s) and amount(s) of
any impurities in mass %.
Relative amount of the constituent in mass %, as well as
chemical identity of any impurities and their relative
amounts in mass % should be provided.
SiO2 97.6%
NaSO4 1.4%
Al2O3 0.3%
Production process
component
Name of the production
process
The production process of the component should be
described since it can have a signiﬁcant effect on the
properties of the nanomaterial, e.g. pyrogenic or
precipitated silica, sulfate or chloride process for TiO2
precipitation
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Appendix C – Characterisation techniques
The techniques in Table C.1 below are based on light scattering, microscopy, spectrometry,
chromatography and other size separation methods such as electrophoresis and centrifugation, surface
characterisation methods, and their different variants and combinations. Adequate characterisation of a
nanomaterial will generally require multiple methodologies to measure various characteristics, the use
of which should be justiﬁed and documented with a detailed description of the protocols used. Method
performance characteristics should also be provided (see Section 4.4).
It should be noted that the list of techniques is not exhaustive and does not constitute a
recommendation for any speciﬁc technique. The best suited technique depends largely on the material
characteristics and on the speciﬁc intended use for the measured data. It is up to the responsibility of
the applicant to select the appropriate measurement method. The fact that a speciﬁc technique is not
listed in the table does not exclude it from being applied. The same holds for newly developed
techniques. Applicants and risk assessors should refer to the most current reviews on the state of the
art in characterisation techniques for nanomaterials. Rasmussen et al. (2017) provide a comprehensive
overview on of current techniques and their use. Furthermore, the NanoDeﬁne Methods Manual
(Gaillard et al., 2015) also provides information on the use of techniques and outlines for which cases
and materials (e.g. chemical composition, powder suspension etc.) which method is best suited.
Standardised methods should preferably be used if available and appropriate for the analytical task
in question. Some examples of standard methods are given in the Table 1B. Mentioning these
guidances (most of them not nanospeciﬁc) does not imply a recommendation. It is up to the applicant
to check the most relevant and up to date guidance. Information on available standards is provided
e.g. by ISO and CEN. ISO standards can be found via the on-line browsing platform which is
searchable for the ISO deﬁnitions of terms and, also for standards on a speciﬁc subject (e.g. ‘nano’):
https://www.iso.org/obp/ui/#home
The work programmes and publications of the ISO Technical Committees (TCs) can also be consulted
on their respective webpage, which can be found via the list of TCs. Most nanomaterial relevant
standards are published in ISO/TC 229 (ISO, 2005), ISO/TC 201 (ISO, 1991) and ISO/TC 24/SC4 (ISO,
1981). https://www.iso.org/technical-committees.html
CEN TC 352 has a mandate from the EC (M/461) to develop a series of European standards and
technical speciﬁcations in the area of nanotechnologies. The database search platform for CEN is
available at: https://standards.cen.eu/dyn/www/f?p=CENWEB:105::RESET::::
Table C.1: Examples of characterisation techniques
Item Suitable techniques Examples of Guidances
Chemical
composition/
identity, purity,
surface
chemistry, mass
concentration
Elemental composition
Atomic absorption spectroscopy (AAS)
Inductively coupled plasma-optical/atomic emission
spectroscopy (ICP-OES/AES)
Inductively coupled plasma-mass spectrometry (ICP-MS) ISO 13278
X-ray ﬂuorescence spectroscopy (XRF)
Energy-dispersive X-ray spectroscopy (EDX) ISO 22489
Electron energy loss spectroscopy (EELS)
X-ray photoelectron spectroscopy (XPS)
(surface analysis)
ISO/TR 14187, ISO 18118
Auger electron spectroscopy
(surface analysis)
ISO/TR 14187, ISO 24236
X-ray photoelectron spectroscopy (XPS) ISO/TR 14187, ISO 18118
Auger electron spectroscopy ISO/TR 14187, ISO 24236
X-ray ﬂuorescence spectroscopy (XRF)
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Item Suitable techniques Examples of Guidances
Energy-dispersive X-ray spectroscopy (EDX) ISO 22489
Electron energy loss spectroscopy (EELS)
Molecular composition
Nuclear magnetic resonance spectroscopy (NMR)
UV/VIS absorption spectroscopy ISO 17466
Fourier transform infrared spectroscopy (FT-IR), Raman
and other molecular spectroscopies
Mass spectrometry (MS) (coupled with separation
methods, e.g. HPLC, GC, CE, etc.):
– Time of ﬂight (ToF)
– Triple quadrupole (QqQ),
– Fourier transform ion cyclotron resonance (FT-ICR-MS,
Orbitrap)
ISO/TS 14101
– Secondary ion MS (SIMS) ISO 13084
using suited ionisation techniques, e.g.:
– Matrix-assisted laser desorption/ionisation (MALDI)
– Electrospray ionisation (ESI)
– Direct analysis in real time (DART)
– Desorption electrospray ionisation (DESI),
Shell/core composition (for encapsulates, micelles)
By a suitable method given above, after disintegration of
the particles and separation of the components by a
suitable method (e.g. HPLC, SEC, CE, HDC, etc.)
Particle size and
size distribution;
agglomeration/
aggregation state
Microscopy techniques
– Transmission electron microscopy (TEM) ISO/WD 21363ISO 13322-1ISO
29301
– Scanning electron microscopy (SEM) ISO/WD 19749ISO 13322-1ISO
16700
– Scanning transmission electron microscopy (STEM)
– Atomic force microscopy (AFM) ISO 25178 seriesIEC 62622
– Scanning transmission X-ray microscopy (STXM)
Separation techniques (coupled with suitable
detectors):
– Field ﬂow fractionation (FFF) ISO/TS 21362 (to be published
in 2018)
– Hydrodynamic chromatography (HDC)
– Size exclusion chromatography (SEC)
– High-performance liquid chromatography (HPLC)
– Differential mobility analysis/ion mobility spectroscopy
(DMA/IMS)
ISO 15900ISO 28439
Centrifugation techniques:
– Centrifugal liquid sedimentation (CLS) ISO 13318 series
– Analytical ultracentrifugation (AUC)
Scattering techniques
– X-ray diffraction (XRD) (for crystal size, crystallite size) ISO 22309
– Small angle x-ray scattering (SAXS) ISO17867
– Laser diffraction methods ISO 13320
– Dynamic Light scattering (DLS) ISO 22412
– Multiangle light scattering (MALS) ISO 18196
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Item Suitable techniques Examples of Guidances
– Light scattering airborne and liquid-borne particle
counters
ISO 21501 series
– Particle tracking analysis (PTA) ISO 19430
other techniques
– Single particle ICP-MS ISO/TS 19590
– Condensation particle counter (CPC) ISO 27891
– Acoustic methods ISO 20998 series
– Electrical sensing zone (ESZ) ISO 13319
– Resonant mass technique (Archimedes)
Shape Microscopy techniques
– TEM
– SEM
– STXM
– AFM
ISO 16700
ISO 25178, ISO/TS 11888, ISO
9276-6
Diffraction
Crystal form and
phase
XRD EN 13925-1, -2, -3
Particle
concentration
Light scattering airborne and liquid-borne particle
counters
ISO 21501 series
Single particle ICP-MS ISO/TS 19590
Scanning mobility particle sizer (SMPS)
CPC ISO 27891, CEN EN 16897
Surface area
(volume, mass
speciﬁc)
Adsorption isotherms methods, e.g. Brunauer Emmett
Teller method (BET)
ISO 9277, ISO 15901-2/-3, ISO
18757
Liquid porosimetry ISO 15901-1
Surface charge Electrophoretic light scattering (ELS)/zeta potential ISO 13099 series
Capillary electrophoresis (CE)
Electroosmosis
Electric sonic amplitude
Colloidal vibration current
Degradation/
Dissolution/
Solubility
Standard tests for water solubility
Degradation rate constants
e.g. OECD TG 105
Chemical
reactivity
Kinetic measurements of the chemical, biochemical
reactions
Catalytic activity Kinetic measurements of the catalysed reactions,
including photocatalytic activity (where applicable)
Density -
Apparent (Bulk)
powder density)
Gravitational sedimentation; centrifugal sedimentation
(for suspensions for submicrometre and nanoparticles).
OECD TG 109
DIN ISO 697, EN/ISO 60
Density -
Effective
(hydrodynamic)
particle density
Gravitational sedimentation; centrifugal sedimentation
(for submicrometre and nanoparticles)
ISO 18747 series
Dustiness Standard methods EN 15051:2006, DIN 33897-2
Viscosity Standard methods OECD TG 114
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Appendix D – Uncertainty Analysis of high degradation rate
This Section provides the rationale for the cut-off value of the degradation rate that is used to
decide whether a nanomaterial quickly degrades (i.e. has a high degradation rate) in the
gastrointestinal tract and can therefore follow the safety assessment according to relevant EFSA
guidance on non-nanomaterials (see Figure 2). Transparency on the rationale for the proposed cut-off
value is important as this value is partly based on pragmatism. Further scientiﬁc knowledge may be
used by the EFSA Scientiﬁc Committee to revise the cut-off value.
The time nanoparticles take to cross the mucus layer adhering to the gastrointestinal tract
epithelium can be short, i.e. within minutes. For some particles, the mucus does not seem to inhibit
the diffusion of particles smaller than 100 nm, whereas 500 nm particles display limited diffusion
(Ensign et al., 2012; Bajka et al., 2015). This is assumed to be due to the pore size in net-like mucin
sheets that was found to be about 200 nm by Bajka et al. (2015), and is considered to be about
100 nm by Fr€ohlich and Roblegg (2012). As an example, Szentkuri (1997) showed the ability of 14 nm
latex particles to cross the mucus layer within 2 min.
The time required for particles to be taken up by intestinal cells also seems to be short, i.e. within
minutes. For example, the accumulation of nanoparticles in lymphatic tissue began 5 min after
administration into the small intestine (Hazzard et al., 1996; Fr€ohlich and Roblegg, 2012).
Based on these observations, the time needed for nanomaterials to cross the gastrointestinal
mucus layer and be taken up by intestinal cells is short (within minutes) and thus cannot be
considered a rate-limiting step compared with degradation under gastrointestinal conditions.
A cut-off value for a degradation rate based on a half-life of 10 min is therefore proposed to
differentiate the quickly dissolving nanomaterials that can follow a safety assessment according to
relevant EFSA guidance on non-nanomaterials. Such a time frame is considered analytically feasible,
and the time required to reach the intestinal epithelium and be taken up by cells is of the same order
of magnitude. It is considered important that information on the degradation in time is obtained by
measuring at different time points. It is proposed that the material is considered to degrade quickly, if
the degradation in the intestinal compartment shows a clear decrease in time (no plateau) and no
more than 12 mass % of the material (compared with the particulate concentration at the beginning
of the in vitro digestion) is present as particles after 30 min of intestinal digestion.
Studies by NANoREG (Deliverable 5.02; available via the NANoREG result repository) show that
silver particles such as nanomaterial-300K < 20 nm and silver particles of 60 nm show low degradation
(< 5 mass %) after 2 h digestion in the intestinal phase. The overall dissolution rate was higher in the
earlier gastric phase, but still incomplete after 2 h. In the same series of studies, zinc oxide particle
(nanomaterial-110, which is rather heterogeneous in size and shape) appeared to degrade completely
in gastric conditions and 25–65 mass% was degraded at the end of the intestinal phase. There are
indications that not all silver and zinc oxide was in fact dissolved because ion-salt/protein complexes
may have formed in the digestive juices and precipitated, resulting in an underestimation of the
degraded fraction. This issue complicated the measurement of the actual degradation rate and needs
to be considered in further testing. Furthermore, these studies indicate that silver and zinc oxide
nanomaterials cannot be assigned as quickly dissolving materials.
The NANoREG results (Deliverable 5.02; available via the NANoREG result repository) indicate that
the degradation rate can be concentration dependent. Therefore, at least three different
concentrations should be studied, with the middle concentration being representative of the human
exposure level. The concentration with the lowest degradation rate should be used for further
assessment.
Taken together, there is some scientiﬁc evidence that the time required to cross the gastrointestinal
mucus layer and be taken up by intestinal cells is of the same order of magnitude as the proposed
cut-off value for quick degradation. The time taken to reach intestinal cells would preferably be the
rate limiting step. For reasons of pragmatism and feasibility, a half-life of 10 min was considered
suitable. As a sub-argument, it is also assumed that even if a fraction of such quickly degrading
materials is absorbed as particles, it is expected that further degradation will occur under e.g.
lysosomal conditions and that they are unlikely to remain as particles for a long time.
This uncertainty in the assessment of quickly dissolving nanomaterials under gastrointestinal tract
conditions needs to be considered, and the cut-off value may need revision in the future.
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Appendix E – Sector Speciﬁc Information
Risk assessment for nanomaterials and the data requested can be different depending on their
origin and intended use. While the general Guidance is for a typical case of a novel food or food
additive more sector-speciﬁc information is given below.
E.1. Feed Additives
Feed additives are substances, microorganisms or preparations other than feed materials and
premixtures that are intentionally added to feed or water to perform one or more functions32
mentioned in Article 5.3 of Regulation (EC) No 1831/200333,34 governing the Community authorisation
of additives for use in animal nutrition. Regulation (EC) No 429/200835 provides detailed rules for the
implementation of Regulation (EC) No 1831/2003 as regards the preparation and presentation of
applications and the assessment and authorisation of feed additives.
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) has
adopted a series of guidance documents that aim at complementing Regulation (EC) No 429/2008 to
support applicants in the preparation and submission of technical dossiers for the authorisation of
additives for use in animal nutrition according to Regulation (EC) No 1831/2003.36
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall undertake an assessment to
determine whether the feed additive is safe (for the target animals, consumer, user and the
environment) and efﬁcacious, when the proposed conditions of use are followed.
To allow EFSA to perform an assessment of a feed additive, its condition of use should be speciﬁed
(at which dose range it is used and for which target species) and the additive and active substance
should be characterised (including details on the impurities and manufacturing process); data on
stability (shelf-life, stability in premixtures and feedstuffs) and homogeneity are also assessed. The
above mentioned Regulations and guidance documents were not developed speciﬁcally for
nanomaterial feed additives, but the ongoing revision of these documents anticipates the provision of
data on particle size for those feed additives whose nature allows the presence of nanoparticles and
the potential for the feed additive to be classiﬁed as an engineered nanomaterial as deﬁned by
European legislation (See Section 1.2.3).
Although nanomaterial forms of different feed additives have been reported to enhance absorption
of nutrients and supplements and improve health of the livestock (Hill and Li, 2017), up to now, no
application for feed additives as nanomaterial has been received in the EU. For future applications the
present Guidance should be followed regarding the general considerations for risk assessment of
nanomaterial (Section 3) and physicochemical characterisation (Section 4), in particularly Section 4.3
on the characterisation in matrix.
For safety assessment of nanomaterial-containing feeds, direct exposure of target animals by
ingestion of the nanomaterial should be assessed following the general approach given in Figures 3
and 4 (Sections 5 and 6) and the FEEDAP guidance (EFSA FEEDAP Panel, 2011).
As described in Section 6.2, a justiﬁcation of the validity of an in vitro system to check if the material
under assessment quickly degrades in digestive tract conditions has to be provided by the
applicant and supported by sound scientiﬁc arguments to demonstrate the suitability of the model
proposed for a particular animal species. If a sound argument cannot be provided, then testing should be
performed in vivo. For instance, an in vitro digestion model has already been developed for pigs (Boisen
and Eggum, 1991; Boisen and Fernandez, 1997), although a comparison with in vivo data for
degradation or release of substances or materials from its matrix has not been performed. If a
nanomaterial feed additive is intended to be used in food-producing animals, the exposure of consumers
32 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32003R1831&from=en
33 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition (Text with EEA relevance) OJ L 268, 18.10.2003, p. 29–43.
34 The feed additive shall: (a) favourably affect the characteristics of feed, (b) favourably affect the characteristics of animal
products, (c) favourably affect the colour of ornamental ﬁsh and birds, (d) satisfy the nutritional needs of animals, (e)
favourably affect the environmental consequences of animal production, (f) favourably affect animal production, performance
or welfare, particularly by affecting the gastro-intestinal ﬂora or digestibility of feedingstuffs, or (g) have a coccidiostatic or
histomonostatic effect.
35 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives (Text with EEA relevance) OJ L 133, 22.5.2008, p. 1–65. Available
online: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32008R0429&from=EN
36 http://www.efsa.europa.eu/en/publications/advanced-search?page=0&subject=62281&type=guidance&results_per_page=5
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to nanomaterials present in animal food products (indirect exposure, carry-over) should be assessed.
To this end, data should be provided on nanomaterial residues in tissues/products from target animals
receiving the nanomaterial feed additive under the conditions of the use requested (see FEEDAP
guidance on the safety for the consumer) (EFSA FEEDAP Panel, 2012b). Assessment of carry-over for
consumer safety is particularly relevant when there is a concern that the nanomaterial is persistent and
bioaccumulative. If the same nanomaterial is also intended to be used as a food additive, there needs to
be also an assessment of the nanomaterial for food use. In such cases, carry-over of the feed additive
can also be supported by the food use evaluation (e.g. by the safe intake level).
The hazard identiﬁcation and characterisation of the nanomaterial feed additive should follow the
principles in the current EFSA guidance documents and European Commission guidelines for feed
additives (see above) taking into account the additional aspects to be considered for nanomaterials
(Section 6.9 of the present guidance).
It should be noted for instance that toxicological data derived from laboratory species may not be
directly applicable for nanomaterial foreseen to be administered in feed to target animals. For
example, when evaluating the nanomaterial as feed additive, the risk assessor will have to consider if
the results from a modiﬁed 90-day study are sufﬁcient to extrapolate to a target farm animal species
or if additional testing in a speciﬁc farm animal species is necessary, e.g. tolerance tests for the target
species might be needed.
It should be noted that sheep, dogs, rabbit and cow have been reported to have two types of
Payer’s Patches that differ in cellular composition, location, structure and function, and this differs from
human and rodents where no such differences have been reported (Gebert et al., 1996). Such species
differences must be taken into account when considering regional differences or similarities in terms of
mechanisms and structures involved in particulate uptake in the large intestine.
As part of the safety assessment, inhalation of nanomaterial feed additives contained in feed
should be considered as an important route of exposure. This is because of the likelihood that, while
consuming the (dry) feed, animals will also inhale certain quantity of the particulate materials.
The inhalation and deposition of particles (including nanoparticles) in the lung is known to be
dependent on a number of factors, such as particle size, shape, breathing rate of the animal, etc.
(Sarangapani, 2000; Geiser and Kreyling, 2010). Although clearance mechanisms are similar in humans
and most mammals, it is known that clearance rates may differ signiﬁcantly between species (Elder
et al., 2005; Kreyling et al., 2013).
Where the inhaled particles are solubilised in the lung, they are likely to be quickly removed from
the lung through absorption. The poorly soluble particles on the other hand are cleared by different
mechanisms depending on the region where they are deposited (Bakand et al., 2012; Kreyling et al.,
2013). Large particles (≥ 5 lm) generally only reach the extrathorasic (mouth and throat) and/or
trachea-bronchial regions where they are cleared mechanically via coughing and are largely swallowed
into the gastrointestinal tract. Small particles, particularly nanoparticles, can reach and deposit in the
alveolar region (deep lung), where they can be retained for much longer periods before being cleared
via phagocytosis by the alveolar macrophages. It is important to note that, contrary to clearance from
the tracheo-bronchial region, clearing of particles from the alveolar region is much slower and may
take weeks to years (M€oller et al., 2008) as nanoparticles deposited in the lung may escape both
mucociliary clearance and alveolar macrophages (El-Sherbiny et al., 2015).
A small proportion of the inhaled particles may pass through the pulmonary epithelial barrier and
reach systemic circulation. Although penetration through the endothelial cell layer has been shown for
particles of different chemical identities, this seems to be restricted to ‘small’ nanoparticles (Geiser and
Kreyling, 2010; Kreyling et al., 2013). A trace fraction of nanoparticles may also reach the brain
directly via the olfactory bulb (Oberd€orster et al., 2009). It is therefore important that potential
adverse effects of animal exposure to nanoparticles through feed are carefully investigated considering
both the oral as well as the inhalation routes.
Safety for the user
Users/workers are deﬁned as the persons who may be exposed to the additive while handling it,
when incorporating it into premixtures or feedstuffs or using feedstuffs supplemented with the
additive. The safety of the user of nanomaterial feed additives should be assessed following the
general approach given in Regulation (EC) No 429/2008 and the speciﬁc FEEDAP guidance (EFSA
FEEDAP Panel, 2008).
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Risks to users/workers should be assessed in a series of studies using the additive in all forms of
the ﬁnal product for which the application has been submitted. Any other available toxicological data
should be used to assess the potential systemic toxicity of the additive.
The requirements to assess the effect on the respiratory system, skin and eye irritation and skin
sensitisation potential indicated in the FEEDAP guidance (EFSA FEEDAP Panel, 2011), should be
followed.
E.2. Recommended guidance for nanomaterial pesticides
The developments in the ﬁeld of nanosized active ingredients and formulations have also opened up
new avenues for enhancing the delivery and efﬁcacy of pesticides and other agrochemicals (not
necessarily in the remit of EFSA). The expected worldwide use of nanopesticides in the future may
contribute to a reduction in overall pesticide use through enhanced efﬁcacy and better control of
applications in the ﬁeld as well as better stability of the dispersions, and slow- or controlled-release of the
active ingredients (Perlatti et al., 2013; Kah and Hofmann, 2014; Cano Robles and Mendoza Cantu,
2017).
The term nanopesticides in this Guidance is used as a synonym for plant protection products (PPP) in
a broad way. In addition to active substances, PPPs may also contain other materials such as solvents,
carriers, inert material, wetting agents referred to as co-formulants that can also form nanoparticles.
Therefore, the recommended Guidance for nanomaterial pesticides covers nano plant protection product
active substances, its co-formulants and formulations (i.e. the plant protection product). In general,
pesticides is a broader term that also covers products as biocides, but biocides are not falling under the
scope of this Guidance document Plant protection products (PPPs) may also contain other materials such
as solvents, carriers, inert material and, wetting agents, referred to as co-formulants that can also form
nanoparticles. The term ‘nanopesticide’ as used herein therefore covers nano plant protection product
active substances, its co-formulants and the formulations (i.e. the plant protection product). However, it
is acknowledged that there are many similarities between plant protection products and biocides
products since same active substances can be used for both purposes.
Several examples of nanopesticides have been quoted in published literature (Kah et al., 2013;
Perlatti et al., 2013; Kah and Hofmann, 2014; Kookana et al., 2014; Cano Robles and Mendoza Cantu,
2017). However, a clear and agreed deﬁnition of nanopesticide is currently not available,37 and many
of the publications have regarded products containing particles ranging from the typical nanoscale
(between 1 and 100 nm) to much larger sizes (up to 1,000 nm) as nanopesticides. Most publications
did not differentiate between pesticides and biocides and have categorised both as nanopesticides.
Commercial sensitivities over nanopesticides pose further difﬁculties in identifying the scale of industrial
activity in this area. With these constraints in view, the available information suggests that
developments in this area are largely under R&D and as such there is little evidence of an apparent
• The present Guidance should be followed when evaluating a nanomaterial as a feed additive.
The direct exposure of target animals to the nanomaterial should be assessed following the
general approach given in Figures 3 and 4 of this Guidance and the FEEDAP guidance to
assess the safety for the target species (EFSA FEEDAP Panel, 2011).
• The risk assessor must consider if the results from an extended 90-day study (Step 2) are
sufﬁcient to conclude on the safety of target animal species, or if testing in a speciﬁc target
species is necessary.
• As part of the safety assessment of nanomaterial-containing feeds, inhalation of the
nanomaterial feed additives should also be considered as an important route of exposure for
animals feeding on a nanomaterial-containing feed.
• Risks to users/workers should be assessed in a series of studies using the nanomaterial
additive in all forms of the ﬁnal product for which the application has been submitted.
• All available toxicological data should be used to assess the potential systemic toxicity of the
additive.
37 There is currently no deﬁnition for ‘nanopesticides’. A (possible) deﬁnition based only the size in the nanoscale (1–100 nm)
could exclude many recent formulations that are larger (e.g. ‘nanoemulsions formulation’). On the other hand, some products
(e.g. ‘microemulsion formulation’) maybe contain fractions in the 1–100 nm range and that have been on the market for
decades without previously being classiﬁed as ‘nano’.
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example of a nanopesticide that is currently available on the market. It has, however, been reported
that microemulsions of some already available pesticides may contain droplets in the nanoscale range
(Kah et al., 2013).
Under Biocides Regulation (EU) No 528/2012, nanomaterial means ‘a natural or manufactured
active or non-active substance containing particles, in an unbound state or as an aggregate or as an
agglomerate and where, for 50% or more of the particles in the number–size distribution, one or more
external dimensions is in the size range 1 nm to 100 nm’. When test methods are applied to
nanomaterials under the Biocides Regulation, an explanation shall be provided of their scientiﬁc
appropriateness for nanomaterials, and where applicable, of the technical adaptations/adjustments
that have been made in order to respond to the speciﬁc characteristics of these materials (according
to the legal requirement for biocides under Reg. (EU) No 528/2012). An example of an approved
nanomaterial for use in biocidal products in Europe is that of synthetic amorphous silica, which is
approved under the Biocides Regulation (EU) No 528/201238 as an active substance for use in biocidal
products used for product type 18, insecticides, acaricides and products to control other arthropods, as
deﬁned in the Annex to the relevant Regulation.39 The approval covers synthetic amorphous silicon
dioxide (CAS No 112926-00-8) as a nanomaterial in the form of stable aggregated particles of size
> 1 lm, with primary particles in the nanosize scale (< 25 nm). It is also noteworthy that there is a
searchable database available for active substances approved in the EU under Regulation (EC)
No 1107/2009 for use in plant protection products40), which conﬁrms that currently there are no
nanomaterial-based pesticides. However, there is no such database for formulations, and it is not clear
if there are any nanomaterials already approved in the EU to be used as a pesticide formulation.
The currently available information on R&D relating to active substances in the form of
nanopesticides indicates that they are most likely to fall under one of following types of formulations
where the active substance is:
a) in the form of a nanoparticle as such or surface modiﬁed, or is contained in a nanoparticle
carrier - such as porous nanosilica;
b) in the form of nanosized droplets in an emulsion, or in solid lipid particles;
c) nanoencapsulated in a natural or synthetic (usually degradable) polymer shell.
From a risk assessment perspective, but deviating from the current legal requirements,41 the
Scientiﬁc Committee notes that safety considerations for a nanopesticide used in agriculture will be
necessary in the future. From the current perspective, these considerations cover two aspects: (1)
safety of the individual components (the active substances, co-formulants or other adjuvants), and (2)
safety of all the components that together form the nanopesticide entity.
To ensure a high level of consumer protection, it is necessary to develop a uniform deﬁnition for
nanomaterials and to specify that the approval of an active substance does not include the nanomaterial
form unless explicitly mentioned, which is comparable to the biocide legislation. It can then be
considered as a new entity. Safety of the individual components of a nanopesticide may not represent
safety of all the components put together to form a nanosized pesticide active substance and/or
formulation (Kookana et al., 2014). As discussed before, because nanosizing of substances may impart
certain changes in properties, behaviour and effects compared with the corresponding conventional
forms, an explanation of their scientiﬁc appropriateness for nanomaterials shall be provided for all test
methods applied to nanomaterials. Where applicable, an explanation of the technical adaptations/
adjustments that have been made in response to the speciﬁc characteristics of these materials shall be
provided. For example, nanodimensions may enable a nanopesticide to penetrate different biological
membrane barriers and thus manifest a different ADME proﬁle in the exposed organism compared with
its conventional form. A change in physicochemical properties and/or bio-kinetic behaviour may also lead
38 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available
on the market and use of biocidal products Text with EEA relevance, OJ L 167, 27.6.2012, p. 1–123.
39 Commission Implementing Regulation (EU) No 408/2014 of 23 April 2014 approving synthetic amorphous silicon dioxide as an
existing active substance for use in biocidal products for product-type 18, Ofﬁcial Journal of the European Union, L 121, 24
April 2014.
40 http://ec.europa.eu/food/plant/pesticides/eu-pesticides-database/public/?event=homepage&language=EN
41 In the current legal framework the co-formulants used in the pesticide products are regulated under REACH and Pesticides
Regulation. The European Commission is currently working on a Regulation setting out rules for the implementation of article
27 of the Regulation (EC) No 1107/2009 for the identiﬁcation of non-acceptable co-formulants. Based on the information
available, Member States shall consider taking action according to other Regulations than Regulation (EC) No 1107/2009.
EFSA will be requested to peer-review the assessment of co-formulants when the Pesticides Regulation appears to be the
relevant legal framework.
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to altered toxicological effects. Therefore, the properties, behaviour and effects of a
nanopesticide should not be automatically assumed to be similar to its conventional form,
even when the individual components of the nanopesticide are considered to be safe on
their own. This means that in addition to the data and information generally considered in risk
assessment of the same pesticide in a conventional form certain additional nanospeciﬁc aspects would
need to be considered for a nanopesticide.
Therefore, and since requested by the Network Representatives of Member States to give guidance
(see Minutes of the 17th meeting of the Network on Pesticide Steering point 5.6.442), the Scientiﬁc
Committee recommends National Authorities to request from the applicants that for authorisation
purposes it should be declared in the dossier if a PPP does not include any nanomaterial form or to
explicitly mention it and then follow this guidance when a nanomaterial is used in a PPP, e.g. as active
substance, co-formulant or synergist. Furthermore, in line with spirit of the overall protection goal for
human and animal health as outlined in Regulation (EC) No 1107/2009 Art.4.(2.a) for active
substances, when National Authorities are assessing a formulation (i.e. the active substance together
with a co-formulant), it is also advisable to follow the approach outlined in this Guidance not only for
food safety, but also for application safety (for operators, workers, bystanders and residents).43
The current level of knowledge relating to the human health effects and environmental fate,
behaviour and impacts of nanopesticides is still nascent, and therefore, this Guidance has only
highlighted the main aspects that need considering in regard to hazard identiﬁcation and hazard
characterisation of nanopesticide active substances and formulations.
Data requirements
According to the EFSA PPR Panel Scientiﬁc Opinion of 2009, the PPR Panel could not give at that time
a deﬁnitive statement on whether or not the data requirements given in Annex II and III of the Biocidal
Products Regulation (BPR, Regulation (EU) 528/2012) are sufﬁcient to gauge the risks of nanopesticides
owing to the emerging nature of this new technology. Here below, the Scientiﬁc Committee provides an
update of the situation based on the currently available knowledge. However, the Scientiﬁc Committee
notes that a comparable request to Annexes II (Information requirements for active substances) and III
(Information requirements for biocidal products) would also be very helpful for PPP.
‘When test methods are applied to nanomaterials, an explanation shall be provided of their scientiﬁc
appropriateness for nanomaterials, and where applicable, of the technical adaptations/adjustments that
have been made in order to respond to the speciﬁc characteristics of these materials.’ This should be
completed by the request from Annex IV (Common principles for the evaluation of dossiers for biocidal
products):’ In the case of biocidal products containing nanomaterials, the principles set out in this Annex
will also need to be adapted and elaborated in technical guidance to take account of the latest scientiﬁc
information. For pesticides, this Guidance of the EFSA Scientiﬁc Committee cannot be regarded as legal
data requirements. For legal data requirements in the area of pesticides, EFSA Guidance Documents
should be taken note in the PAFF meeting in order to be implemented. This is not the case for other Units
in EFSA or ﬁelds of application.
Data requirements – Physical, chemical and technical parameters
According to Commission Regulations (EU) No 283/201344 and (EU) No 284/201345 setting up the data
requirements for active substances and for PPPs, in accordance with Regulation (EC) No 1107/2009,46
there is a request for the submission of data on the identity of active substance, the identity and content of
additives and impurities.
Because of the above mentioned safety considerations, the Scientiﬁc Committee is of the opinion
that detailed physicochemical characterisation of a nanopesticide active substance as well as other
42 http://www.efsa.europa.eu/sites/default/ﬁles/event/141111a-m.pdf
43 For the environment (non-target organisms, ecotoxicology as well as fate and behaviour) will be addressed in Part 2 (see
Section 1.2.1).
44 Commission Regulation (EU) No 283/2013 of 1 March 2013 setting out the data requirements for active substances, in
accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant
protection products on the market Text with EEA relevance. OJ L 93, 3.4.2013, p. 1–84.
45 Commission Regulation (EU) No 284/2013 of 1 March 2013 setting out the data requirements for plant protection products, in
accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant
protection products on the market Text with EEA relevance. OJ L 93, 3.4.2013, p. 85–152.
46 Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of
plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. OJ L 309, 24.11.2009,
p. 1–50.
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co-formulants in a formulation is an essential prerequisite for risk assessment. This is currently not
expected for co-formulants. The parameters listed in Table 1 that are relevant to nanopesticides would
therefore need to be measured by methods that are suitable for nanomaterials. It is also important
that other technical parameters for dispersions/formulations such as stability, susceptibility, wettability,
etc., are also determined for nanopesticides.
Data on particle size distribution are very important in this regard, because it is the nanosize
dimensions that are likely to bring about changes in the properties, behaviour and effects of a
nanopesticide.
From the active substance evaluation process for conventional (non-nano) pesticides, two main
formulation types could be considered relevant to nanopesticides. These are capsule suspension or
micro encapsulated particles (CS), and micro encapsulated emulsions (ME). There is already a data
requirement for particle size distribution under Art. 2.8 of Reg. (EU) No 284/2013 setting up the data
requirements for plant protection products. A test on particle size distribution might be asked for a
pesticide CS of microencapsulated active substances in an aqueous continuous phase intended for
dilution with water before use. Such a test is not requested for ME in the regulation. Particle size range
is requested, however, if the representative formulation for a conventional (non-nano) pesticide is a
multiple phase formulation, to restrict the sizes of suspended particulates to a sufﬁciently narrow range
to ensure optimum efﬁcacy and/or safety of the product. The analytical method used for measurement
of size distribution is CIPAC method MT 187, which is based on ISO 13320-1:1999(E) (ISO, 1999)
(revised by ISO 13320:2009) (ISO, 2009) particle size analysis – Laser diffraction methods, and the
particle size distribution is calculated using a model (e.g. Fraunhofer model (ISO 13320:2009;
Commission communication 2013/C 95/0147)).
Also, as discussed before, unless a valid justiﬁcation can be provided, each formulation should
be assessed for any change(s) in the properties and behaviour of the nanopesticide. This is
because different formulations may alter the degree of particle dispersion, agglomeration and
aggregation. Thus, data on physicochemical parameters, including particle size distribution, will be
required both for an active substance(s) and the formulation(s) intended for use. Any signiﬁcant
changes in the physicochemical properties of a nanopesticide, either as such or in a formulation, would
make it difﬁcult to justify the use of toxicological data on conventional equivalents in risk assessment.
Toxicity assessment of active substances and co-formulants
According to Commission Regulations (EU) No 283/201344 and (EU) No 284/201345 setting up the
data requirements for active substances and for PPPs, in accordance with Regulation (EC) No 1107/
2009,46 the submission of data on the toxicity of active substance and PPP is requested. The
toxicological data currently required for the safety assessment of an active substance include studies
on ADME (both intravenous and oral), acute toxicity (oral, dermal, inhalation), skin and eye irritation,
skin sensitisation, short-term toxicity (90-day study in two species), genotoxicity (in vitro and in vivo),
carcinogenicity and, reproductive toxicity as well as other endpoints, such as neurotoxicity and
immunotoxicity studies. For co-formulants, such data requirements (currently) do not exist. For
formulations, the data requirements are currently limited to acute toxicity (oral, dermal, inhalation),
skin and eye irritation, skin sensitisation, dermal absorption and exposure assessment for operators,
workers, bystanders and residents (Regulation EU 284/2013; EFSA, 2014).
In a scenario of data rich substances, like pesticide active substances, for nanoformulations of such
pesticides a read-across hypothesis could be allowed on the condition that toxicokinetic behaviour has
been addressed (e.g. a described in this Guidance in Step 2a). The allowance of read-across
hypothesis as well as the comparative assessments are described in the Guidance for the Residue
Deﬁnition (EFSA PPR Panel, 2016). If a full read read-across case cannot be built, as a further study an
enhanced 28-day (OECD 407) for comparative assessment would be accepted.
As mentioned before, nanosize may bring about certain changes in the properties and behaviour of
a pesticide, and may alter its toxicological effects. Any data relating to the toxicity and exposure of a
conventional (non-nanomaterial) pesticide would therefore also be applicable to its nanopesticides if it
can be justiﬁed that physicochemical properties and toxicokinetic behaviour of the active substance (as
such, or in a formulation) have not signiﬁcantly changed at the nanoscale (also see Section 6.3 on
read-across). This means that data on physicochemical properties and ADME proﬁle of nanopesticides
47 Commission communication in the framework of the implementation of Commission Regulation (EU) No 284/2013 of 1 March
2013 setting out the data requirements for plant protection products, in accordance with Regulation (EC) No 1107/2009 of the
European Parliament and of the Council concerning the placing of plant protection products on the market.
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are crucial elements needed to decide whether any new toxicological data would be needed on the
pesticide nanoformulation. A signiﬁcant departure in the properties and/or behaviour of a
nanopesticide compared with non-nano equivalents should trigger the need for new toxicological
studies according to this Guidance in consideration of the relevant routes of exposure. It is noted that
this proposal from the Scientiﬁc Committee is compatible to the current practice for active substances,
for example by taking nanospeciﬁc aspects into account during the standard 90-day oral toxicity study
that is to be provided. However, such studies are not provided under the current framework for
pesticides formulations (meaning PPP).
In general, the toxicity data requirements for a nanopesticide will be similar to those for a
conventional (non-nano) PPP and the toxicological testing methods used for conventional (non-nano)
PPP will also be applicable to nanopesticides. However, the tests need to be carried out using the
nanopesticide and considering of the nanospeciﬁc aspects (e.g. dispersion, agglomeration/aggregation)
in accordance with this Guidance. It should also be noted that some of the currently available testing
methods may need certain adaptations to take account of the special nanoscale features of
nanopesticides (Rocks et al., 2008; SCENIHR, 2009; OECD, 2009a). For example, most of the currently
available in vitro methods have been developed and validated for substances that can be solubilised,
whereas nanopesticides are likely to comprise poorly soluble nanomaterials, either as such, or in a
suspension, dispersion, or formulation. It is also known that, owing to high surface energies,
nanoparticles generally tend to stick together to form larger sized agglomerates and aggregates (Simon
and Joner, 2008). The testing protocols should therefore take account of the potential agglomeration,
sedimentation, binding with other moieties in the medium, or sticking of the particles to glass/plasticware
used in handling/testing, because this could change the concentration of the material during a test (Alger
et al., 2014; Ong et al., 2014; DeLoid et al., 2017a). Data on stability of a nanodispersion/formulation
are therefore important to ensure that an applied concentration is maintained and the target cells are
exposed during the test to avoid false negative results from in vitro tests. As an example, any negative
results from in vitro genotoxicity studies also need to be provided with an assessment of the cellular and
nuclear uptake of the nanomaterial to demonstrate target exposure (see Section 6.4).
Nanomaterials are also known to bind various moieties on the particle surfaces and may thus
transport other (potentially harmful) substances to various organs and into cells. Detailed
characterisation of the actual nanopesticide active substances and formulations used in a toxicological
test would therefore be essential. It is also important to use appropriate dispersions/formulations in the
toxicity tests because different co-formulants and dispersion methods may differently affect the degree
of particle aggregation/agglomeration, which may in turn inﬂuence the results of a toxicological test.
According to Commission Regulation (EU) No 283/201344 setting up the data requirements for
active substances and Regulation (EU) No 284/201345 for PPPs, the submission of data on the active
substance is requested. For conventional pesticides, the same applies to (at least) one representative
formulation, which should be assessed as part of the active substance evaluation process. At present,
little is known about the effects of different dispersions/formulations on the properties, behaviour and
toxicological effects of nanopesticides, and it may not be appropriate to regard one or a few selected
formulations as representative for safety evaluation of all other formulations without a valid scientiﬁc
justiﬁcation. It is therefore requested under this Guidance that all the nanopesticide formulations that
are intended for ﬁnal use are always tested in toxicological studies. In view of the ability of
nanomaterials to penetrate different membrane barriers, and the potential for altered biokinetics in the
test organism, the toxicological studies should also consider new/unexpected target sites when testing
a nanopesticide.
Exposure assessment of active substances and co-formulants
The EFSA PPR Panel has published guidance on the assessment of exposure of operators, workers,
residents and bystanders in risk assessment for plant protection products (EFSA, 2014), that in general
should also be applied to nanopesticides. Like other PPPs, the potential for consumer exposure to a
nanopesticide would be dependent on the concentration of the active substance, the type of formulation,
the mode of application, as well as the persistence of the nanopesticide and the level of its residues in
foodstuffs. Information on the persistence of a nanopesticide should be provided in the registration
dossier, whereas determining the level of residues is subject to post-market monitoring/surveillance of
speciﬁc food/feedstuffs by the competent authorities of the European Member States.
The likely scenarios for direct human and animal exposure to a nanopesticide can be envisaged from
accidents and (mis)handling during manufacture, transportation and storage, but most importantly
during preparation and application at the farm. While intentional (suicidal) or accidental ingestion cannot
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be ruled out, oral exposure from normal use of a nanopesticide is unlikely. On the other hand, dermal
and/or inhalation exposure is possible for the operators as well as farm animals, workers, bystanders and
residents in the vicinity during manual handling, mixing/loading, and (spray) application of a
nanopesticide. Other potential exposure scenarios may include in and around the home and gardens,
seed treatment facilities, etc. pending conﬁrmation. The relevant Regulation (EU) No 284/2013 requires
estimation of acute and chronic exposure to operators, workers, residents and bystanders considering
each relevant type of application. The exposure estimation for operators and workers is ﬁrst carried out
assuming that they are not using personal protective equipment, followed, where appropriate, by further
estimation on the assumption they are using effective and readily obtainable protective equipment. For
bystanders and residents, exposure estimation should assume that they do not use any personal
protective equipment.
Dermal exposure/toxicity
Under Regulation (EU) No 284/2013 setting out the data requirements for plant protection products
(the formulations), dermal absorption studies would be required where dermal exposure is a signiﬁcant
exposure route, and no acceptable risk is estimated using a default absorption value. The EFSA PPR
Panel has published guidance on dermal absorption (EFSA, 2017), that should in general also be
applied to nanopesticides. These studies should provide a measurement of the absorption through the
skin of the active substances.
Dermal absorption studies can be performed using in vivo (OECD TG 427 (2004a)) or in vitro (OECD
TG 428 (2004b)) methods. As Regulation (EU) No 284/2013 stipulates, the dermal absorption data
should preferably be derived from studies on human skin in vitro. In this regard, EFSA PPR Panel (2011)
has published a scientiﬁc opinion on the science underpinning the assessment of dermal absorption of
PPPs and a detailed Guidance on dermal absorption (EFSA PPR Panel, 2017). These should be referred to
when conducting dermal absorption studies on nanopesticides with additional consideration of the
relevant nano-aspects. It is also important for dermal absorption studies to consider whether a
formulation can affect bioavailability of the active substances and/or other toxicologically relevant
compounds in a PPP.
For nanopesticide active substances and formulations, the likelihood and extent of the absorption
through skin, lung, and gastrointestinal tract (if relevant) should be determined whilst mimicking the
potential exposure scenarios, with due considerations to the nanoaspects. Dermal absorption is
generally determined by chemical analysis of the receptor ﬂuid (in vitro tests), or blood/tissues (in vivo
studies). However, most analytical methods can indicate the chemical nature but not the particle
nature of the absorbed substances. Thus, where chemical analysis of skin sections, tape-strippings,
and/or receptor ﬂuid has indicated dermal absorption of a nanopesticide, further investigations should
be carried out to ascertain whether the absorbed substance(s) are still nanomaterial or have degraded.
From a risk assessment point of view, this is important because the loss of nanostructure due to
degradation (dissolution, enzymatic or chemical breakdown), would render a nanomaterial to the
corresponding non-nanomaterial. Certain analytical methods – e.g. electron microscopy based imaging,
ﬂuorescence labelling, and single-particle ICP-MS, etc., have been used to establish the particle nature
of the substances absorbed in or through the skin/lung (Vogt et al., 2014; Lin et al., 2015).
Where the absorption of a nanopesticide cannot be ruled out either by experimental data or on the
basis of information on degradation, a default value of 100% absorption as a nanomaterial should be
applied in risk assessment, unless data become available that prove otherwise and trigger a revision of this
default value. Also, irrespective of the presence of a nanomaterial pesticide active substance/formulation,
requirements under the existing regulations for safety assessment must be followed. As described in
Section 4, detailed characterisation data on the identity, chemical composition and purity/impurity proﬁle
of the nanopesticide active substances and formulations must be provided.
Inhalation exposure/toxicity
Regulation (EU) No 284/2013 setting out the data requirements for PPPs (formulations) requires
acute inhalation toxicity studies. For this purpose, head/nose exposure shall be used, unless body
exposure can be justiﬁed. The studies are carried out following the OECD Guidelines Tests 403
(OECD, 200b).
In regard to a nanopesticide (especially nanoformulations), it is important to note that particle size
and the mode of application (e.g. dusting or spraying) will determine the extent of the exposure in
terms of whether the particles/droplets can be inhaled and which part of the respiratory tract they can
reach.
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The human respiratory tract is divided in three Sections: the nasopharyngeal, tracheobronchial and
pulmonary regions. Particle fractions reaching these regions are designated inhalable (size > 30 lm),
thoracic (size 10–30 lm), and respirable fractions (size < 10 lm). The particle fraction in the size
range < 10 lm (including nanoparticles) is generally considered respirable, i.e. particles can potentially
reach the alveolar region of the lung and this may lead to local or systemic effects in/through the
respiratory system. In view of this, data on the particle/droplet size alone will not be considered
sufﬁcient for estimation of inhalation exposure of a sprayable nanopesticide emulsion/dispersion, and
• Although an agreed deﬁnition of nanopesticide is currently not available, the deﬁnition
provided in Biocides Regulation (EU) No 528/2012 may be used as a guide.
• It is advisable that a pesticide active substance or formulation should be considered within
the scope of this Guidance if it is:
 in the form of a nanoparticle as such or surface modiﬁed, or is contained in a
nanoparticle carrier;
 in the form of nanosized droplets in an emulsion, or in solid lipid particles; nanoencapsulated in a natural or synthetic polymer shell.
• Risk assessment of a nanopesticide should consider both the individual components (the
active substances and co-formulants), as well as all the components together that form the
nanopesticide entity.
• The approach outlined in this Guidance should be followed for food and, application safety
(for operators, workers, bystanders and residents) as well as for the environment
(non-target organisms, ecotoxicology fate and behaviour). The EFSA PPR Panel has
published guidance on the assessment of exposure of operators, workers, residents and
bystanders in risk assessment for plant protection products (EFSA, 2014), that should be in
general also applied to nanopesticides.
• Detailed physicochemical characterisation of a nanopesticide active substance and other co-
formulants in a formulation must be carried out considering relevant parameters listed in
Table 1, along with additional parameters for dispersions/formulations such as stability,
susceptibility, wettability, etc.
• Toxicity data requirements for a nanopesticide are similar to that for a conventional (non-
nano) PPP and testing methods used for conventional (non-nano) PPP will also be applicable
to nanopesticides. However, the tests need to be carried out using the nanopesticide and
cover the nanospeciﬁc aspects (e.g. dispersion, agglomeration/aggregation) in accordance
with this Guidance.
• Under Regulation (EU) No 284/2013 setting out the data requirements for PPPs (the
formulations), dermal absorption studies would be required where dermal exposure is
signiﬁcant route, and no acceptable risk is estimated using default absorption value. The
EFSA PPR Panel has published guidance on dermal absorption (EFSA, 2017) that should be in
general also be applicable to nanopesticides.
• It is also important for dermal absorption studies to consider whether a formulation can
affect bioavailability of the active substances and/or other toxicologically relevant compounds
in a PPP.
• For nanopesticide active substances and formulations, the likelihood and extent of the
absorption through skin, lung, and gastrointestinal tract (if relevant) should be determined
whilst mimicking the potential exposure scenarios, giving due considerations to the
nanoaspects.
• Where studies indicate dermal absorption of a nanopesticide, further investigations should be
carried out to ascertain whether the absorbed substance(s) are in nanoform, or a degraded
or dissolved form. Where the absorption of a nanopesticide cannot be ruled out either by
experimental data or on the basis of information on dissolution/degradation, a default value
of 100% absorption in nanoform should be applied in risk assessment.
• Regulation (EU) No 284/2013 setting out the data requirements for PPPs (formulations)
requires acute inhalation toxicity studies. For this purpose, head/nose exposure should be
assessed, unless body exposure can be justiﬁed. The studies should be carried out following
OECD Guidelines Test 403.
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data on dried particles will also be required for risk assessment. This is because, depending on the
dispersion medium, larger air-borne droplets may dry out quickly and become small enough to reach
the alveolar region of the lung. Currently, this cannot be simulated in any of the available
computational models, and the applicant for a nanopesticide should provide measurement data on the
size range of both the spray droplets as well as the dried particles.
E.3. FCM
The development of new FCMs is a major area of current nanomaterial applications (Smolander and
Chaudhry, 2010; Bradley et al., 2011; Duncan, 2011; Wyser et al., 2016). In these cases, exposure to
nanomaterial can principally occur indirectly because of migration or transfer of the nanomaterial from
FCM, into food. EFSA has published a few opinions on the application of nanomaterials such as carbon
black, inorganic substances like TiN and metal oxides, and nanoclays in food contact polymers (EFSA
CEF Panel, 2012a,b, 2014a,c, 2015a,b, 2016b). In all cases, it was concluded that no signiﬁcant
migration or transfer of the nanoparticles was expected under the deﬁned conditions of use. Recently,
a critical review of the published literature on the migration potential of nanomaterials from food
contact polymers has been published by Stormer et al. (2017). One important conclusion is that
analytical observations reporting migration of nanomaterials in many cases did not demonstrate that
the measured migrants were in nanoparticulate form. This reemphasises that the amount migrated or
transferred, particularly its particle properties, should be determined. More information about the
migration of engineered nanomaterial from polymer-based food-contact materials has been reviewed
by Jokar et al. (2017).
E.4. Novel food
The Novel food legislation is not prescriptive, but EFSA needs to check if the best test protocols are
being used. This novel legislation stipulates that vitamins, minerals or other substances that contain or
consists of a engineered nanomaterial be considered as novel foods. It remains to be clariﬁed whether
the wording ‘contains or consists’ would also warrant an assessment of these nutrients or other
substances if they are encapsulated or in other forms of carrier nanomaterials as mentioned in this
Guidance. Testing of whole food is the ultimate alternative for testing after the nanomaterial speciﬁc
testing in vitro and in vivo. For the testing of a novel food material, it depends on the case if the
applicant needs to test the whole food and/or parts of it.
E.5. Nano(plastic) contaminants
There is the possibility that certain nanomaterials enter the food and feed chain as contaminants
from anthropogenic or natural sources through traditional processes of waste disposal. In principle, the
data resulting from toxicity testing of nanomaterials as recommended in this Guidance, can also be
used for assessing the human health risk from nanomaterials as contaminants of food/feed.
Guidance summary for FCM
• Detailed physicochemical characterisation of the nanomaterial used as an additive or applied
as a surface coating on a food contact material must be provided.
• Exposure to a nanomaterial must be assessed based on the experimental data on migration
or transfer from a FCM to food. Potential release of the nanomaterial from the FCM due to
mechanical stress or physical disintegration of a FCM polymer matrix should also be
considered.
• Appropriate techniques should be used to both quantitatively and qualitatively determine the
migrating species, and to establish whether they are in nanoparticulate or solubilised/
degraded form.
• A case may be made for exemption from carrying out toxicological investigations where it
can be shown that either the migrating species are not in nanomaterial form (in that case
standard risk assessment should apply), or migration of the nanomaterial is only in trace
amounts.
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It is known that waste nanoplastics are generated and that exposure of humans and animals
occurs through the food chain (Chae and An, 2017). However, this topic is considered outside of the
scope of this working group and is not addressed in this Guidance.
E.6. Nanocarriers
Currently the European Commission recommended deﬁnition of nanomaterial might be modiﬁed
towards ‘solid particles’. As explained in Rauscher et al. (2015) ‘Solid’ is one of the four fundamental
states of matter (the others being liquid, gas, and plasma). It is characterised by structural rigidity and
resistance to changes of shape or volume. This excludes emulsions (liquid particles in liquid media)
and micelles. A rationale for this is the fact that for these materials the external dimensions generally
depend more on chemical and physical (mechanical) forces from their surroundings than those of solid
particles. For micelles, also the high frequency of molecules leaving and entering the structure makes
their structure highly dynamic’.
Also previous guidance on nanomaterials has concentrated on manufactured particulate
nanomaterials since many of the observed biological effects reported occurred with micro- and
nanoparticles (such as exhaust particulates). However, it is recognised that uses of nanotechnology in
food and feed (and other areas) is wider than manufactured nanoparticles per se.
As mentioned in the scope Section 1.3, organic nanomaterial, such as encapsulates are considered
subject to this Guidance. Such nanoencapsulates can function as a delivery system for nutrient sources
and to incorporate food additives into products (such as lipophilic colours in hydrophilic beverages).
Nanoencapsulation is an extension of drug delivery systems based on liposomes and (bio)polymers
that have existed for 30–40 years and were designed to increase the bioavailability of pharmaceuticals.
These generally consist of an amphiphilic compound (such as a phospholipid) which can be organised
into bilayer structures such as spheres so that one surface is hydrophilic and the other lipophilic. These
can be structured with either the hydrophilic or lipophilic surface on the interior and the other on the
exterior depending on the intended use. A compound of relevant ‘philicity’ is contained within the
interior surface. In general, the components of the shell are either normal constituents of the body or
approved food additives such as emulsiﬁers. The amounts of the shell components derived from food
materials for use in delivery systems are generally far lower than their normal intake from dietary
sources or other approved uses. As such there would be little concern over the shell components,
unless these were neither normal constituents of the body or approved food additives. If
nanoencapsulates function as intended, however, there will be increased bioavailability (systemic
exposure) of the encapsulated material. This represents a potential concern since health based
guidance values are currently set based on the external rather than the internal dose and may no
longer provide an appropriate level of protection to the consumer.
Nanomaterials used as carrier systems for other food components (e.g. vitamins) may increase
their bioavailability. The, effects of the increased bioavailability need to be considered in terms of
toxicity (if these encapsulation materials are not disintegrated in the gastrointestinal tract) for (1) the
active ingredient per se, (2) the encapsulating material, and (3) the encapsulate/nanocarrier as a
whole. The exposure assessment of a nanoscale delivery system should include assessment of the
amount of encapsulated bioactive compound (in addition to the assessment of the nanocarrier system
itself) and the amount present in free form in the food. For this, the analytical isolation, detection and
characterisation procedures need to meet such requirements. It might also be necessary, when
appropriate and possible, to analyse the relevant chemical components of a nanocarrier system as
such.
Guidance summary for nanocarriers
• For nanomaterials used as carrier systems for other substances, the implications of any
signiﬁcant alteration (increase) in bioavailability to potential harmful effects must be
considered – especially when a nanocarrier is not disintegrated in the gastrointestinal tract.
• The safety assessment should consider the active ingredient per se, the encapsulating
material, and the encapsulate/nanocarrier as a whole.
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